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ABSTRACT 
 
Specially prepared 2-amino-5-bromo-3-iodoacetophenone and 5-bromo-2-hydroxy-3-
iodoacetophenone were subjected to Claisen-Schmidt aldol condensation with benzaldehyde 
derivatives followed by sequential and/or one-pot palladium catalyzed Sonogashira cross-
coupling and heteroannulation of the 3-alkynylated intermediates to afford indole-chalcones 
and benzofuran-chalcones, respectively. The indole-chalcones derivatives were, in turn, 
subjected to trifluoroacetic anhydride in tetrahydrofuran under reflux to afford the 
corresponding 3-trifluoroacetyl substituted indole-chalcone derivatives. The coupling constant 
values (Jtrans) of about 16.0 Hz for the chalcone derivatives corresponding to the vinylic protons 
confirmed the trans geometry of the α,β-unsaturated carbonyl framework in all the cases. Their 
trans geometry of the chalcone derivatives was further confirmed by single crystal X-ray 
diffraction (XRD) analyses. Further structural elaboration of the ambident electrophilic α,β-
unsaturated carbonyl (chalcone) moiety of the indole-chalcones and the analogous benzofuran-
chalcones with 2-aminothiophenol afforded novel benzothiezapine-appended indole and 
benzofuran hybrids, respectively. Sonogashira cross-coupling of 5-bromo-2-hydroxy-3-
iodoacetophenone with terminal acetylenes followed by heteroannulation of the intermediate 
3-alkynylated 5-bromo-2-hydroxyacetophenones afforded the corresponding 7-acetyl-2-aryl-
5-bromobenzofurans in a single-pot operation. The oximes derived from the 7-acetyl–
substituted 2-aryl-5-bromobenzofurans were subjected to Beckmann rearrangement with triflic 
acid in acetonitrile under reflux. We isolated the corresponding 7-amino-2-aryl-5-
bromobenzofuran derivatives formed from hydrolysis in situ of the intermediate 7-acetamide-
2-aryl-5-bromobenzofurans. Amino-dechlorination of the 4-chloroquinazoline derivatives with 
the 7-aminobenzofurans afforded novel benzofuran 4-aminoquinazoline hybrids. The prepared 
compounds were characterized using a combination of nuclear magnetic resonance (1H-NMR 
vi 
 
& 13C-NMR including 19F-NMR), infrared (IR) and mass spectroscopic techniques 
complemented with single crystal X-ray diffraction (XRD) analyses and/or density functional 
(DFT) method. 
 
The benzofuran-chalcone 203a–y derivatives were evaluated for anti-growth effect against the 
breast cancer (MCF-7) cell line by the MTT cell viability assay. Their mode of cancer cell 
death (apoptosis versus necrosis) was detected by Annexin V-Cy3 SYTOX staining and 
caspase-3 activation. The most cytotoxic compounds 203i and 203o were also evaluated for 
potential to inhibit tubulin polymerization and/or epidermal growth factor receptor-tyrosine 
kinase (EGFR-TK) phosphorylation. The experimental results were complemented with 
theoretical data from molecular docking into ATP binding site of the EGFR and colchicine 
binding site of tubulin, respectively. The benzofuran–4-aminoquinazoline hybrids 215a–j, on 
the other hand, were evaluated for antiproliferative propeties in vitro against the human lung 
cancer (A549), epithelial colorectal adenocarcinoma (Caco-2) and hepatocellular carcinoma 
(C3A) cell lines. The benzofuran-aminoquinazoline hybrids were also evaluated for potential 
to induce apoptosis and for their capability to inhibit EGFR-TK phosphorylation 
complemented with molecular docking (in silico) into the ATP binding site of EGFR. 
Mechanistic studies demonstrated that the benzofuran-appended aminoquinazoline hybrids 
215d and 215j induced apoptosis via activation of caspase-3 pathway. Moreover, compounds 
215d and 215j exhibited significant and moderate inhibitory effects against EGFR (IC50 = 29.3 
nM and 61.5 nM, respectively) when compared to Gefitinib (IC50 = 33.1 nM). Molecular 
docking of compounds 215 into EGFR-TK active site suggested that they bind to the region of 
EGFR like Gefitinib does. 
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Chapter 1: Introduction 
 
1.1 Importance of heterocyclic compounds in the treatment of cancer 
 
Nitrogen-, oxygen- and sulphur-containing heterocyclic compounds represent the key structural 
components of many of the anticancer drugs available on the market today. Of the novel 
molecular anticancer agents approved by the US Food and Drug Administration (FDA) between 
2010 and 2015, for example, almost two-thirds contained heterocyclic moieties within their 
frameworks.1 The prevalence of heterocyclic moieties in anticancer drug design is partly credited 
to their occurrence in nature accompanied by their involvement in various cellular processes and 
interesting mechanisms evolved to interact with them.1 Despite the wide range of heterocyclic 
anticancer drugs that are currently available on the market, there are still challenges around 
multi-drug resistance, poor therapeutic efficacy, adverse side effects and poor bioavailability, 
which necessitate the continued development of new anticancer agents. Resistance to some of 
the anticancer drugs currently in the market has resulted in a desperate need to develop new 
strategies to combat this deadly disease. As such, the use of combinatorial therapies of anticancer 
drugs has superseded monotherapy drug use. Combinatorial therapy makes up the basis of drug 
synergy and is defined as the use of two or more drugs simultaneously for cancer treatment. In 
2010 the FDA-approved a combination of lapatanib with capecitabine in women with advanced 
breast cancer resistant to trastuzumab.2 A combination of cetuximab with irinotecan has also 
been employed in patients with metastatic colorectal carcinoma.2 Concurrent inhibition of DNA 
repair enzymes (eg. PARP1) or checkpoint kinases (eg. CHK1) with chemotherapy has also 
significantly improved the standard of care in a variety of cancers.2 The major drawback of the 
combinatorial approach is that the half-life of inhibitors affects drug efficacy.3 The other 
disadvantages attributed to combination chemotherapy include patient noncompliance due to the 
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increased number of administrations, forgetting to take medication and increased drug dose with 
consequent side effect and the negative impact on patient’s health.4 The problems associated 
with combination chemotherapy due to patients’ noncompliance led to the invention of 
molecular hybridization in which two or more of the drugs are linked together on the same 
molecular framework and available to patients as a single entity.5 Molecular hybridization 
involves the fusion of two or more pharmacophoric units of known bioactive molecules to 
produce a new compound with improved affinity and efficacy compared to the individual parent 
drugs.6 The selection of the drugs or pharmacophores is usually based on their observed 
pharmacological activities to enable the identification of highly active novel chemical entities 
and it is expected that the hybrid molecules might exhibit different and/or dual modes of action, 
modified selectivity profile and reduced side effects.7 The hybridization approach has already 
been applied in the development of novel antibacterial and anticancer agents to overcome drug 
resistance. Indoles, benzofurans, quinazolines, chalcones and their derivatives, for example, are 
among the most valuable compounds proven to induce antiproliferative effect in several cancer 
cell lines. Our group has for some time focused on the synthesis and structural property studies 
of quinolinones and their quinoline derivatives,8 and the analogous quinazolinones3 and their 
quinazoline derivatives.9 The quinolinone derivatives were mainly accessible via acid-mediated 
cycloisomerization of the corresponding chalcone precursors.10 We became inspired by the 
prevalence of the indole and benzofuran scaffolds in naturally occurring and synthetic 
heterocyclic compounds with anticancer properties. We asked ourselves whether it was possible 
to merge these scaffolds with the chalcone and quinazoline moieties to construct novel 
heterocycle-appended chalcone and quinazoline hybrids for further evaluation as potential 
anticancer agents. To realise our goal, we performed a thorough literature search on the known 
examples of biologically-relevant indole derivatives and benzofuran analogues and their 
corresponding molecular hybrids. In the next sections we describe some of the examples of the 
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indoles and benzofurans as well as the known molecular hybrids of biological importance that 
are based on these heterocyclic frameworks. 
 
1.2 An overview of indoles and indole-appended molecular hybrids of biological 
importance 
 
The indole nucleus is an important scaffold in numerous natural and synthetic alkaloids found to 
exhibit a wide range of biological activities including anticancer, antioxidant and anti-
inflammatory properties.11 The 3-carbaldehyde substituted 2-arylindole derivative 1 shown in 
Figure 1 has been found to exhibit increased inhibitory activity against tumour growth and 
tubulin polymerization.12 Indoles also represent valuable synthons for the preparation of nano- 
and meso structures with enhanced electronic and photonic properties.13 The 4-[(3a,7a-dihydro-
1H-indol-3-yl)(1H-indol-3-yl)methyl]-2,6-dimethylphenol dye 2 shown in Figure 1, for 
example, has been prepared from the reaction of 1H-indole with 4-hydroxy-3,5-
dimethylbenzaldehyde in methanol and, in turn, used as a probe for the determination of water 
content in polar aprotic organic solvents such as acetone, acetonitrile, tetrahydrofuran and 
dioxane.14 Likewise, the blue electroluminescent device, ITO/NPB/2/TPBI/Alq3/Mg–Ag, 
comprising of indium tin oxide (ITO) as a substrate, 4,4’-bis[N-(1-naphthyl)-N-
phenylamino]biphenyl(NPB) as a hole, methyl-5-cyano-2-(3,4-dimethoxyphenyl)-1H-indole-3-
carboxylate 3, 1,3,5-tris(N-phenylbenzimidazol-2-yl)benzene (TPBI) as a hole blocking 
material, tris(8-hydroxyquinoline)aluminium (Alq3) as electron transporting material and 
magnesium-silver (Mg-Ag) as electrode has been developed.15 
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Figure 1: Examples of indoles with biological and photophysical properties. 
 
Phidianidines 4a and 4b shown in Figure 2 have been isolated from the shell-less marine 
opisthobranch mollusk Phidiana militaris and found to exhibit antitumour activity against the 
glioma brain tumour (C6) and cervical cancer (HeLa) cells with the IC50 values within nanomolar 
range.16 These compounds have also been synthesised by Lin and Snider by coupling the 
corresponding 2-(1H-indol-3-yl)acetyl chloride with (5-azidopentyl)-2-hydroxyguanidine in the 
presence of triethyl amine in dichloromethane.17 The analogous 3-[2-(5-chloro-2-phenyl-1H-
indol-3-yl)-1-(dimethylamino)ethyl]naphthalen-2-ol 5 shown in Figure 2, on the other hand, has 
been synthesised via multicomponent reaction of 2,5-disubstituted indole-3-carboxaldehyde, 
secondary amine and 2-naphthol and was found to exhibit  antifungal activity.18 
                                  
                              4: R = H (a), Br (b)          5 
Figure 2: Examples of biologically active indole derivatives 4a, b and 5. 
 
When an indole moiety is linked to a chalcone framework or another heterocyclic scaffold, the 
two pharmacophores tend to enhance the overall photophysical (electronic absorption and 
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emission) properties19 and/or the biological efficacy of the resultant molecular hybrids.20 Indole-
based chalcones are associated with high-affinity benzodiazepine receptor ligands, interleukin, 
selective cyclooxygenase-2 (COX-2) and phosphodiesterase (PDE4) inhibition, as well as 
anticancer and anti-inflammatory properties.19,20 The 3-substituted 5-methoxy-2-methyl-1-H-
indol-3-yl)-1-(pyridin-4-yl)chalcone derivative 6 shown in Figure 3, on the other hand, has been 
found to induce methuosis in glioblastoma and other cancer cells.21 Likewise, the phosphonate 
indole-chalcone derivative 7 (see Figure 3) has been found to be a potent tubulin polymerization 
inhibitor, which binds to the colchicine binding site.22 Moreover, these compounds inhibited 
tumour growth in xenograft models in vivo without apparent toxicity.22 
                            
                                     6                                                                         7 
Figure 3: Examples of medicinally important indole-based chalcones. 
 
Six-membered benzo-fused nitrogen-containing heterocycles such as quinolines have recently 
earned great interest in targeted therapies as antimalarial drugs.23 Among quinoline-based 
compounds, the 4-aminoquinolines have been found to inhibit the hematin formation by 
complexing with ferriprotoporphorin IX (FPIX) and thereby prevent its polymerization into 
hemozoin, which results into the malarial parasite death.24 Linking an aminoquinoline moiety on 
the indole framework has been found to enhance the overall biological efficacy of the resultant 
indole-aminoquinoline hybrids. For example, indole-aminoquinolines 8 have been found to 
significantly inhibit β-hematin formation and to compromise the mitochondrial function of the 
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parasite (Figure 4).25 Song et al.26 have recently reported the synthesis of the indole-based 
thiochromanone derivatives 9 by an ionic liquid approach. These compounds have been found to 
be more potent against a wide range of fungi species when compared to the commercially 
available antifungal drug, fluconazole, which has been used as a reference standard for the 
assays. 
                                                                            
                                    8                                                                    9 
Figure 4: Example of indole-based quinolines 8 and thiaflavanone 9 of medicinal importance 
 
Luth et al., recently merged quinazoline and indole nuclei directly to afford the 4-(indole-3-
yl)quinazolines 10.27 These compounds have been found to exhibit moderate receptor protein 
tyrosine kinase (ErbB-2) activity with little or no activity against epidermal growth factor 
receptor (EGFR).27 The N4-(1H-indol-5-yl)quinazoline-4,6-diamines 11, on the other hand, have 
been found to exhibit significant anti-inflammatory properties in a dose-dependent manner in 
lipopolysaccharide-induced microphages and inhibit TNF-α and IL-6 inflammatory mediators.28 
The analogous indole-ether quinazoline hybrid 12 has been found to inhibit vascular endothelial 
growth factor (VEGF) inhibitor that selectively inhibits VEGF tyrosine kinase activity associated 
with VEGFR-1, -2 and -3.29 
 
 
 
 7 
 
          
                     10    11           12             
Figure 5: Examples of indole-appended quinazoline hybrids with biological properties  
 
The benzofurans, which are distinguished from indoles by the presence of oxygen in the 
heterocyclic ring instead of nitrogen are also important heterocycles in the field of medicine and 
materials.30 Some of the few examples of benzofurans of biological importance and their hybrids 
are described in the next section. 
 
1.3 An overview of benzofuran and benzofuran-appended hybrids of biological        
importance 
 
Benzofurans represent another class of oxygen-based heterocycles with a wide range of 
biological properties and some derivatives serve as cytotoxic,31 antimicrobial,32 fungicidal,33 
anti-inflammatory,34 and anti-oxidant agents.35 The N-(4-hydroxy)phenylamide-substituted 
benzofuran derivative 13 shown in Figure 6, for example, has been found to exhibit significant 
cytotoxicity against the colon (HCT15), renal (ACHN), gastric (NUGC-3), breast (MM231), 
prostate (PC-3) and lung (NCI-H23) cancer cell lines and to inhibit the NF-κB transcriptional 
activity.1 
 
 
 8 
 
 
13 
Figure 6: Structure of benzofuran derivative 13 with anticancer properties 
 
The naturally occurring ailanthoidol 14 represented in Figure 7 isolated from the Chinese herb 
(Zanthoxylum ailanthoide) has been found to supress lipopolysaccharide-stimulated 
inflammatory reactions in RAW264.7 cells and endotoxin shock in mice.36 Papp et al.,37 
previously synthesized a 4-(5-methoxy-7-bromobenzofuranyl)-2-piperidine 15 (Figure 7) 
commonly known as brofaromine and this compound has been found to be a potential anti-
depressant after clinical trials. Besides the wide range of bioactivities, benzo[b]furan derivatives 
also act as insecticides and herbicides. The substituted benzo[b]furan derivative 16 shown in 
Figure 7, for example, has been found to be a potential herbicide showing a strong effect against 
weeds.38 
                                              
                                14                                         15                                                       16 
Figure 7: Examples of benzofurans with applications. 
 
Conjugates consisting of the benzofuran and chalcone framework linked together tend to exhibit 
a wide range of biological and pharmacological properties.39,40 The benzofuran-chalcone hybrids 
17 shown in Figure 8, for example, have been found to exhibit significant inhibitory properties 
against acetylcholine (Ach) in the micro molar levels in vitro, which make them potential 
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candidates for the treatment of Alzheimer’s disease.39 The benzofuran-chalcone derivative 18, 
on the other hand, has shown strong inhibitory effects against the lung (A549), breast (MCF-7) 
and prostate (PC-3) cell lines with IC50 values of 9, 2, and 10 µM, respectively.
40 Molecular 
analysis indicated that compound 18 induced apoptosis through caspase-dependent pathways in 
prostate, lung and breast cancer cells.40 
                                  
                                 17                                                                                     18 
Figure 8: Examples of benzofuran-chalcone hybrids with medicinal applications. 
 
Benzothiophenes comprise another class of five-membered benzo-fused heterocycles 
characterised by the presence of a sulphur atom in the ring instead of nitrogen or oxygen atom 
found in the analogous indoles and benzofurans, respectively. This class of compounds and 
their molecular hybrids are described in the next section. 
  
1.3.1 An overview of benzothiophene-based compounds of biological importance  
 
Several benzothiophene-based compounds have been found to exhibit antifungal,41
 
5-
lipoxygenase inhibition
 
and anti-inflammatory properties.42
 
Raloxifene 19 shown in Figure 9 is 
an example of a 3-carbonyl substituted 2-arylbenzo[b]thiophene which exhibits selective 
estrogen receptor modulator activity and has been employed in the treatment of cervical and 
breast cancers as well as osteoporosis.43 Sertaconazole nitrate derivative 20, on the other hand, 
is an antifungal agent and this compound also exhibits anti-inflammatory activity by activation 
of the p38–COX-2–PGE2 pathway.41 
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                                         19                                                               20 
Figure 9: Examples of benzothiophene derivatives with medicinal applications. 
 
Molecular hybrids comprising benzothiophene and chalcone moieties linked together also exist 
in the literature. The benzothiophene-chalcone hybrids 21 shown in Figure 10 below, for 
example, have been prepared before and found to exhibit significant bioactivity against several 
fungi species.44  
 
      21: R = H (a), OCH3 (b) 
Figure 10: Examples of benzothiophene-chalcone derivatives with medicinal applications. 
 
Another class of nitrogen-containing heterocycles of our group’s interest are the quinazolines. 
The biological properties and application of this class of compounds and their molecular 
hybrids are described in the next section.  
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1.5  An overview of quinazolines and quinazoline-based hybrids of biological 
importance 
 
The 4-aminoquinazolines represent an important class of epidermal growth factor receptor 
tyrosine kinase phosphorylation inhibitors.45 This tyrosine kinase receptor is over expressed in 
several human tumours including lung cancer, prostate, breast and ovarian cancers46 and 
correlates with a poor prognosis in many cancer patients.47 Thus, EGFR has become an attractive 
target for the design and development of compounds that can specifically bind to the receptor 
and inhibit its tyrosine kinase (TK) activity and its signal transduction pathway in cancer cells. 
Gefitinib 22 shown in Figure 11 is an example of a 4-anilinoquinazoline derivative that has been 
found to selectively inhibit EGFR tyrosine kinase and to inhibit tumour pathogenesis, metastasis 
and angiogenesis, as well as promoting apoptosis.48 Lapatinib 23, on the other hand, is an 
example of a 6-heteroaryl substituted 4-anilinoquinazoline derivative that has been found to 
exhibit dual inhibitory activity against both EGFR and human epidermal growth factor receptor 
2 (HER2) in breast cancer cells and solid tumors.49 Likewise, 6-arylquinazoline-4-amine 24 has 
been found to inhibit Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-
regulated kinase 1A (Dyrk1A), which are protein kinases that are targets for the treatment of 
diseases caused by abnormal gene splicing.50 
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                           22                                                                    23                                                 
 
  
         24 
Figure 11: The 4-aminoquinazolines 22–24 with anticancer properties 
 
The indole-aminoquinazoline 11 and the indole ether-quinazoline, Cediranib 12, shown in Figure 
5 above are examples of indole-appended quinazolines (refer to Figure 5 above) in which the 
two moieties are linked by an oxygen or a nitrogen. Benzofuranyloxoquinazoline-ethyl-1H-
imidazolium chloride 25 shown in Figure 12, on the other hand, was found to exhibit significant 
antifungal activity against Candida albicans and also significant cytotoxicity against the breast 
cancer cell line, MCF7, with an IC50 value of 0.57 μM when compared to the chemotherapeutic 
drug, doxorubicin (IC50 = 3.62 μM) used as a reference standard in the assay.51 Moreover, 
molecular modelling studies of compound 25 against the enzyme aromatase, which is highly 
expressed in the MCF-7 cell line have revealed that compound 25 was well accommodated in 
the hydrophobic cavity and the 5,6-substituted methoxy groups interacted well with the protein 
residues around the pocket.51 
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                                                                            25                                                                              
Figure 12: Example of a benzofuran-appended quinazolinone 25 hybrids of biological 
importance  
 
We considered previous work from our group on the antiproliferative properties of the 2-
arylindoles52 and 4-aminoquinazolines53 in combination with the literature analysis on cytotoxic 
benzofurans30 and chalcones54 and decided to design and synthesize molecular hybrids 
comprising this five-membered heterocyclic scaffold merged with either the chalcone or 
quinazoline framework, respectively. To achieve this goal, we performed an extensive literature 
review on the methods developed to-date for the synthesis of the corresponding subunits and 
how to merge the benzo-fused 5-membered heterocycles with the chalcone or quinazoline 
scaffold. The methods for the synthesis of the benzo-fused 5-membered heterocycles containing 
one heteroatom, namely, indoles, benzofurans and their benzothiophene analogues are described 
in detail in the next sections 
 
1.6 Construction of benzo-fused 5-membered heterocycles containing one heteroatom in 
the ring 
 
Although there are several examples of benzo-fused five-membered heterocycles described in 
the literature the focus of this investigation is on the design and synthesis of indoles and 
benzofurans, which are discussed in detail in the next section. An overview of the methods for 
the synthesis of benzothiophene analogues will also be presented. The conventional and non-
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conventional methods for the synthesis of these structurally related five-membered heterocycles 
and their derivatives are described in sequence in the following sections. 
 
1.6.1 Methods for the synthesis of indole derivatives 
 
Examples of the classical methods for the synthesis of indoles include the Fischer indole 
synthesis from aryl hydrazones,55 the Madelung cyclization of N-acyl-o-toluidines56 in the 
presence of strong base. These conventional methods for the synthesis of indole derivatives form 
part of several review papers.55,56 Nonconventional methods which involve the use of transition 
metal as catalysts for C–C or C–N bond formation in the construction of the indole skeleton have 
also been developed. Since our interest is on the application of transition metals in the 
construction of the indole framework, we limit the discussion to these nonconventional methods 
and these are discussed in detail below. 
 
1.6.1.1 Transition metal-mediated methods for the synthesis of indoles 
 
Transition metal-based compounds continue to attract considerable attention in C‒C or C‒N 
bond formation and this approach has also been employed for the construction of indole 
framework. Methods which employ nitrostyrenes as substrates for the construction of indole 
derivatives in the presence of a reducing agent have been developed. Indoles 27, for example, 
have been prepared in 52–87% yield by reductive cyclization of o-nitrostyrenes 26 in the 
presence of a stoichiometric amount of aqueous TiCl3 (8.0 equiv.) dissolved in 2.0 N HCl in 
acetonitrile and/ or acetone as a solvent at room temperature (Scheme 1).57 The use of 1-(2'-
nitrophenyl)cyclopentene as a substrate under the same reaction conditions required an addition 
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of NH4OAc buffer solution to afford the corresponding indole. The absence of NH4OAc led to 
the corresponding aniline with no traces of indole. 
 
   26                                                          27 
Scheme 1: Reductive cyclization of 26 to afford 27. 
 
Palladium acetate (Pd(OAc)2) catalysed reaction of 2-bromoanilines 28 with vinylmagnesium 
bromide 29 in the presence of triphenylphosphine (PPh3) in THF at 0 ºC to reflux conditions 
afforded 2-vinyl-phenylamines 30 (Scheme 2).58 The latter were, in turn, cyclized in the presence 
of PdCl2 catalyst, stoichiometric amount of p-benzoquinone (3.2 equiv.) and LiCl (10.0 equiv.) 
in THF at room temperature to reflux to afford the corresponding indoles 31. 
  
 
 28              29                                      30                                            31 
Scheme 2: PdCl2-catalysed heterocyclization of 30 to afford 31. 
 
Larock developed a method for the synthesis of indoles, which involves the one-pot palladium 
catalyzed cross-coupling and subsequent heteroannulation of the o-haloanilines and internal 
alkynes to afford the 2,3-disubstituted indole derivatives.59 The outcome of the reaction depends 
on the type of palladium(0) catalyst source and the phosphine ligands used. The heteroannulation 
of 2-iodoaniline 32 with diphenylacetylene 33 in the presence of Pd(OAc)2 as a catalyst, sodium 
carbonate as a base and lithium chloride (LiCl) as an additive in DMF at 80 °C, for example, 
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afforded 2,3-diphenylindole 34 in 67% yield (Scheme 3).59 Poor yields of the product (15-28% 
yields) were observed when the temperature was increased to 120 °C in the presence or absence 
of LiCl as an additive. However, the use of phosphine-based palladium catalysts such as 
palladium dichlorobistriphenylphosphine PdCl2(PPh3)2 or palladium dichlorobis(benzonitrile) 
PdCl2(PhCN)2 under LiCl-free conditions at 120 °C resulted in increased yields (ca.73%) of the 
product. Improved yields in this case were attributed to the use of phosphine-based palladium 
catalysts. However, the use of homogenous Pd(0) catalyst sources and the ligands often make it 
difficult to separate the product from the reaction mixture. Reduced yields were observed when 
diphenylacetylene was used as a coupling partner in the absence of bulky ligands due to side 
products resulting from di- or oligomerisation.60 Modifications of the Larock synthesis that make 
use of heterogeneous palladium catalysts have since been developed to avoid the problem of 
isolation of the products from the homogenous catalysts and ligands. Pd/C, for example, was 
used as a catalyst in the presence of sodium carbonate (Na2CO3) as a base in DMF at 120 °C to 
promote the reaction of 2-iodoaniline 32 with internal alkyne 33. Under these reaction 
conditions, 2,3-diphenylindole 34 was isolated in 70% yield (Scheme 3).61 
 
                      32        33                                                 34  
Scheme 3: Larock heteroannulation of 32 with 33 to afford 34. 
 
A combination of Sonogashira cross-coupling and the Larock synthesis has also been employed 
before in the synthesis of the 2,3-disubstituted indole derivatives. Sonogashira cross coupling of 
butyne alcohols 35 with pyridine chlorides or bromides 36, for example, afforded the alkynes 
37, which were in turn, annulated with 2-bromoaniline in the presence of Pd(OAc)2-dppf 
complex and KHCO3 as a base in DMF at 110 °C to afford the desired indoles 38 (Scheme 4).
62 
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35                        36               37                                        38 
Reagents and conditions: (i) PdCl2(PPh3)2, CuI, NEt3; (ii) 2-bromoaniline, Pd(OAc)2, dppf, 
KHCO3, DMF, 110 °C 
Scheme 4: Sequential Sonogashira and Larock indole synthesis reactions. 
 
Methods that employ intramolecular Heck cross-coupling reactions of N-allyl-2-
halobenzenamines to construct the indole framework have been developed. For example, the 
intramolecular Heck cross-coupling reaction of allylated N-sulfonyl or N-tosyl 2-haloaniline 39 
in the presence of Pd(OAc)2 as a catalyst, NEt3 as a base and PPh3 as a ligand in anhydrous 
acetonitrile afforded the 3-methyl-N-substituted-1H-indoles 41 (Scheme 5).63 N-sulfonyl or N-
tosyl 2-haloanilines 40 were prepared independently by reacting 2-haloaniline 39 with allyl 
bromide in the presence of NaH in DMF. 
 
      39                               40                             41 
Scheme 5: Synthesis of indoles via intramolecular Heck cross coupling reaction. 
 
Copper-based catalysts have also been employed in the construction of carbon–heteroatom and 
carbon–carbon bonds and this strategy has also been extended to the construction of indole 
derivatives. Copper-catalyzed N-arylation/hydroamination of o-alkynyl bromoarenes 42 with 
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aniline derivatives 43a in the presence of tBuOK or with less nucleophilic amides 43b in the 
presence of K2CO3 as a base and N,N'-dimethyl-ethane-1,2-diamine ligand in toluene at 105 °C 
produced N-aryl-indoles 44a in 60‒84% yields or N-acylindoles 44b in 55‒71% yields as 
potential Chek1/KDR kinase inhibitors (Scheme 6).64 
         
42       43a                    43b    44a   44b 
Reagents and conditions: (i) tBuOK, toluene, 105 °C. (ii) K2CO3, N,N'-dimethyl-ethane-1,2-
diamine, in toluene, 105 °C 
Scheme 6: Copper-catalyzed N-arylation/hydroamination domino synthesis of indoles. 
 
In another example, a one-pot reaction of acyl chlorides 45 and Wittig reagents 46 in the presence 
of NEt3 in dichloromethane at room temperature (RT) afforded allenes 47 (Scheme 7).
65 These 
allenes were, in turn, reacted with 2-iodoanilines 48 in the presence of CuBr as catalyst and 8-
hydroxylquinolone as a ligand, K2CO3 as a base in 1,4-dioxane- hexane solvent mixture under 
reflux to give indoles 49 (EWG = -CO2Et, R = -CH3; EWG = -CO2Et, R = Et). The use of other 
ligands such as 1,10-phenanthroline, enaminone, and l-proline produced indole 49 in less than 
50% yield. A change of a catalyst to other copper(I) and copper(II) salts such Cu(OAc)2, CuI, 
and Cu2O led to poor yields. 
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            45   46        47          49  
Reagents and conditions: (i) NEt3, CH2Cl2, RT (ii) CuBr, K2CO3, 8-hydroxyl quinolone, 1,4-
dioxane, reflux. 
Scheme 7: Copper-catalysed one-pot tandem reactions toward the synthesis of indoles using 2-
iodoaniline, acyl chlorides, and Wittig reagents. 
 
The gem-dihalovinylanilines have also been found to undergo transition metal-catalysed 
reactions to form the indole framework. The Pd(OAc)2 catalysed tandem intramolecular C‒N 
coupling of gem-dihalovinylaniline 50a (X = Br) and intermolecular Suzuki cross-coupling with 
phenyl boronic acid in the presence of S-Phos as a ligand, K2CO3 as a base in toluene at 100 °C 
afforded 2-phenylindole 51a (Scheme 8).66 However, under the same reaction conditions, the use 
of 3-(2,2-dibromo-vinyl)-pyridin-2-ylamine 50b (X = Br) as a substrate failed to produce the 
analogous 7-azaindole 51b. This was presumably due to the hindering of the Pd-catalyzed C‒N 
coupling cycle of aminopyridines with free a amino group in the presence of monodentate 
phosphine ligand which forms an aryl palladium bis-amine complex and does not undergo 
reductive elimination.66 The introduction of a benzyl substituent on nitrogen of 3-(2,2-dihalo-
vinyl)-pyridin-2-ylamine (X = Br or Cl) afforded, under the same reaction conditions used to 
prepare 50a, N-benzyl 7-azaindole 50b in 74% (X = Br) and 90% (X = Cl). 
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       50a, b                                                         51: A = C (a); A = N (b) 
Scheme 8:  Tandem intramolecular C‒N coupling and intermolecular Suzuki-Miyaura cross-
coupling of gem-dihalovinylanilines with phenyl boronic acid. 
 
Transition metal-based catalysts have also been employed to promote the cyclization of 2-
alkynylaniline derivatives to afford indole derivatives. The 2-alkynylaniline derivatives are 
easily synthesized via Sonogashira cross-coupling of 2-haloanilines with terminal alkynes in the 
presence of Pd(0)-Cu(I) catalyst mixture. 2-Phenylethynylaniline 53, for example, was prepared 
via PdCl2(PPh)3-CuI catalyzed Sonogashira cross-coupling of 2-haloanilines 52 with 
phenylacetylene in the presence of NEt3 as a base in tetrahydrofuran (THF) at room temperature 
and then subjected to one-pot Sodium tetrachloroaurate(III) dihydrate (NaAuCl4·2H2O) 
promoted cyclization in ethanol at RT to afford phenylindole 54 (Scheme 9).67 Further 
halogenation of 54 with either N-bromosuccinimide (NBS) in ethanol at room temperature or 
molecular iodine in the presence of potassium hydroxide in ethanol at room temperature afforded 
halogeno-phenylindoles 55a and 55b, respectively. 
 
   52: X = Cl, Br, I  53   54   55: X = Br (a);  
      X = I (b) 
Reagents and conditions: (i) Phenylacetylene, CuI, NEt3, PdCl2(PPh3)2, THF, RT (ii) EtOH, 
NaAuCl4∙2H2O, RT (iii) NBS, EtOH, RT; or I2, KOH, EtOH, RT 
Scheme 9: Synthesis of halo-indoles through cyclization of 2-alkynylaniline. 
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The 2-alkynylanilines 56 were cyclised in the presence of 1,3-bis(2,6-diisopropylphenyl-
imidazol-2-ylidene)gold(I) chloride (lPrAuCl) as a catalyst, silver tetrafluoroborate (AgBF4) as 
an additive in hexane at 40 °C to afford indoles 57 (X = H, Br, 5,7-dimethyl-; R = H, CH3, benzyl; 
R′ = n-hexyl-, Ph) in 81‒97% yields (Scheme 10).68 The starting material was recovered 
unchanged when 2-(hex-1-yn-1-yl)quinolin-8-aniline or 2-alkynylaniline with trimethylsilyl 
substituent on acetylene group were employed as substrates. 
 
    56                                       57 
Scheme 10: lPrAuCl-catalysed cyclization of 56 to afford 57. 
 
A one-pot Sonogashira cross-coupling of N-substituted 2-iodoanilines 58 with phenylacetylenes 
59 in the presence of 10% Pd/C-ZnCl2 catalyst complex, NEt3 as a base and PPh3 as a ligand in 
DMF at 110 °C afforded 2-alkynylanilines 60 in situ, followed by cyclization of the incipient 2-
alkynylanilines to afforded the 2,5-disubstituted indoles 61 (R1 = H, CH3; R2 = -C6H5, 4-
MeOC6H4-) (Scheme 11).
69 The use of anhydrous ZnCl2 led to homocoupling to afford diynes as 
the predominant products. The authors argued that the released hydroxyl group from moist ZnCl2 
facilitates generation of zinc acetylide in situ which, in turn, undergoes annulation with N-
substituted 2-iodoanilines. This observation was further confirmed using NaOH or KOH as bases 
in the presence of anhydrous ZnCl2, which afforded the desired indoles in appreciable yields. 
     
58        59                                              60                          61 
Scheme 11: Synthesis of 2-substituted indoles through annulation promoted by catalytic ZnCl2. 
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2-Alkynylanilines have also been found to undergo halocyclization in the presence of a base to 
afford 3-haloindole derivatives.70-71 Iodine-promoted cyclization of 2-alkynylanilines 62 (R = 2-
HO-C6H4, 2-MeOC6H4), for example, afforded 3-substituted indoles 63 in 70–80% (Scheme 
12).71 
 
                           62                                                                   63 
Scheme 12: I2-promoted cyclization of 62 to form 63. 
 
In another approach the 2-alkynylanilines bearing electron donating groups on nitrogen have 
been found to undergo halocyclization with ease to afford the 3-haloindole derivatives in high 
yields.71,72  For example, 3-iodoindoles 66 (R1 = H, NO2, CH3, OCH3, CO2Et; R2 = Ph, hex-1-
ene, SiMe3, t-Bu) were prepared via iodocyclization of N,N-diamethyl-o-(1-alkynyl)anilines 65 
in dichloromethane at room temperature (Scheme 13).72 2-(1-Alkynyl)anilines 64 were, in turn, 
prepared by PdCl2(PPh3)2-CuI catalyzed Sonogashira cross-coupling of the corresponding N,N-
diamethyl-o-iodoanilines 64 with terminal alkynes in NEt3 at room temperature. The yields of 
66 were found to be dependent on the substituents on the alkynyl group and aniline moiety of 
65. High yields (85‒100%) were obtained with 65 bearing phenyl or vinyl groups that were 
involved in conjugative effect with the triple bond. However, no indole was isolated when 65 
was substituted with a bulky trimethylsilyl group on the acetylene moiety. Substituents on the 
para position of the phenyl ring relative to the amino group such as the strong electron 
withdrawing nitro or ester group or a weak electron donating methyl group were found to 
enhance iodocyclization and to afford the corresponding 3-iodoindoles in high yields (84‒100%) 
in 30 min. Derivatives substituted with a strong electron donating methoxy group meta to the 
amino group required 2 h to afford the corresponding 3-iodoindoles in 84‒100%. 
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                         64      65         66 
Reagents and conditions: HC≡CR2, PdCl2(PPh3)2, CuI, NEt3, RT, I2, K2CO3, CH3CN 
Scheme 13: I2-promoted cyclization of 65. 
 
Benzo[b]furan is another class of five-membered benzo-fused heterocycles characterised by 
the presence of an oxygen atom in the ring instead of a nitrogen atom found in the analogous 
indoles. The development of general and efficient methods for preparation of functionalized 
benzo[b]furan from simple and easily accessible starting materials remains an active research 
field. A selection of some of the reported synthetic approaches for the construction of the 
benzo[b]furan core will be discussed in the following section. 
 
1.6.2 Methods for the synthesis of benzofuran derivatives 
 
There are several methods available for the synthesis of the 2-arylbenzo[b]furans and the most 
common approaches focus on the annulation of the furan ring on the benzene ring. 2-Alkoxyaryl 
aldehydes or ketones were reported to undergo base-mediated intramolecular cyclization to 
afford the corresponding 2-aryl 3-unsubstituted (in the case of aldehydes) or 2-aryl 3-substituted 
(in the case of ketones) benzo[b]furans.73 Substituted 2-arylbenzo[b]furans 68, for an example, 
were prepared via a ring closure of 2-alkoxyketones 67 in ethanol using KOH as a base under 
reflux for 3 h (Scheme 14).73 These type of intramolecular condensation reactions, use strong 
alkali metal bases (NaOH, KOH, NaOEt, KOtBu) in dipolar aprotic solvents, and under these 
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conditions cyclization only works for compounds containing highly electron withdrawing 
substituents on the aryl ring of the benzyl moiety to stablilize the intermediate benzylic anion. 
 
                                     67                                                                         68 
Scheme 14: Base mediated cyclization of 2-arylalkoxy ketones 67. 
 
Hellwinkel et al.,74 previously reacted benzyl phenyl ester 69 containing an ortho-acetyl group 
and an electron withdrawing group on the benzylphenyl ring with cesium fluoride aluminium 
oxide (CsF-Al2O3) base system in DMF at 150 °C to afford the 2-(4-nitrophenyl)-substituted 
benzo[b]furans 70 in 57–74% yield (Scheme 15). The presence of a strong electron-withdrawing 
nitro group activates the methyl group and facilitates deprotonation by a base. 
 
                         69                                                                                        70 
Scheme 15: CsF-Al2O3 mediated cyclization of 2-arylalkoxy ketone 69. 
 
Methods which employ O-aryloximes as substrates for the construction of benzo[b]furan 
derivatives in the presence of an acid have also been developed. These methods are analogous 
to the Fischer indole synthesis and have been extended to the synthesis of benzo[b]furan. The 
sequential [3,3]-sigmatropic rearrangement and condensation between N-3 and C-2 of the O-
aryloxime 71 is easily achieved using oxidants such as hydrochloric,75 sulphuric acid,76 formic 
acid,77 phosphoric acid,78 boron trifluoride etherate79 and phosphorylchloride/DMF80 mixture to 
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yield the benzo[b]furan. The O-aryloximes 71, for example, were reacted with H2SO4 in the 
presence of ethanol at 80 °C to afford the corresponding substituted-benzo[b]furan 72 in 81–
90% yield (Scheme 16).76 The reaction was found to be more rapid and to be complete within 
2.5–6 h with O-aryloximes bearing electron-withdrawing groups and to be relatively slow (18 h 
to completion) with unsubstituted derivatives. 
 
                                                    71                                         72 
Scheme 16: Sequential [3,3]-sigmatropic rearrangement and condensation of O-aryloxime 71 to 
lead to substituted-benzo[b]furan 72. 
 
In the case of allyl arylethers the reaction for benzo[b]furan proceeds via sequential Claisen 
rearrangement followed by an acid or metal mediated oxidative cyclization.81 A series of 
benzo[b]furans 74 were prepared via hydrochloric acid catalysed cyclization of allyl aryl ethers 
73 under reflux for 4–8 h in 51–77 % yield (Scheme 17).81 
 
                                            73                                                      74 
Scheme 17: Acid promoted oxidative cyclization of allylaryl ether 73 to afford benzo[b]furan 
74. 
 
The aryl propargyl ethers 75 have previously been reacted with cesium fluoride in diethyl aniline 
under reflux to afford benzo[b]furan derivatives 76 (Scheme 18).82 The thermal rearrangement 
of the aryl propargyl ethers 75 containing electron withdrawing groups has been found to afford 
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2-methyl benzo[b]furan 76, whilst aryl propargyl ethers containing electron donating groups 
yielded 2-H-benzopyrans or 2-H-chromenes.82 
 
                                          75                                                         76 
Scheme 18: Base promoted oxidative cyclization of propargyl ethers 75 to afford benzo[b]furans 
76. 
 
Phenols and β-ketosulfoxides have also been employed as substrates in the synthesis of 
substituted-benzo[b]furan derivatives. One-pot reaction of phenols 77 with β-ketosulfoxides 78 
in the presence of para-toluenesulphonic acid (p-TSA) in dichloroethane (DCE) under reflux for 
1 h afforded benzo[b]furans 79 in 65–71% yield (Scheme 19).83 The reaction takes place via the 
Pummerer-type rearrangement. The transformation proceeds via intermolecular nucleophilic 
attack of the aromatic ring on the 1-acyl-1-thiocarbocation derived from the β-ketosulfoxides 78 
in the presence of PTSA and successive dehydrocyclization to afford 79.83 
   
    77                          78                                                      79 
Scheme 19: Synthesis of benzo[b]furans 79 from phenols 77 and β-ketosulfoxides 78. 
 
The gem-dihalovinylphenols have also been found to undergo base promoted reactions to form 
benzo[b]furans framework. For example, NaH-catalysed intramolecular C‒O cyclization of gem-
dihalovinylphenol 80 (X = Br) in DMF at 60 °C for 2 h afforded 2-bromobenzo[b]furans 81 in 
99% yield (Scheme 20).84 
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                                                80                                                   81 
Scheme 20: Base-mediated intramolecular cyclization of gem-dihalovinylphenols to afford 2-
bromobenzo[b]furans.  
 
When considering routes based on metal mediated reactions, the most common approach for the 
synthesis of benzofurans based on benzenoids involves the intramolecular addition of the 
phenolic moiety to a C–C triple bond in a 2-alkynylphenol. The most employed strategies to 
carry out this heterocyclization turn to transition metal catalysis and catalytic systems based on 
palladium, copper or a combination of both. Palladium catalyzed Sonogashira cross-coupling 
reaction of 2-iodophenol with terminal acetylenes has been employed for the synthesis of 
benzo[b]furan 84. 2-Iodophenol 82 and benzyl acetylene 83, for example, were reacted in the 
presence of palladium acetate bis(triphenylphosphine)[Pd(OAc)2(PPh3)2], copper iodide and 
piperidine in dimethylformamide (DMF) at 60 °C to afford the substituted-benzo[b]furan product 
in 61–71% yield (Scheme 21).85  
 
                82                          83                                                                            84 
Scheme 21: Sonogashira cross-coupling reaction of iodophenols 82 with terminal acetylenes. 
 
Liang and coworkers, on the other hand, employed palladium bromide as a catalyst to selectively 
annulate the alkynylphenols.86 A simple and one-pot synthesis of 2-substituted 3-
halobenzo[b]furans 86 as major product has been achieved through annulation of 2- 
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alkynylphenols 85 with PdBr2-CuBr catalyst system and HEt3NBr as a base in DCE at room 
temperature for 8–16 h (Scheme 22).86 
 
                                     85                                                                      86 
Scheme 22: Palladium-Catalyzed annulations of 2-alkynylphenols to form 2-Substituted 3-
halobenzo[b]furans. 
 
There is an increasing interest in the use of copper metal as a catalyst source in the synthesis of 
novel heterocycles. Substituted benzo[b]furans 89, for an example, were prepared in 62–89% 
yield in a single-pot operation via copper(I) bromide catalyzed reaction of 2-alkynylphenol 87 
and N-tosylhydrazones 88 using lithium tert butoxide in dioxane at room temperature for 3 h 
(Scheme 23).87 
 
                    87                               88                                        89 
Scheme 23: Copper-catalyzed heteroannulation of hydrazone 88 with 2-alkynylphenols 87. 
 
Another copper-catalyzed approach involves the combination of 5 mol % Cu(OTf)2 and CuCl in 
the presence of 4-dimethylaminopyridine (DMAP) to effectively catalyzed a three-component 
coupling reaction involving an alkynylsilane 91, an o-hydroxybenzaldehyde derivative 90, and 
a secondary amine 92 to afford substituted benzofuran 93 in 61–95% yield (Scheme 24).88 The 
reaction proceeded via intramolecular 5-exo-dig cyclization, resulting in direct synthesis of the 
corresponding benzofuran derivatives in moderate to excellent yields. 
 29 
 
 
         90     91                 92                                                                            93 
Scheme 24: Copper-catalyzed synthesis of substituted-benzofuran 93. 
 
1.6.3  Methods for the synthesis of benzothiophene derivatives  
 
Several approaches for the construction of benzothiophene nucleus have been developed. The 
most common approach towards synthesis of benzothiophenes makes use of intramolecular 
condensation reactions. The industrial synthesis of Raloxifene 95, for example, uses a 
polyphosphoric acid-catalyzed domino cyclization rearrangement reaction of the ketosulfide 94 
to form the  2-arylbenzothiophene 95  (Scheme 25).89
 
                               
 
                94                                                          95 
Scheme 25: PPA-promoted cyclization of 94 to afford 95. 
 
Another approach for the synthesis of benzothiophenes utilizes the Knoevenagel condensation of 
an S-benzyl ortho-acylthiophenol generated in situ from the base mediated reaction of ortho-
haloketone 96 with benzyl mercaptans 97 in DMF to yield the required 2-arylbenzo[b]thiophene 
derivatives 98 (Scheme 26).90 
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       96    97                                                               98 
Scheme 26: K2CO3-promoted cyclization of 96 to afford 98. 
 
Cabiddu et al.91 previously used anionic cyclization method for the construction of the 
benzo[b]thiophenes 102 (Scheme 27). A series of benzo[b]thiophenes 102, for example, was 
synthesized from the treatment of 4-thioanisole 99 with butyllithium using 
tetramethylethylenediamine (TMEDA) in hexane at 40–58 °C, followed by carboxylation 
with methylchlorocarbonate in diethyl ether at -80 °C to afford the diester 101 in 71% yield. 
Ring closure of the resultant diester 101 in the presence of lithium diisopropylamide (LDA) 
in THF at -80 °C gave the target compound 102 in 75 % yield (Scheme 27). 
 
       99                          100                                        101                                102 
Reagents and conditions: (i) BuLi, TMEDA, hexane, 40–58 °C, 2 h; ClCO2CH3, Et2O, at -
80 °C, 2 h; (ii) LDA, THF, -80 °C, 2 h 
Scheme 27: Synthesis of benzo[b]thiophene 102 via anionic cyclization method. 
 
The Gewald reaction is another known method employed for the preparation of 
benzo[b]thiophene derivatives.92 It is a common protocol employed for the preparation of 2-
aminobenzothiophene but can also be modified to synthesize the 3-amino regioisomers. Beck 
and Yahner, for example, previously applied the modified approach to the synthesis of 3-
aminobenzo[b]thiophene-2-carboxylate 105 (Scheme 28).93 This was achieved by the reaction 
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of nitrobenzonitrile 103 with sodium sulphide, followed by alkylation with appropriate 
chloromethylene derivatives to form intermediate 104 and subsequent ring closure in DMF at 0 
°C. 
 
103                                                    104            105 
Scheme 28: Synthesis of benzo[b]thiophene derivatives 105 by Gewald reaction. 
 
The benzo[b]thiophene derivatives 108 have also been synthesized via intramolecular Wittig 
reaction. Syu et al.,94 for example, previously reacted 106 with carbonyl chlorides in the presence 
of organophosphorus and a base under reflux to form an ylide 107, which cyclizes spontaneously 
to afford compound 108 (Scheme 29). 
 
               106                                    107          108 
Scheme 29: Intramolecular Wittig reaction of 106 and acid chlorides to yield 108. 
 
The electrophilic-mediated cyclization and the metal-catalyzed cyclizations of alkynes are the 
most common among the numerous methods available in the literature for the synthesis of 
benzo[b]thiophenes. Nakamura et al.,95 recently subjected the S-substituted ortho-
alkynylthiophenol 109 to 2 mol% a Gold(I) catalyst in toluene at room temperature to afford the 
2,3-disubstituted benzothiophene derivatives 110 (Scheme 30). The reaction proceeds via the 
formation of the sulfonium intermediate, followed by the 1,3-migration of the substituent on 
sulphur. 
 32 
 
 
                                           109                                                           110 
Scheme 30: Nakamura’s gold-catalyzed cyclization of alkynyl thiophenols 109. 
 
The Grignard reaction of the ketothiophenols 111 with alkynes 112 in the presence of THF 
at 50 °C followed by palladium-mediated cyclization and subsequent dehydration of the 
intermediate 113  afforded the corresponding benzo[b]thiophenes 114 in 52–82% yield 
(Scheme 31).96 
 
          111                    112                                   113                                         114 
Reagents and conditions: (i) THF, 50 °C, 2h; (ii) PdI2, KI, CH3CN, 80-100 °C, 5-15 h 
Scheme 31: Synthesis of benzo[b]thiophene 114 by Palladium catalysed cyclocondensation 
reaction. 
 
Larock and Yue developed an alternative method to the transition metal-mediated cyclization of 
the alkynyl intermediates, which involves the use of an electrophilic halogen species to promote 
the halocyclization to afford the 2-substituted 3-halobenzo[b]thiophenes.97 Intermediates 117 
substituted with an alkynyl group adjacent or ortho to the nucleophilic heteroatom undergo 
halocyclization in the presence of an electrophilic halogen source (eg., NBS, I2, ICl) to afford 
the 3-halobenzothiophene derivatives 118 in high 94–100% yields (Scheme 32). Compounds 
117 were, in turn, prepared via Sonogashira cross-coupling of 115 with terminal acetylenes 116. 
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The halocyclization step works well for bromo- and iodocyclization but is not applicable for the 
synthesis of the analogous 3-chloro- and 4-fluoro substituted derivatives. 
 
                    115     116      117    118 
Reagents and conditions: (i) PdCl2(PPh3)2 (2 mol%), CuI (1 mol%), NEt3, 25 °C, 6 h; (ii) E
+ (I2 
or NBS), DCM, 25 °C, 10 min  
Scheme 32: Synthesis of benzo[b]thiophenes 118 via electrophilic cyclization. 
 
Lu and Wu have since developed an alternative approach for the synthesis of the 3-
chlorobenzo[b]thiophenes.98 Thioanisole 119 was subjected to cupric chloride in acetonitrile 
under reflux for 2.5 h to afford 3-chloro-2-phenylthiophene 120 (Scheme 33). The bromo 
analogue was prepared under similar reaction conditions using cupric bromide. Attempted 
fluorocyclization failed to yield 3-fluorobenzo[b]thiophene when cupric fluoride was used as a 
source of electrophilic fluorine. 
 
                                      119                                                               120 
Scheme 33: Synthesis of 3-chlorobenzo[b]thiophene 120. 
 
Apart from cyclization methods, benzo[b]thiophene derivatives can also be prepared from 
rearrangement reactions of six-membered rings. An example is the ring contraction of 
thiochroman previously developed by Cozzi and Pillan (Scheme 34).99 Thiochromanone 121 was 
first converted with ethylene glycol 122 into the corresponding ketal 123, which rearranged in 
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the presence of imidazole 124 at high temperature to yield benzo[b]thiophane derivative 125. 
Cleavage of the ketal moiety in the presence of PTSA afforded a 2,3-disubstituted 
benzo[b]thiophene 126. 
Reagents and conditions: (i) PTSA, benzene, reflux, 24 h; (ii) DMF, 120 °C, 6 h; (iii) 2-butanone, 
reflux, 3h 
Scheme 34: Synthesis of benzo[b]thiophene 126 by ring rearrangement. 
 
1.7 Methods for the synthesis of chalcones 
 
Chalcones are characterised by the presence of an α,β-unsaturated enone moiety attached to two 
aryl rings A and B (Scheme 35) and they belong to the naturally occurring flavonoid family. 
Several methods for the construction of chalcones have been reported in the literature. Claisen-
Schmidt condensation100,101 of acetophenones and aldehydes under aqueous basic or acidic 
conditions still stands as the most popular method for the synthesis of chalcones. Non-
conventional methods which involve the use of transition metal as catalysts for C–C bond 
formation in the construction of the chalcone skeleton have also been developed. Examples 
include the Suzuki using aryl boronic acids102 and Heck cross-coupling.103 In the traditional 
Claisen-Schmidt condensation, acetophenones and benzaldehyde derivatives are reacted in the 
 35 
 
presence of a base as a catalyst in an appropriate solvent to afford the chalcone derivative.100 
Different inorganic and organic bases have been employed as catalysts for the Claisen-Schmidt 
condensation under both homogeneous54 and heterogeneous100 conditions. Among the inorganic 
bases, hydroxides of alkali and alkaline earth metals such as NaOH, KOH, Ba(OH)2, LiOH, etc. 
continue to be employed to facilitate this reaction. Acetophenone 127 and aldehyde 128, for 
example, were condensed in the presence of sodium hydroxide (NaOH) in methanol at room 
temperature to afford the substituted chalcones 130 in more than 80% yield (Scheme 35).104 The 
base catalyzed Claisen-Schmidt condensation proceeds via the formation of an enolate ion from 
the ketone which then attacks the electrophilic aldehyde to form the β-hydroxyketone 129. The 
latter undergoes dehydration spontaneously to afford a fully conjugated and more stable α,β-
unsaturated chalcone as product.  
 
                                                                                                                    130 
Scheme 35: Synthesis of substituted-chalcone 130 by Claisen-Schmidt condensation. 
 
Solvent free conditions have also been applied for the synthesis of chalcones. Rateb et al.105 
developed a grinding method, which utilizes NaOH as a catalyst under solvent free conditions to 
condense 127 and 128 to yield the substituted chalcones 130 in 80–90 % yield. The grinding 
 127                       128                                                                        129      
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process in this case increases the surface area to facilitate the reaction. The product was isolated 
by aqueous work-up and recrystallization. Bases such as LiOH.H2O,
54 Ba(OH)2.8H2O,
54 and Mg-
Al-OtBu hydrotalcite107 were also utilized for the synthesis of chalcones under homogeneous 
conditions. Quantitative yields were obtainable when the aromatic rings of the aldehyde and the 
acetophenone contained no hydroxyl group except in the ortho position.101 However, in the case 
of the 2-hydroxyacetophenones there is strong intramolecular hydrogen bonding between the 
hydroxyl group and the carbonyl oxygen, which masks the polarities in the molecule and make 
them not available for intermolecular hydrogen bonding. There is an increasing interest in the 
use of organic bases for the synthesis of chalcones. Chalcone derivatives 133, for example, were 
prepared via piperidine catalyzed reaction of 3-acetyl substituted-chromen-2-ones 131 with 
aldehydes 132 in chloroform at 80 °C for 3 h in 71–81% yields (Scheme 36).108 
 
    131    132                               133 
Scheme 36: Piperidine catalyzed synthesis of coumarinyl chalcones 133. 
 
Claisen-Schmidt condensation of substituted acetophenones with aldehydes has previously been 
effected using various acids to afford the substituted chalcones. Sulphuric acid, for example, has 
been widely used as a reagent for the synthesis of heterocyclic compounds including substituted 
chalcones. Kim et al.109 used H2SO4 to catalyze the reaction of acetophenone 134 and aromatic 
aldehydes 135 in the presence of methanol to afford the corresponding chalcones 137 (Scheme 
37). The acid catalysed version of Claisen-Schmidt condensation proceeds through the formation 
of an enol, which then attacks the protonated aldehyde to yield the addition product 136. This is 
followed by elimination of a water molecule to give the product chalcone. When screened against 
HEK-293 cells, the substituted chalcone derivatives were found to activate and inhibit the 
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TREK2 channel.109 The advantage of the Claisen-Schmidt condensation via enol mode over the 
enolate mode is that, it can be directly applied for the synthesis of hydroxychalcones without 
prior protection of the hydroxy group.100 
 
                                                                                                              137 
 Scheme 37:  Sulphuric acid catalyzed Claisen-Schmidt condensation. 
 
Claisen-Schmidt condensation of acetophenones with aldehydes has also been effected using 
various Lewis acid catalysts to afford substituted chalcone derivatives.54 Narender et al.,110 used 
BF3-Et2O as a catalyst to promote the condensation of 138 with aldehyde derivatives 139 in 
dioxane at room temperature to afford the substituted chalcones 140 (Scheme 38). Wang et al.111 
on the other hand, used 10% iodine as catalyst to afford the substituted chalcones 140 in 83–95% 
under solvent free and grinding conditions. 
 
 
  
    134                                    135                                                            136 
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                138                         139                                                     140 
Reagents and conditions: (i) BF3-Et2O, dioxane, RT, 24 h; (ii) I2 (10 mol%), grinding, RT, 30 
min. 
Scheme 38: Lewis acid mediated synthesis of substituted-chalcones 140. 
 
Transition metal-based compounds continue to attract considerable attention in C‒C bond 
formation and this approach has also been employed for the construction of chalcones. Examples 
of these methods include Suzuki cross coupling of haloarenes with arylboronic acid and Heck 
cross-coupling of aryl vinyl ketones and aryl halides.54 Palladium-catalyzed Suzuki cross 
coupling of haloarenes with arylboronic acid is among the most powerful C–C bond formation 
reactions available to synthetic organic chemists. Like in many other organic syntheses, 
palladium catalysed cross coupling reactions find their application in chalcone synthesis. Eddarir 
et al.112 developed a method for the synthesis of chalcones based on the Suzuki reaction either 
between cinnamoyl chlorides and phenylboronic acids or between benzoyl chlorides and 
phenylvinylboronic acids (Scheme 39). Synthesis of chalcones 143 via Suzuki reaction involves 
the coupling of benzoyl chloride 141 and phenylvinylboronic acid 142 in the presence of cesium 
carbonate solution as base and anhydrous toluene as solvent.112 The reaction is not affected by 
substituents located either on the acyl chloride or on the boronic acid. 
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                 141                     142                                                                               143 
Scheme 39: Chalcone synthesis via Suzuki coupling. 
 
Al-Masum and co-workers developed a method for the direct cross-coupling reaction of benzoyl 
chlorides 145 and potassium styryltrifluoroborates 144 to the corresponding α,β-unsaturated 
aromatic ketones 146 in the presence of PdCl2(d
tbpf) catalyst under microwave irradiation. This 
method was used for the synthesis of chalcones with a variety of substituents (Scheme 40).113 
  
      144                              145                                                                                146 
Scheme 40: Palladium catalysed Suzuki cross-coupling for the synthesis of chalcones 146. 
 
Methods that employ Heck cross-coupling reactions of aryl vinyl ketone and aryl iodides to 
construct chalcones have also been developed.103 For an example, the Heck cross-coupling 
reaction of substituted aryl vinyl ketone 147 and aryl iodide 148 in the presence of Pd(OAc)2 as 
a catalyst, NEt3 as a base and PPh3 as a ligand in anhydrous acetonitrile afforded the substituted 
chalcone 149 95-96 % yield (Scheme 41).114 
 
              147      148               149  
Scheme 41: Synthesis of chalcones 149 via intramolecular Heck cross coupling reaction. 
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Meagawa and co-workers recently described a palladium catalysed direct synthesis of chalcones 
from anilides with phenyl vinyl ketones by Oxidative Coupling through C−H Bond activation.115 
The reaction of substituted-anilides 150 and phenyl vinyl ketone 151 using palladium 
trifluoroacetate (Pd(OCOCF3)2 (20%) and copper acetate (Cu(OAc)2 (20%) in dichloromethane 
at 50 ℃ for 24 h under oxygen atmosphere afforded 2-aminochalcones 152 in 51–79 % yields 
(Scheme 42). Selective palladium C−H bond activation occurred at the position ortho to the 
acetamide group to allow the double bond insertion to afford 2-aminochalcone derivatives. 
 
            150                             151                                          152 
Reagents and conditions: (i) Pd(OCOCF3)2 (20%), Cu(OAc)2 (20%), CH2Cl2, 50 ℃, O2, 0.5 M, 
24 h. 
Scheme 42: Synthesis of chalcones 152 via palladium-mediated C-H bond activation. 
 
Chalcones are recognized as a privileged scaffold because they can be synthetically modified  to 
incorporate different molecules or pharmacophores with various biological activities. Indole- 
and benzofuran-appended chalcone hybrids have gained great interest due to their enhanced 
biological and photophysical properties. The synthesis of these hybrids or conjugations typically 
uses the classical condensation or the synthesis methods discussed in the above section to build 
the chalcone core. In addition to the biological activities for multi-targeting mechanisms, hybrid 
molecules are also selected for other reasons, such as improving the solubility and oral 
bioavailability. The methods for the synthesis of the indole- and benzofuran-appended chalcone 
hybrids is discussed in the next section. 
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1.8 Methods for the synthesis of indole- and benzofuran-appended chalcones 
 
Sashidhara et al.116 previously synthesized the indole-chalcones 156 by subjecting the 
commercially available substituted indoles 153 to Vilsmeier-Haack reaction conditions in 
presence of the POCl3 and DMF at 0 ℃ to afford the corresponding indole-3-carbaldehydes 154. 
The subsequent Claisen-Schmidt condensation of the indole-3-carbaldehydes 154 with the 
acetophenone 155 in the presence of catalytic amount of piperidine in MeOH or EtOH under 
reflux conditions yielded the desired indole-chalcone 156 in 75–82%, and the trans isomer was 
obtained exclusively (Scheme 43). The indole-chalcones 156 were found to exhibit in vitro 
antioxidant and significant in vivo antidyslipidemic ativities.116 
 
Scheme 43: Synthesis of indole-chalcones 156. 
 
In another example, Jain et al.117 reacted indole 157 with acetylchloride in chloroform at 0 ℃ to 
generate the 3-acetylindole 158 followed by condensation with aldehydes 159 in the presence 
NaOH as a catalyst in methanol to afford the indole-chalcones 160 (Scheme 44). These indole-
chalcones 160 were found to show promising antibacterial and antifungal activities.117 
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     157                                                  158                                                       160 
Scheme 44: Synthesis of indole-chalcones 160. 
 
Another type of indole-chalcones where α,β-unsaturated ketone group is at the C-5 have been 
previously synthesized from indole-5-carbaldehyde.118 The key step in the synthesis is also the 
base-catalyzed Claisen condensation reaction. Compounds 163 were obtained from the reaction 
of substituted acetophenones 162 and 1H-indole-5-carbaldehyde 161 in the presence of sodium 
methoxide catalyst (28%) in ethanol at room temperature in 58–60% yield (Scheme 45). These 
indole-chalcones were used as β-amyloid imaging probes for detecting Alzheimer’s disease 
(AD), targeting Aβ1−42 aggregates with high affinity (Ki = 1.97 nM).118 
 
                      161                      162                                                                  163 
Scheme 45: Synthesis of indole-chalcones 163. 
 
A series of benzofuran-chalcones 168 have been obtained by the reaction of substituted 
salicylaldehyde 164 derivatives with chloroacetone 165 using K2CO3 as a base to afford the 2-
acetylbenzofuran 166 (Scheme 46). Base mediated Claisen-Schmidt reaction of the 2-
acetylbenzofuran 166 with different aromatic aldehydes 167 gave substituted benzofuran-
chalcone derivatives 168 (Scheme 46).40 The compounds exhibited the highest activity against 
tumor cell growth (IC50 < 1 μM) and 10−100-fold increases in potency. The mechanism of action 
159 
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has only been preliminarily studied, and the compounds appear to induce apoptosis mediated by 
the involvement of the mitochondria and the activation of caspase-3 and 7.40  
 
Reagents and conditions: (i) K2CO3, dry acetone; (ii) piperidine, n-BuOH, MW, 150 °C, 30 min. 
Scheme 46: Synthesis of benzofuranchalcones 168. 
 
Sashidhara and co-workers developed a method for the synthesis of 5-substituted benzofuran-
chalcone hybrids 171 starting from the dicarbaldehyde derivative 169.39 The Rap-Stoermer 
condensation of compound 169 with various phenacyl bromides in the presence of potassium 
carbonate gave the benzofuran carbaldehyde derivatives 170 in quantitative yields. Introduction 
of the chalcone scaffold was carried out by the reaction of 170 with various acetophenones in 
methanolic potassium hydroxide at room temperature to yield the final benzofuran-chalcone 
hybrids 171 (Scheme 45). These compounds 171 were found to decrease acetylcholinesterase 
(AChE) levels, reduce oxidative stress in the transgenic Caenorhabditis elegans worms, lower 
lipid content, and to provide protection against chemically induced cholinergic 
neurodegeneration.39 
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169    170           171 
Reagents and conditions: (i) phenacyl bromide derivatives, K2CO3, CH3CN, 110 ℃, 3 h;  
(ii) R2COCH3, KOH (10% in MeOH), 3 h, RT 
Scheme 47: Synthesis of benzofuranchalcones 171. 
 
The use of transition metal-catalyzed C–H bond activation as an efficient method for the 
synthesis of novel heterocycles has also been applied to the synthesis of indole-chalcones. The 
analogous indole-chalcone derivative 174, for example, was prepared in 97% yield via 
palladium(II)-catalyzed intermolecular C-3 alkenylation of indoles 172 with alkenes 173 with 
TFA in DMSO under reflux in an O2 atmosphere (Scheme 48).
119 
 
       172                     173                                                                    174 
Scheme 48: Synthesis of indole-chalcones via the palladium-catalyzed intermolecular direct C-
3 alkenylation of indoles. 
 
We could not find in the literature examples of benzofuran- or indole-chalcones in which the 
α,β-unsaturated moiety is linked directly to the fused benzo ring through the carbonyl carbon to 
generate linear or angular heterocycle-appended chalcone derivatives. The α,β-unsaturated 
carbonyl system of chalcones possesses two electrophilic centers, which allows this moiety to 
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participate in nucleophilic reactions via nucleophilic attack to the carbonyl group (1,2-addition) 
or to the β-carbon (1,4-conjugate addition). The chalcone framework also constitutes a useful 
scaffold for the reaction with binucleophilic reagents to append 5-, 6- and 7-membered nitrogen-
containing heterocycles such as pyrazoles, tetrazoles, imidazoles, isoxazoles and 
benzothiezapines onto the α,β-unsaturated arm.120 The methods for the reactions of chalcones 
with binucleophiles to form 5-, 6- and 7-membered nitrogen-containing heterocycles are 
described briefly below. 
 
1.9 Chalcone moiety as scaffold for heteroannulation with binucleophiles to afford 5- , 6- 
and 7-membered heterocyclic derivatives 
 
The reaction of this α,β-unsaturated carbonyl framework with ambident heteroatom-based 
nucleophiles such as hydroxylamine,120 hydrazine derivatives,121-123 1,2-alkyl/aryldiamines120 or 
1,3-alkyldiamines124 or aminoalkylthiols,125-127 on the other hand, result in novel 5-, 6- or 7-
membered heterocyclic compounds such as pyrazoles, pyrimidines, isoxazoles, 
benzothiezapines, etc. (Scheme 49). 
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Scheme 49: Examples of reactions of chalcones with binucleophiles. 
 
Another class of molecular hybrids are the indole-appended quinazolines, which may be linked 
directly through C–C bond or through a heteroatom bridge (O or N). The methods for the 
construction of the quinazoline skeleton and indole-appended quinazoline hybrids are described 
in detail below. 
 
1.10 Methods for the synthesis of quinazolines  
 
The quinazoline-based compounds are associated with rich biological activities and excellent 
pharmacological properties.128 Quinazolin-4(3H)-ones represent versatile building blocks for the 
design and synthesis of novel polysubstituted quinazolinones129 and their quinazoline derivatives 
using the principles of lactam-lactim dynamic equilibrium phenomena.130 The potentially 
tautomeric quinazolin-4(3H)-one moiety itself is readily accessible via dehydrogenation of the 
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corresponding 2,3-dihydroquinazolin-4(1H)-one precursors using stoichiometric or large excess 
of oxidants such as KMnO4,
131 CuCl2,
132 DDQ133 and MnO2.
134 The 2-substituted quinazolin-
4(3H)-ones have also been synthesized directly from anthranilamide and aldehydes using 
reagents such as NaHSO3,
135 DDQ,133 CuCl2 (3 equiv.),
132 FeCl3.6H2O
136 or I2.
137 Quinazolines, 
on the other hand, are mostly synthesized by the aromatization of the quinazolin-4(3H)-one 
moiety using reagents such as thionyl chloride (SOCl2),
138 phosphoryl chloride (POCl3)
139 or a 
combination of phosphorus pentachloride (PCl5) and POCl3
139 to afford the 4-chloroquinazoline 
derivatives. This strategy has previously been employed in our laboratory to transform the 2-
aminobenzamides 174 bearing different halogen atoms as precursors for cyclocondensation with 
benzaldehyde derivatives 175 followed by dehydrogenation of the incipient quinazolin-4(1H)-
one intermediates to afford the requisite 2-aryl-6,8-dihalogenoquinazolin-4(3H)-ones 176 
(Scheme 50).129 Compounds 2-aryl-6-bromo-8-iodoquinazolin-4(3H)-ones 176 were futher 
subjected to oxidative aromatization with phosphoryl chloride–triethylamine mixture under 
reflux to afford the corresponding 2-aryl-6-bromo-4-chloro-8-iodoquinazolines 177. 
 
                                                                                                                    177                                                   
Scheme 50: Oxidative aromatization of quinazolin-4(3H)-one 
 
174                             175                                                       176                       
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The Csp2–Cl bond of the 4-chloroquinazoline moiety is highly reactive towards substitution with 
heteroatom-containing nucleophiles, the 4-chloroquinazoline moiety also facilitates metal-
catalyzed cross-coupling to afford carbo-substituted quinazoline derivatives. The application of 
4-chloroquinazolines in the synthesis of carbo-substituted or heteroatom-substituted 
quinazolines is described in detail below. 
 
1.11 Methods for the synthesis of C–C and C–heteroatom linked indole-quinazoline 
hybrids  
 
Luth et al.27 reported the synthesis of 4-(indole-3-yl)quinazolines 183 via the coupling reaction 
of indolyl-magnesium compounds 180 with 4-chloroquinazolines 181 in diethyl ether under 
reflux followed by hydrolysis of the intermediates 182 (Scheme 51). The indole-quinazoline 
hybrids exhibit EGFR inhibitory activity have also been found to inhibit HER-2 TK-induced at 
100 nM.27 
 
 Reagents and conditions: (i) Mg, I2, CH3I, Et2O, 5 °C; (ii) Et2O, reflux; (iii) H2O 
Scheme 51: Heteroarylation of indole 180 and quinazoline 181. 
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A series of 4-(3-indolyl)quinazolines 186 have been synthesized by the aluminium chloride-
catalyzed hybridization of indoles 184 with 2,4-dichloroquinazoline 185 in dry dichloroethane 
under nitrogen atmosphere at 75‒80 °C (Scheme 52).140 The synthesized compounds were found 
to exhibit significant anti-leishmanial and/or anti-proliferative activities against a panel of 
mammalian cancer cell lines such as prostate carcinoma (DU145), breast adenocarcinoma 
(MCF-7), oral epidermal carcinoma (KB) and cervical carcinoma (C33A).140 
 
     184           185            186 
Scheme 52: Aluminium chloride-mediated cross-coupling of 184 with 185 to afford 186. 
 
Lewis acids such as Indium(III) chloride (InCl3) have also been utilized for the hybridization of 
indole 157 with 4-chloroquinazoline 189 in acetonitrile under microwave irradiation at 150 W 
and 120 °C to afford the substituted 4-(1H-Indol-3-yl)-2-phenylquinazoline 190 in 78–89% yield 
(Scheme 53).141 Compound 190 was obtained in 82–84% yields when boron trifluoride diethyl 
etherate (BF3∙Et2O), indium(III) trifluoromethanesulfonate or gallium trichloride were used as 
catalysts, respectively.  
 
 157             189       190 
Scheme 53: Hybridization of 157 with 189 to afford 190. 
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An alternative route involving condensation and Dimroth rearrangement of the starting anilines 
with imines obtained from anthranilonitriles with formamide dimethylacetal to afford the 4-
aminoquinazolines has also been reported.28 N'-(2-Cyano-4-nitro-phenyl)-N,N-dimethyl-
formamidine 192 was reacted with 5-aminoindoles 193 in acetic acid under reflux to afford (6-
nitro-quinazolin-4-yl)-(1H-indol-5-yl)-amines 194 (R = -CH3, propyl, allyl) (Scheme 54). 
Compound 192 used as precursor was, in turn, prepared via the condensation of 2-amino-5-
nitrobenzonitrile 191 with dimethylformamide dimethyl acetal in toluene under reflux (Scheme 
54). Compounds 194 were further reduced to their corresponding N4-(1H-indol-5-yl)-
quinazoline-4,6-diamine derivatives which were also found exhibit anti-inflammatory properties 
against lipopolysaccharide-induced TNF-α and IL-6 expression.28 
 
Scheme 54: Preparation of 194 from reaction of 192 with 193. 
 
Despite what looks like a simple molecular framework, there is no literature precedent for the 
merging benzofuran moiety with the quinazoline scaffold to generate analogues of the indole-
aminoquinazoline hybrids shown here or in Figure 5 above. 
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1.12 Main focus of this investigation 
 
Based on the above literature precedents, we asked ourselves whether molecular hybridization 
strategy could be employed to construct novel indole-chalcones or benzofuran-appended 
chalcone hybrids and their benzothiazepine-appended derivatives as well as benzofuran- or 
indole-quinazoline hybrids for evaluation of biological activity as potential anticancer agents. 
 
1.12.1  Aim of the study  
 
The main aim of this investigation was to synthesize novel indole- and benzofuran-appended 
chalcone hybrids as well as the benzofuran-aminoquinazoline hybrids for further studies of 
chemical transformation and antiproliferative activity as potential anticancer agents. We 
envisaged that sequential and/or one-pot successive palladium catalyzed Sonogashira cross-
coupling of the 3-halogenated 2-aminochalcones or their 2-hydroxychalcone analogues followed 
by cycloisomerization of the intermediate 3-alkynylated 2-amino/hydroxychalcone derivatives 
would afford novel angular indole-chalcones or benzofuran-chalcones, respectively. The 
presence of the strongly nucleophilic carbon-3 of the indole or benzofuran moiety and the 
electrophilic α,β-unsaturated carbonyl framework in these compounds would enable further 
chemical transformation with electrophilic reagents or dinucleophiles, respectively. The mixed 
3,5-dihalogenated acetophenone 197(a) and 197(b) derivatives prepared via the sequential 
halogenation of 2-aminoacetophenone 195(a) and 2-hydroxyacetophenone 195(b) (Scheme 55) 
were envisaged to represent suitable precursors for the synthesis of the target compounds as 
shown in Figure 13. The presence of the acetyl group in the 3,5-dihalogenated 2-
amino/hydroxyacetophenones would probably facilitate base-mediated Claisen-Schmidt aldol 
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condensation with benzaldehyde derivatives to afford the 2-amino-5-bromo-3-iodochalcones 
198 (X = NH) or 5-bromo-2-hydroxy-3-iodochalcones (X = O) 198, respectively. 
  
       195: X = NH (a); O (b)             196: X = NH (a); O (b)          197: X = NH (a); O (b) 
Scheme 55: Design and synthesis of mixed 3-,5-dihalogenated acetophenone derivatives. 
 
Palladium catalysed Sonogashira cross-coupling of 198 (X = NH) with terminal acetylenes 
would yield the 3-arylalkynyl–substituted 2-aminochalcones 200 which upon cyclization would 
afford the indole-chalcones 201. The sonogashira cross-coupling of the analogous 5-bromo-2-
hydroxy-3-iodochalcones 198 (X=O) with arylacetylenes under the same reaction conditions 
employed for the synthesis of 200 would afford the benzofuran-chalcones 203. Further chemical 
transformation of the indole-chalcones via C-3 acetylation with trifluoroacetic anhydride would 
afford the 3-trifluoroacetyl–substituted indole-chalcones 204. The α,β-unsaturated carbonyl 
moiety of the indole-chalcones 200 and benzofuran-chalcones 203 could be reacted with a 
binucleophile such as 2-aminothiophenol to yield the benzothiezapine-appended hybrids 205. 
Tandem Sonogashira cross-coupling and heteroannulation reaction of 5-bromo-2-hydroxy-3-
iodoacetophenone 197 (X = O) with terminal alkynes would afford the 7-acetyl-2-aryl-5-
bromobenzofurans 207. Beckmann rearrangement of the oximes 208 derived from 207 and 
subsequent hydrolysis of the intermediate 209 derivatives would afford the 7-aminobenzofurans 
210 in a single-pot operation. The latter could be condensed with the 4-chloroquinazolines 214 
to afford the quinazoline-benzofuran hybrids 215 analogues of the 4-anilinoquinazolines or 
Cediranib (12). 
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Figure 13: Generalized scheme depicting reaction pathways followed to prepare the                   
compounds described in this investigation. 
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1.12.2  Specific objectives of the study  
 
Based on thes above assumptions, the aim of this investigation was structured into the following 
specific objectives according to Figure 13. 
(i) To prepare the mixed 3ʹ,5ʹ-dihalogenated 2-amino- and 2-hydroxychalcone derivatives 198 
based on 2-amino 197a and 2-hydroxyacetophenone 197b as precursors. 
(ii) To transform the 3ʹ,5ʹ-dihalogeno–substituted 2-aminochalcones and their 2-
hydroxychalcone analogues 198 into the corresponding angular indole-chalcones 201 and 
benzofuran-chalcones 203, respectively; 
(iii) To effect site-selective C-3 trifluoroacetylation of the indole-chalcones 201; 
(iv) To react the α,β-unsaturated carbonyl framework of the heterocycle-appended chalcones 
201 and 203 with a dinucleophile; 
(v) To synthesize the 7-amino-2-aryl-5-bromobenzofurans 210 for condensation with the 4-
chloroquinazoline 214 to afford benzofuran-aminoquinazoline hybrids 215; 
(vi) To study the structural properties of the prepared compounds using a combination of NMR, 
IR and mass spectrometric techniques complemented with single crystal X-ray diffraction 
and/or density functional theory (DFT) methods; and 
(vii) To evaluate some of the prepared compounds for anti-proliferative activity in vitro 
complemented with molecular docking studies. 
 
 
 
 
  
 55 
 
Chapter 2: Results and Discussion 
 
2.1 Preparation of substrates 
 
The synthesis of 2ʹ-amino-5ʹ-bromo-3ʹ-iodoacetophenone and 5ʹ-bromo-2ʹ-hydroxy-5ʹ-
iodoacetophenone used as precursors in this investigation and their transformation into the 
corresponding chalcone derivatives are described in the next sections. 
    
2.1.1  Synthesis of 2ʹ-amino-5ʹ-bromo-3ʹ-iodoacetophenone and 5ʹ-bromo-2ʹ-hydroxy-3ʹ-
iodoacetophenone 
 
Literature review revealed that 2ʹ-amino-5ʹ-bromoacetophenone and the analogous 5ʹ-bromo-2ʹ-
hydroxyacetophenone have been prepared before. Baker et al.142 synthesised 2ʹ-amino-5ʹ-
bromoacetophenone in 80% yield from the reaction of 2-aminoacetophenone with pyridinium 
tribromide in dichloromethane (DCM) at room temperature (RT). The analogous 2-
hydroxyacetophenone, on the other hand, was previously brominated with NaBr-oxone in 
methanol or N-bromosuccinimide (NBS) in acetic acid under reflux to afford 2ʹ-hydroxy-5ʹ-
bromoacetophenone, exclusively.143 Under the same reaction conditions, 2-aminoacetophenone 
furnished a 3,5-dibromo product.144-145 The 5ʹ-bromo-2ʹ-hydroxyacetophenone has been 
subjected to further halogenation using pyridinium iodochloride in methanol under reflux to 
afford 5ʹ-bromo-2ʹ-hydroxy-3ʹ-iodoacetophenone.146 To our knowledge, the 2ʹ-amino-5ʹ-
bromoacetophenone has not been transformed into the mixed dihalogenated derivatives. In this 
investigation we adapted the method described in literature142 and subjected 2-
aminoacetophenone 195a (X = NH) to pyridinium tribromide in dichloromethane at room 
temperature (RT) for 4 h to afford 196a (Scheme 56). Thin layer chromatography of the crude 
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product revealed the presence of 2ʹ-amino-5ʹ-bromoacetophenone 196a (X = NH) as the major 
product along with traces of the 2ʹ-amino-3ʹ,5ʹ-dibromoacetophenone. The resultant crude 
product was recrystalized from hexane to afford 196a in high purity. Treatment of 2-
hydroxyacetophenone 195b (X = O) with N-bromosuccinimide (NBS) in acetic acid at RT 
following a literature procedure,142 on the other hand, afforded 5ʹ-bromo-2ʹ-
hydroxyacetophenone 196b (X = O).  
 
Although, both the 3- and 5-positions of 195a or 195b are doubly activated by the ortho-para 
directing effect of the amino or hydroxyl group and the meta-directing effect of the acetyl group, 
monobromination occurred almost exclusively at the 5-position to generate the 5-bromo–
substituted 2-amino- 196a or 2-hydroxyacetophenone 196b, respectively. Bromination of 2-
aminoacetophenone 195a by pyridinium tribromide (PTB) is known to release hydrogen 
bromide, which presumably coordinates with the amino group and reduce its propensity for π-
electron delocalization.147 The steric hindrance at the ortho position relative to NH3
+ and the meta 
directing effect of the acetyl group would favour attack at the 5-position by the bulky PTB to 
form 2ʹ-amino-5ʹ-bromoacetophenone 197a. The observed site-selective 5-monobromination of 
the 2-hydroxyacetophenone 196b, on the other hand, is presumably due to the formation of 
hydrogen bonds between the phenolic proton and the acetic acid, which would hinder attack at 
the ortho position by the bulky NBS and thus favour para attack.148 Compounds 196a and 196b 
were each subjected to N-iodosuccinimide in acetic acid at RT or under reflux to afford the 
previously undescribed 2ʹ-amino-5ʹ-bromo-3ʹ-iodoacetophenone 197a (X = NH) and the known 
5ʹ-bromo-2ʹ-hydroxy-3ʹ-iodoacetophenone 197b (X = O), respectively (Scheme 56).  
 
The 1H NMR spectra of compounds 196a and 196a each revealed the presence of a broad singlet 
at δ 6.29 ppm and δ 6.97 ppm, respectively, integrating for two protons of the amino group. The 
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1H-NMR spectrum of 196a shows the presence of doublet at δ 6.56 ppm (d, J = 8.5 Hz) for H-3, 
doublet of doublets at δ 7.34 ppm (d, J = 8.5 Hz and 2.5 Hz) for H-4, and doublet due to long 
range coupling at δ 7.80 ppm (d, J = 2.5 Hz) for H-6.  The 1H-NMR spectrum of 197a, on the 
other hand, is distinguished from that of 196a by the presence of two sets of doublets at δ 7.83 
ppm and δ 7.88 with coupling constant (J) value of 2.0 Hz, which correspond to H-4 and H-6, 
respectively. The hydroxyl proton of compounds 196b and 197b each resonates as a singlet at δ 
12.1 ppm and δ 13.1 ppm, respectively. The 1H-NMR spectrum of 196b shows the presence of 
additional signals in the aromatic region at δ 6.87 ppm (d, J = 8.5 Hz), 7,53 ppm (dd, J = 2.5 and 
8.5 Hz) and 7.81 ppm (d, J = 2.5 Hz) corresponding to H-3, H-4 and H-6, respectively. 
Incorporation of an iodine atom in compound 197b was confirmed by the presence of a set of 
doublets at δ 7.83 ppm and δ 8.04 with coupling constant (J) value of 2.1 Hz and these signals 
were assigned to H-4 and H-6, respectively. The melting point values of compounds 196a and 
196b were found to be comparable to the literature values (Table 1). Although the observed 
melting point value for compound 197b was found to be slightly higher than the reported value, 
its spectroscopic data was found to be consistent with the assigned structure. 
      
                195a, b                                         196a, b                                          197a, b  
Reagents and conditions: (i) PTB, DCM, RT 6 h (ii) NBS, AcOH, reflux 1.5; (iii) NIS, AcOH, 
RT, 2 h; (iv) NIS, AcOH, reflux, 2 h 
Scheme 56:  Sequential bromination and iodination of 195a (X = NH) and 195b (X = O). 
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Table 1: Substitution pattern, percentage yields and melting point values of 196–197. 
Compound X %Yield m.p. °C (Lit.) 
196a NH 76 81 (83)142 
196b O 59 75 (73)143 
197a NH 74 97 
197b O 93 112 (105)146 
 
Compounds 197a and 197b were, in turn, subjected to further transformation via Claisen-
Schmidt aldol condensation with benzaldehyde derivatives as described in the next section. 
 
2.1.2 Preparation of the 2-amino- (198a–d) and 2-hydroxy-5-bromo-3-iodochalcones 
(198e–i)  
  
Numerous methods have been reported in the literature for the synthesis of chalcones and these 
include the Aldol condensation,100 Claisen-Schmidt condensation,101 Wittig reaction,54 Friedel-
Crafts acylation with cinnamoyl chloride,54 The other methods include the Photo-Fries 
rearrangement of phenyl cinnamates,54 Suzuki cross-coupling reaction of benzoyl chloride and 
arylboronic acid 102 and the Heck cross-coupling reaction of arylhalide and unsaturated ketone.103  
The acid or base mediated Claisen-Schmidt aldol condensation is the most widely used method 
for the synthesis of chalcones.101 The method involves relatively cheaper reagents and mild 
reaction conditions accompanied by aqueous work-up and recrystallization of the products 
without the need for tedious column chromatographic separation. Consequently, in this 
investigation, we opted for the Claisen-Schmidt aldol condensation of 2ʹ-amino-5ʹ-bromo-3ʹ-
iodoacetophenone 197a and 197b with benzaldehyde derivatives. Compound 197a was reacted 
with benzaldehyde derivatives in the presence of potassium hydroxide in ethanol at RT for 6 h 
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(Scheme 57) and we isolated by aqueous work-up and recrystallization the corresponding 2-
amino-5-bromo-3-iodochalcones 198a–d (X = NH) in 81–93% yield (Table 2). 5-Bromo-2-
hydroxy-3-iodoacetophenone 197b, on the other hand, was condensed with benzaldehyde 
derivatives in the presence of aqueous sodium hydroxide in methanol at RT for 48 h to afford 
the corresponding 2-hydroxychalcones 198e–i (X = O) (Scheme 57; Table 2). The prepared 
chalcones were characterized using a combination of NMR (1H & 13C), IR, and mass 
spectroscopic techniques. The 1H NMR spectra of the chalcones are easily distinguished from 
those of the corresponding substrates by the absence of the intense singlet for CH3 in the aliphatic 
region and the presence of an increased number of signals in the aromatic region along with a 
set of doublets for the the vinylic protons with coupling constant values (Jtrans) in the region J = 
15.5–16.0 Hz. These confirm the E-geometry of the olefinic moiety in analogy with the literature 
assignment for the analogous derivatives.104-105 The 1H NMR spectra of products 198e–i also 
revealed the presence of increased number of signals in the aromatic region with a singlet for the 
phenolic proton resonating around δ 13.00 ppm. This singlet resonates significantly downfield 
presumably because of hydrogen bonding with the adjacent carbonyl group. Their olefinic nature 
and E-geometry were also confirmed by the presence of the set of doublets around δ 7.48 (α-H) 
and 7.89 ppm (β-H) with coupling constant values Jtrans = 15.5–16.0 Hz, respectively. Their IR 
spectra, on the other hand, reveal the presence of intense absorption bands νmax 1634 cm-1 and 
3676 cm-1, which correspond to C=O and OH groups, respectively. The mass spectra of 
compounds 198a–i showed peaks corresponding to their molecular formula. 
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                   197a (X = NH)                                                                     198a–d 
                   197b (X = O)                                                                        198e–i 
Scheme 57: Condensation of 197 (X = NH2 or OH) with benzaldehyde derivatives. 
Table 2: Substitution pattern, percentage yields and melting points of 198a–i  
Compound  X  R  % Yield Mp ℃  
198a  NH  H  81 103–105  
198b  NH  F  84  146–149  
198c  NH  Cl  91  142–144  
198d  NH  OCH3  93  139–142  
198e  O  H  72  152–154  
198f  O  F  80  177–179  
198g  O  Cl  80  184–186  
198h  O  OCH3  69  173–175  
198i  O  OCF3  74  106–107  
 
 
The presence of fluorine atom in a molecule is easily confirmed by the 1H NMR and 13C NMR 
spectroscopic methods. The presence of a para-fluorophenyl group in compound 198f, was 
confirmed by the presence of a set of triplets of doubles at δH 7.15 with and at δH 7.69 with 
coupling constant values JHH = 8.5 Hz and JHF = 5.3 Hz for H-2',6'; and JHH = 8.5 Hz and JHF = 
9.7 Hz for H-3',5'. The 13C NMR spectrum, on the othe hand, shows the presence of sets of 
doublets with different coupling constant values reflecting the proximity or distance from F. The 
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carbon-13 signals of the 4-fluorophenyl ring of 198f resonate as doublets at δ 115.9, 129.3, 134.3 
and 162.7 ppm with coupling constant values 2JCF 21.4 Hz (C-3ʹ, 5ʹ), 3JCF 8.0 Hz (C-2ʹ, 6ʹ), 4JCF 
3.3 Hz (C-1ʹ) and 1JCF 250.2 Hz (C-4ʹ) respectively (Figure 14).  
 
 
 
 
Figure 14: 1H- and 13C-NMR spectra of 198f in CDCl3 at 500 and 125 MHz, respectively. 
 
 
 
 
OH 
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2.2  Design and synthesis of the angular indole- and benzofuran-appended chalcones  
 
The structures of the indole-chalcones and the benzofuran-chalcones described in the literature 
have the unsaturated carbonyl arm attached to the C-2 or C-3 position of the five-membered ring. 
Those were generally accessible via the Claisen-Schmidt condensation of the 2- or 3-carbonyl 
substituted indole or benzofurans with benzaldehyde or acetophenone derivatives.116-119 The 
isomeric benzo[c]indole/furan–chalcones, on the other hand, have not been prepared before and 
such angular hybrids do not feature in the recent review by Zhuang et al. on chalcones and 
chalcone hybrids of medicinal importance.54 This encouraged us to employ the 3,5-dihalogenated 
2-amino- 198a–d and the 2-hydroxychalcones 198e–i as scaffolds to append an indole or 
benzofuran moiety, respectively. 
 
2.2.1  Sonogashira cross-coupling of the 2-amino-5-bromo-3-iodochalcones 198a–d  
 
The N-unsubstituted 2-alkynylaniline derivatives undergo heteroannulation with ease,68,71 
however, some derivatives have also been found to fail to react further to afford indole 
derivatives. In such cases, the amino group of the 2-halogenoanilines is usually activated as the 
N-acetyl,71 N-formyl69 or N-mesyl/tosyl64 to promote direct one-pot Pd(II) or CuI catalysed 
Sonogashira cross-coupling and heteroannulation to yield the indole derivatives with either 
retention or extrusion of the activating group. The halogenated 2-aminochalcones 198a–d were 
subjected to palladium catalysed Sonogashira cross-coupling with aryl acetylenes 199 (1.2 
equiv.) in the presence of PdCl2(PPh3)2–CuI catalyst mixture and cesium carbonate as a base in 
ethanol under reflux for 2 h (Scheme 58). Aqueous work-up and purification by column 
chromatography on silica gel afforded the corresponding 3-alkynylated 2-amino-5-
bromochalcones 200a–f in 76-82% yield (Table 3) without traces of the indole derivative 
 63 
 
detected in the reaction mixture or crude product. The observed selectivity of Csp2–Csp bond 
formation through the Csp2–I bond is a consequence of the relative Csp2–halogen bond strengths 
(I < Br < Cl < F), which makes it possible to substitute the iodides in the presence of bromides 
or chlorides. The 1H NMR spectra of compounds 200 still retained some of the characteristic 
features observed in the spectra of corresponding substrates, the difference being the presence of 
the arylalkynyl moiety which was confirmed by the increase in the number of proton signals in 
the aromatic region (Figure 15) and the presence of the acetylenic carbon signals at δC 88.7 and 
96.7 ppm in their 13C NMR spectra (Figure 15). Their alkynyl nature was further confirmed by 
the presence of the IR absorption band around vmax 2201 cm
-1, whch correspond to the C≡C 
stretch. 
198a–e               199                                                                    200a–f 
Scheme 58: Sonogashira cross-coupling of 198a–f with terminal acetylenes 199. 
Table 3: Substitution pattern, percentage yields and melting point values of 200a–f. 
Compound R1 R2 % Yield Mp ℃ 
200a 4-H 4-H 76 106–108 
200b 4-F 4-H 81 121–123 
200c 4-Cl 4-H 71 110–113 
200d 4-OMe 4-H 62 108–110 
200e 4-Cl 4-OCF3 78 120–123 
200f 4-OMe 4-OCF3 82 125–127 
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Figure 15: 1H NMR spectrum of compound 200e in CDCl3 at 500 MHz 
 
Alkynylated anilines in which the alkynyl group is tethered to the nucleophilic heteroatom are 
known to undergo heteroannulation with ease in the presence of metal or Lewis acid catalyst.70 
This heteroannulation strategy represents a versatile and efficient pathway to polynuclear 
compounds. The ortho-alkynylated 2-aminochalcones 200a–f were, in turn, subjected to PdCl2–
mediated cycloisomerization in acetonitrile at 90 °C for 3 h (Scheme 59). The crude products 
 
 
 
CF3 
 
NH2 
β-H 
α-H 
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were passed through columns of silica gel to remove the catalyst and we isolated the 
corresponding novel indole-chalcones 201a–f in 63–81% yield (Table 4). The 1H NMR spectra 
of compounds 201 show the absence of the signal for NH2, which is present in the spectra of the 
corresponding substrates (Figure 16). The spectra further revealed the presence of a singlet 
around δ 6.83 ppm corresponds to H-3 with the NH signal resonating around δ 11.00 ppm. The 
other set of doublets around δ 7.99 and 8.00 ppm with coupling constant value J = 1.5 Hz, on the 
other hand, correspond to the 4-H and 6-H, respectively (Figure 16). Their 13C NMR spectra 
reveal the absence of the signals in the region δ 84.4-95.2 ppm attributed to the acetylenic carbons 
and the presence of signals around δ 103.2 and 114.4 ppm, which correspond to C-2 and C-3 as 
well as the resonance around δ 189.6 ppm for the carbonyl carbon. Moreover, their IR spectra 
lack the absorption bands corresponding to NH2 and C≡C groups found in the spectra of the 
corresponding precursors, but showed the bands corresponding to the NH and C=O around vmax 
3411 and 1641 cm-1, respectively.  
 
200a–f               201a–f 
Scheme 59: Palladium chloride-mediated cyclization of 200a–f. 
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Table 4: Substitution pattern, percentage yields and melting point values of 201a–f. 
Compound R1 R2 % Yield Mp ℃ 
201a 4-H 4-H 75 197–199 
201b 4-F 4-H 63 187–237 
201c 4-Cl 4-H 71 184–186 
201d 4-OMe 4-H 53 176–178 
201e 4-Cl 4-OCF3 63 252–254 
201f 4-OMe 4-OCF3 54 197–198 
 
 
Figure 16: 1H NMR spectrum of compound 201f in CDCl3 at 500 MHz. 
 
The molecular ion regions of the high-resolution mass spectra (HR-MS) of the compounds 201 
revealed the presence of the M+ and M+2, in the ratio of about 1:1, which are typical for 
molecules containing 79Br and 81Br isotopes (Figure 17). 
NH C-H 
OCH3 
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Figure 17: HR-MS of 201e using positive electrospray ionisation time-of-flight mass 
spectrometry. 
 
Crystals of quality suitable for X-ray diffraction were obtained for compound 201e by slow 
evaporation of acetonitrile. The molecular structure of compounds 201 and the geometry about 
the C–C double bonds were distinctively confirmed by single crystal X-ray diffraction analysis 
(Figure 18). In the context of the X-ray analyses for this compound and other examples to follow, 
crystallographic numbering has been used in the text in place of regular systematic numbering. 
The crystal structure shows the existence of the α,β-unsaturated framework in E configuration 
with strong intramolecular hydrogen bonding between N-H of the indole ring and the carbonyl 
oxygen with N–H…O angle and H…O distance of 122° and 2.18 Ǻ, respectively (Figures 18 and 
19). Figure 19 shows stacking of the molecules in the unit cell with π-interactions between C11-
C12 and C16-C17. The crystallographic data of compound 201e is summarized in Table 5. 
 
[M]+  
 
[M+2]+  
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Figure 18: Oak Ridge Thermal Ellipsoid Plot (OTERP) diagram (50% probability level) of 
compound (201e). H atoms are shown as small spheres of arbitrary size and for clarity they are 
not labelled. 
 
 
 Figure 19: Packing diagram of compound 201e. 
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Table 5: Crystallographic data of compound 201e. 
Formula C24H14BrClF3NO2 
Mr 520.72 
Temperature/K 173(2) K 
Wavelength/Å 0.71073 
Crystal size/mm3 0.1 x 0.1 x 0.4 
Crystal system Monoclinic 
Space group P2(1)/n 
a/Å 17.1066 (17) 
b/Å 5.4615 (4) 
c/Å 22.279(2) 
α/° 90 
β/° 101.447(4) 
γ/° 90 
V/Å3 2040.1(3) 
Z 4 
ρ (calcd)/Mg m-3 1.695 
μ/mm-1 2.196 
F(000) 1040 
ϴ Range for data collection/° 3.26 to 28.00° 
Reflections collected 36165 
No. of unique data [R(int)] 4921 [ 0.0527] 
   No. data with I ≥ 2σ(I) 4921 
Final R(I ≥ 2σ(I)) 0.0334 
Final wR2 (all data) 0.0835 
CCDC deposition number 1490129 
 
The Sonogashira cross-coupling reaction conditions were extended to the analogous 2-
hydroxychalcones as described in the next section. 
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2.2.2 Sonogashira cross-coupling of the (E)-2-hydroxy-5-bromo-3-iodochalcones 198e–i    
  
The 2-alkyl/aryl–substituted benzofurans were previously synthesized via palladium catalyzed 
cross coupling-heteroannulation of the 2-bromo/iodophenol derivatives with terminal 
acetylenes.84-88 It has however been observed before that PdCl2(PPh3)2 was a more efficient 
catalyst than Pd(PPh3)4 giving better yields and reproducibility.
86 We subjected the 5-bromo-2-
hydroxy-3-iodochalcones 198e–i to Sonogashira cross-coupling with terminal acetylenes in the 
presence of PdCl2(PPh3)2-CuI catalyst complex in cesium carbonate under reflux and inert 
atmosphere for 2 h. Column chromatography on silica gel afforded compounds characterized 
using a combination of spectroscopic techniques as the corresponding benzofuran-chalcones 
203a–y (Scheme 60). The ortho-alkynylated phenol intermediate 202 implicated in the reaction 
mechanism was not detected by thin layer chromatography or isolated by silica gel column 
chromatography. This observation is attributed to the increased acidity of the hydroxyl proton 
when compared to the amino group of 201. In our view, the cesium carbonate generated 
phenoxide anion would attack the activated metal coordinated C≡C bond to promote tandem 5-
endo-dig cyclization to afford benzofuran-appended chalcones 203a–y. The 1H-NMR spectra of 
compounds 203a–y (Figure 20) revealed the absence of the signal for OH and the presence of an 
increased number of signals in the aromatic region δ 7.00–7.50 ppm with a singlet around δ 7.07 
ppm for H-3. A set of doublets in the region δ 7.74 and 7.80 ppm with coupling constant (J) 
values of about 16.0 Hz are characteristic of the trans geometry for the chalcone framework. The 
signal of the β-H resonates at a lower field than that of the α-H due to π-electron delocalization 
towards the carbonyl group. The 13C NMR spectra of compound 203f for an example, show the 
presence of doublets due to the C-F interaction of the 4-fluorophenyl ring with the resonances at 
about δ 116.3, 130.5, 131.3 and 164.2 ppm corresponding to 1JCF 239.0 Hz (C-4ʹ), 2JCF 21.8 Hz 
(C-3ʹ & 5ʹ), 3JCF 8.5 Hz (C-2ʹ & 6ʹ) and 4JCF 2.9 Hz (C-1ʹ), respectively (Figure 20). The 
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resonance for the C=O appears at about δ 186.4 ppm. The accurately calculated m/z values for 
the molecular ions reveal the presence of the M+ and M+2 peaks in comparable intensities typical 
of molecules containing 79Br and 81Br isotopes. Their presence confirmed cross-coupling through 
the most reactive Csp2–I bond. 
 
     198e–i                                                    202a–y                                 203a–y 
Scheme 60: Sonogashira cross-coupling of compounds 198e–i with terminal acetylenes. 
Table 6: Substitution pattern, percentage yields and melting point values for 203a–y. 
Compound Ar1 Ar2 %Yield of 203 Mp ℃ 
203a C6H5- C6H5- 66 197–195 
203b 4-FC6H4- C6H5- 79 220–223 
203c 4-ClC6H4- C6H5- 78 242–245 
203d 4-MeOC6H4- C6H5- 72 206–208 
203e 4-CF3OC6H4- C6H5- 67 177–178 
203f C6H5- 4-FC6H4- 70 224–226 
203g 4-FC6H4- 4-FC6H4- 76 239–242 
203h 4-ClC6H4- 4-FC6H4- 77 231–233 
203i 4-MeOC6H4- 4-FC6H4- 73 252–254 
203j 4-CF3OC6H4- 4-FC6H4- 64 203–204 
203k C6H5- 3-FC6H4- 70 243–245 
203l 4-FC6H4- 3-FC6H4- 77 266–267 
203m 4-ClC6H4- 3-FC6H4- 68 234–235 
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Table 6 continues 
203n 4-MeOC6H4- 3-FC6H4- 73 221–222 
203o 4-CF3OC6H4- 3-FC6H4- 87 186–187 
203p C6H5- 3-ClC6H4- 75 218–219 
203q 4-FC6H4- 3-ClC6H4 69 232–233 
203r 4-ClC6H4- 3-ClC6H4- 77 257–258 
203s 4-MeOC6H4- 3-ClC6H4 71 214–215 
203t 4-CF3OC6H4- 3-ClC6H4- 71 196–197 
203u C6H5- 4-CH3OC6H4- 72 255–256 
203v 4-FC6H4- 4-CH3OC6H4- 82 241–242 
203w 4-ClC6H4- 4-CH3OC6H4- 79 209–210 
203x 4-MeOC6H4- 4-CH3OC6H4- 69 216–217 
203y 4-CF3OC6H4- 4-CH3OC6H4- 67 187–188 
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Figure 20: 1H- and 13C-NMR spectra of 203f in CDCl3 at 500 and 125 MHz, respectively. 
  
The structure of these compounds and the E-geometry around the olefinic framework were 
distinctly confirmed by single crystal X-ray diffraction (XRD) analysis of compound 203a 
(Figure 21). Compound 203a crystallizes in the P212121 space group with each asymmetric unit 
containing one molecule of 203a. In the asymmetric unit, there is intramolecular hydrogen 
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bonding between the oxygen acceptor (O1) and the α- hydrogen bond donor [d(C(16)-
H(16)...O(1) = 2.24 Å] forming an 𝑆11(6) ring (Figures 22). The molecule packs into a one-
dimensional ribbon via bifurcated hydrogen bonding from the oxygen acceptor (O2) and the C–
H…O hydrogen bond donors (H2 and H4). The crystallographic data of compound 203a is 
summarized in Table7. 
 
Figure 21: Oak Ridge Thermal Ellipsoid Plot (ORTEP) diagram of 203a. Displacement 
ellipsoids are drawn at the 50% probability level and H atoms are shown as small spheres of 
arbitrary radii  
  
Figure 22: Packing diagram of 203a showing the 1D ribbon  
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Table 7: Crystallographic data for compound 203a. 
Formula C23H15BrO2 
Mr 403.26 
Temperature/K 173(2) 
Wavelength/Å 0.71073 
Crystal size/mm3 0.3 x 0.1x 0.040 
Crystal system Orthorhombic 
Space group P212121 
a/Å 4.7121(7) 
b/Å 15.719(2) 
c/Å 23.152(3) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 1714.9(4) 
Z 4 
ρ (calcd)/Mg m-3 1.562 
μ/mm-1 2.412 
F(000) 816 
ϴ Range for data collection/° 2.940 to 25.496 
Reflections collected 19664 
No. of unique data [R(int)] 3190 [0.0721] 
No. data with I ≥ 2σ(I) 2641 
Final R(I ≥ 2σ(I)) 0.0299 
Final wR2 (all data) 0.0697 
CCDC deposition number 1561911 
 
2.3 Transformation of the indole-chalcones and benzofuran-chalcone hybrids     
 
The 3-acetyl moiety on the indole framework is an important hydrogen-bond acceptor for 
interaction with biological receptors.149 As a result, acylation of the C-3 position of the indole 
moiety has become one of the most important reactions in indole chemistry because of the 
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reactivity and biological activities of the resultant 3-acylated indoles. The electron-withdrawing 
effect of -CF3, on the other hand, has been found to increase the lipophilicity, metabolic stability 
and activity profile compared to that of the methyl analogues.150 Trifluoroacetylation of indole 
moiety is a well-established procedure,151 this method has not been applied to the indole-
chalcone derivatives. Indole-chalcones 201 have ambident nucleophilic and electrophilic 
characters. The nucleophilic character is distributed at the C-3 position and at the N-1 position 
of the indole nucleus. The electrophilic character of the α,β-unsaturated carbonyl arm is 
distributed at the carbonyl and β-carbons. We took advantage of the ambident nucleophilic 
character of the indole moiety and decided to incorporate a trifluoroacetyl group on indole-
chalcones as described in the next section. 
 
2.3.1 Trifluoroacetic acid-promoted C-3 trifluoroacetylation of the indolechalcones  
  
Friedel-Crafts fluoroacetylation of indoles was previously achieved with fluorinated acetic acids 
(3 equiv.) in dichloroethane at 100 °C in the absence of catalyst or additive to afford novel 
fluoromethyl indol-3-yl ketones.152 Based on this literature precedents, we decided to incorporate 
a trifluoroacetyl group at the C-3 position of the indole moiety of compounds 201a–f. 
Compounds 201a–f were subjected to trifluoroacetic anhydride (1.2 equiv.) in THF under reflux 
and we isolated after 5 h by aqueous work-up and recrystallization the corresponding 3-
trifluoroacetylindole-chalcones 204a–f, exclusively (Scheme 61). The 1H NMR spectra of 
compounds 204 show the absence of the signal for H-3 (Figure 23). Their 19F NMR spectra 
reveal the presence of a signal around δ -72 ppm corresponging to the three fluorine atoms. The 
13C NMR spectra on the other hand, revealed the presence of two set of quartets in the regions δ 
120–121 ppm and δ 176–177 ppm with coupling constant values 1JCF = 288.0 Hz and 2JCF = 37.0 
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Hz. The set of quartets corresponds to the trifluoromethyl (CF3) group and the adjacent carbonyl 
carbon, respectively.  
 
   201a–f                                     204a–f  
Scheme 61: TFAA-promoted C-3 acetylation of compounds 204a–f.  
Table 8: Substitution pattern, percentage yields and melting point values for 204a–f. 
Compound  Ar1 Ar2 % Yield Mp ℃  
204a C6H5- C6H5- 88  195–197  
204b 4-FC6H4- C6H5- 76  164–166  
204c 4-ClC6H4- C6H5- 91  180–183  
204d 4-MeOC6H4- C6H5- 62  173–175  
204e 4-ClC6H4- 4-CF3OC6H4- 90  266–269  
204f 4-MeOC6H4- 4-CF3OC6H4- 88  200–203  
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Figure 23: 1H-, 19F- and 13C-NMR spectra of 204d in CDCl3 at 500 and 125 MHz, respectively. 
 
 
NH 
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Incorporation of the trifluoroacetyl group onto the indole-chalcone framework and the existence 
of the α,β-unsaturated moiety in E configuration were also confirmed by the X-ray crystal 
structure of compound 204e obtained by recrystallization from toluene. The crystal studied of 
this compound shown in Figure 24 (CCDC 1490104) was found to exist in the asymmetric unit 
as an inversion twin. Inversion twins are usually observed for compounds with a chiral centre.153 
Twinning in the case of compound 204e is presumably due to the presence of the prochiral group 
(-C(O)CF3) as this phenonomemnon was not observed in the single X-ray cryustal structure of 
the corresponding chalcone precursor (refer to Figure 18 above). As shown in Figure 25, the 
crystal structure of 204e packs as a 1-dimensional (1D) chain ribbon stabilized by the bromine 
hydrogen bonded network without any π-stacking interactions. The crystallographic data of 
compound 204e is summarized in Table 9. The synthesis of novel 3-(2ʹ,2ʹ,2ʹ-
trifloroacetyl)indole-chalcones based on initial annulation of the indole ring onto the 1,3-diaryl-
2-propen-1-one (chalcone) scaffolds have since been published.154 
 
Figure 24: OTERP diagram (50% probability level) of compound 204e  
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Figure 25: Packing diagram of compound 204e  
Table 9: Crystallographic data of compound 204e. 
Formula C25H15BrF3NO2 
Mr 498.29 
Temperature/K 173(2) 
Wavelength/Å 0.71073 
Crystal size/mm3 0.8 x 0.1 x 0.03 
Crystal system Monoclinic 
Space group P 21/c 
a/Å 18.034(3) 
b/Å 7.8136(15) 
c/Å 30.308(6) 
α/° 90 
β/° 105.298(4) 
γ/° 90 
V/Å3 4119.3(13) 
Z 8 
ρ (calcd)/Mg m-3 1.607 
μ/mm-1 2.046 
F(000) 2000 
ϴ Range for data collection/° 2.956 to 25.498 
Reflections collected 31860 
No. of unique data [R(int)] 7788 [0.1440] 
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Table 9 continues 
No. data with I ≥ 2σ(I) 2236 
Final R(I ≥ 2σ(I)) 0.0832 
Final wR2 (all data) 0.2140 
CCDC deposition number 1490104 
 
Compounds 201 and 203 contain the ambident electrophilic α,β-unsaturated carbonyl moiety 
(carbonyl carbon vs β-carbon), which has previously been shown to facilitate 1,2-addition and/ 
or conjugate addition with nucleophilic reagents. The reactions of chalcone moiety with 
binucleophilic reagents, for example, afford novel heterocyclic compounds with various 
biological properties. The reaction of chalcones with 2-aminothiophenol, for example, has 
previously been found to afford benzothiazepines with anticonvulsant activities.126 Inspired by 
the biological properties of the 1,5-benzothiazepines, we decided to append the 1,5-
benzothiazepine moiety onto the chalcone arm of the benzofuran-chalcones and indole-chalcones 
as described in the next section.  
 
2.3.2 Synthesis of benzofuran-appended benzothiezepines  
  
The non-conventional methods for the synthesis of benzothiazepines make use of transition 
metal-mediated coupling-isomerization sequence of an electron poor aryl/heteroaryl halide and 
a propargyl alcohol derivative followed by a cyclocondensation with 2-amino-, 2-hydroxy-, or 
2-mercaptoanilines.126-127 Michael addition and further cyclocondensation reaction of chalcones 
with 2-aminothiophenol was previously accomplished in refluxing ethanol in the presence of 
glacial acetic acid as a catalyst to afford benzothiazepines.126 We adapted this literature method  
and subjected the Indole–chalcones 201a–c and indole-chalcones 203a–d to 2-aminothiophenol 
as a binucleophilic reagent in acidic medium to afford the corresponding 2,3-
dihydrobenzo[b][1,4]thiazepine–appended indoles 205a–c or -benzofurans 205d–g, respectively 
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(Scheme 62). The structures of the synthesized compounds were characterized based on a 
combination of 1HNMR, 13C-NMR, IR and high-resolution mass spectral data. The aliphatic 
region of the 1H NMR spectra of these compounds represents an ABX system with the two 
diastereotopic protons of the methylene (CH2) group and the methine (CH) proton of the 
dihydrobenzothiazepine ring resonating as three set of doublets of doublet (dd) around δ 3.18, 
3.82 and 5.57 ppm with coupling constant (J) values of 12.5, 13.0 and 4.5 Hz  
 
                            201a–c (X=NH)         205a–c  
                             203a–d (X=O)         205d–g  
Scheme 62: Synthesis of benzothiezapines 205a–c and 205d–g. 
Table 10: Substitution pattern and percentage yields of compounds 205a–g  
Compound X Ar1 Ar2 %Yield  
205a NH C6H5- 4-FC6H4- 92 
205b NH 4-FC6H4- 4-FC6H4- 90 
205c NH 3-FC6H4- 4-FC6H4- 90 
205d O C6H5- C6H5- 86 
205e O 4-FC6H4- C6H5- 79 
205f O 3-ClC6H4- C6H5- 82 
205g O 4-MeOC6H4- 4-OCH3C6H4- 78 
 
We performed through-space correlation 2D selective nuclear overhauser effect spectroscopy 
(NOESY) experiment to be able to assign the set of peaks to specific aliphatic protons (Figure 
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26). The residual signal (B) can be well explained by strong geminal coupling between HA and 
HB (Jgem/AM = 13.0 Hz) and exhibit strong dipole interaction. Signal (A) corresponds to the real 
NOESY resulting from cis (gauche) orientated HA and HB and HX (Jtrans/BX = 12.5 Hz). The 
smallest coupling constant value Jguache/AX = 4.5 Hz is due to the trans oriented HA and HX. The 
signals for the non-equivalent methylene protons (HA and HB) resonate at different frequencies 
and the signal for HA is more downfield presumably due to hydrogen bond interaction with O or 
NH. In 13C-NMR spectra compounds 205 showed a signal at about δ 37.4, 43.2 and 161.8 ppm 
due to C-3, C-2 and C-4 carbons of the benzothiazepine ring. The IR spectra showed absorption 
bands around 1606, 665 and 862 cm-1 corresponding to C=N, C–S and C–Br bond stretches, 
respectively. 
 
Figure 26: NOESY spectrum of the aliphatic region of compound 205a  
 
  
  
A   
B   
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The optimized structure of 205f is shown in Figure 27 below was obtained by the density 
functional theory (DFT) method using hybrid functional Becke’s three parameter nonlocal 
exchange functional with the Lee-Yang-Parr correlation function (B3LYP) using the 6-311G 
basis set. Some of the optimized parameters, namely, the bond lengths, bond angles and torsion 
angles are given in Table 11. Density functional theory at the B3YLYP level revealed that the 7-
membered ring is non-planar with hydrogen bonding interaction between oxygen and HA (Figure 
27). This interaction may account for the observed significant downfield shift of the resonance 
corresponding to this proton in the 1H NMR spectra of these compounds (refer to Figure 26 
above). The dihedral angles of the three protons of the AMX system are 179.0° and 62.6°, which 
represent a staggered conformation as confirmed by the 1H NMR spectral data.  
 
Figure 27: Optimized structure of 205f from DFT calculations. 
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Table 11: Selected theoretical bond lengths (Å) and angles (°) of 205f.  
Geometric parameters 
Bond lengths (Å) 
C(1)-C(6)  1.398 
C(1)-O(12)  1.401 
C(27)-S(29)  1.841 
C(7)-O(12)  1.423 
C(23)-N(28)  1.292 
C(25)-N(28)  1.407 
C(27)-S(29) 1.841 
C(30)-S(29)  1.934 
C(30)-C(24)  1.545 
C(34)-C(38)  1.394 
Bond angles (°) 
C(6)-C(1)-O(12) 128.5 
O(12)-C(7)-C(13) 117.2 
N(28)-C(25)-C(27) 118.1 
C(31)-C(30)-S(29) 112.0 
C(27)-C(30)-S(29) 109.4 
Torsion angles (°)  
O(12)-C(1)-C(6)-C(5) 179.7 
N(28)-C(23)-N(6)-C(1) 178.5 
S(29)-C(27)-C(25)-C(23) 25.1 
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The HOMO and LUMO surfaces of compound 205f were also computed at the B3LYP/6-311G 
level and these are represented in Figure 28. DFT calculations revealed that the HOMO is mainly 
localized on the benzothiazepine moeity and partially on the benzofuran ring. The LUMO, on 
the other hand, is spread throughout the molecule, except for the phenyl ring attached to the 
benzothiazepine framework. The value of the energy separation between HOMO and LUMO is 
-0.138 eV. This small energy gap indicates that this compound could be excited using minimal 
energy. 
  
HOMO (-0.2166 eV)                              LUMO (-0.0781 eV) 
Figure 28. Frontier molecular orbitals of 205f using the B3LYP/6-311++G(d,p) basis set. 
 
Most of the EGFR-tyrosine kinase inhibitors available in the literature have the 4-
anilinoquinazoline framework the difference is on the substituents and the side chains. Therefore, 
the replacement of the aniline structure with a benzofuran nucleus could enhance biological 
activity of the resulting heterocycle-appended quinazoline. Although molecular hybridization 
has been employed before in the synthesis of an indole-ether quinazoline hybrid, 
Cediranib/Recentin™ (12) shown in Figure 5,29 to our knowledge, no attempts have been made 
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towards the synthesis of the analogous quinazoline-benzofuran hybrids linked either through C–
C or C–heteroatom bond.  
 
2.4 Design and synthesis of the benzofuran-aminoquinazoline hybrids 
 
In the next section we decided to synthesize the benzofuran-aminoquinazoline hybrids by 
condensing the 7-aminobenzofurans with the 4-chloroquinazolines to provide a more general 
method to obtain analogues of Cediranib 12. 
 
2.4.1 Synthesis of the 5-bromo-2-arylbenzofuran-7-amines 
 
In order to prepare the 7-amino-2-aryl-5-bromobenzofurans to serve as substrates for the 
amination of the 4-chloroquinazolines, the previously prepared 5-bromo-2-hydroxy-3-
iodoacetophenone 197b were subjected to tandem palladium catalysed Sonogashira cross-
coupling with terminal acetylenes and subsequent endo-dig Csp–O cyclization to afforded the 
corresponding 1-(5-bromo-2-arylbenzofuran-7-yl)ethanones 207a–e in 73–77% yield (Scheme 
63). The 1H- and 13C NMR spectra of compounds 207 revealed the presence of an increased 
number of signals in the aromatic region δH 6.9‒7.9 ppm and δC 100‒160 ppm, respectively, due 
to the incorporated aryl ring. The endo-dig Csp–O cyclization to form the benzofuran ring was 
confirmed by the absence of the signal for OH which was present in the spectra of the previous 
substrates, and there is an observed singlet in the region 7.07 ppm belonging to H-3 of the 
benzofuran ring. 
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      197b                                                                       206 a–e                            207a–e 
Scheme 63: Tandem Pd-catalysed Sonogashira cross-coupling and heteroannulation to afford 
207a–e. 
Table 12: Substitution pattern, percentage yields and melting points of compounds 207a–e.                                
Compound Ar %Yield  Mp ℃ 
207a C6H5- 73 130–133 
207b 3-FC6H4- 76 161–164 
207c 4-FC6H4- 76 178–180 
207d 3-ClC6H4- 74 139–141 
207e 4-CF3OC6H4- 77 170–173 
 
The 1-(5-bromo-2-arylbenzofuran-7-yl)ethanones 207 were then subjected to a nucleophilic 
substitution reaction with hydroxylamine hydrochloride in the presence of pyridine under reflux 
for 1 h followed by aqueous work-up and recrystallization to afforded the corresponding oximes 
208a–e (Scheme 64). Compounds 208 were characterized using a combination of NMR (1H and 
13C NMR) and IR spectroscopic techniques as well as mass spectrometry. Their oxime nature, 
on the other hand, was confirmed by the additional singlet around δH 11.6 ppm and carbon signal 
significantly upfield around δC=N 154 ppm in their 1H-NMR and 13C-NMR spectra, respectively. 
The presence of the OH group was further confirmed by the presence of a broad band around 
νOH 3300 cm-1 in their IR spectra. The Beckmann rearrangement of these oximes 208 with 20% 
mol equivalent of trifluoromethanesulfonic acid (triflic acid, TfOH) in acetonitrile under reflux 
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for 4 h afforded the 7-aminobenzofuran derivatives 210a–e exclusively (Scheme 64). The latter 
are the results of the initial Beckmann rearrangement via aryl carbon migration followed by an 
in situ acid-mediated hydrolysis of the intermediate benzofuranacetamide derivatives 209. 
Compounds 210a–e were easily distinguished from the corresponding precursors by the absence 
of signals corresponding to the oxime group in their 1H- and 13C-NMR spectra. The 1H NMR 
spectra of compounds 210 reveal the presence of a broad singlet at about δ 5.82 ppm 
corresponding to the amino group. The presence of the NH2 groups was also confirmed by the 
corresponding IR absorption bands at about νmax 3385 cm-1. 
 
           207a–e                          208a–e                                    207a–e                    210a–e 
Scheme 64: One-pot Beckmann rearrangement and hydrolysis of oximes 208a–e into amines 
210a–e. 
Table 13: Substitution pattern and percentage yields of compounds 208 and 210. 
Compound Ar %Yield of 208 %Yield of 210 
a C6H5- 93 62 
b 3-FC6H4- 86 78 
c 4-FC6H4- 72 71 
d 3-ClC6H4- 81 65 
e 4-CF3OC6H4- 78 85 
 
The 4-chloroquinazolines were then synthesized to serve as coupling partners with the 7-
aminobenzofurans 210. This was achieved via cyclocondensation of substituted 2-
aminobenzamides with benzaldehyde derivatives as highlighted in the next section. 
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2.4.2 Synthesis of the 4-chloroquinazolines 
 
Quinazolin-4(3H)-ones are readily accessible via cyclocondensation-dehydration of 
anthranilimide with carbonyl compounds (aldehydes and ketones) using reagents such as 
NaHSO3,
135 DDQ,132 CuCl2 (3 equiv.),
133 FeCl3.6H2O
136 or I2.
137
 
 We exploited the combined 
electrophilic and oxidative properties of iodine in ethanol under reflux to effect the 
cyclocondensation of the previously prepared 2-amino-5-bromobenzamide 211 with 
benzaldehyde derivatives and subsequent dehydrogenation of the intermediate quinazolin-
4(1H)-one 212a, b to afford the 2-aryl-6-halogenoquinazolin-4(3H)-ones 213a and 213b in 
single-pot operation without the need for column chromatographic separation (Scheme 65). The 
solid residue was washed with water and then recrystallized from ethanol to afford pure product 
213a, b. Compounds 213 were characterized using a combination of 1H NMR, IR, and mass 
spectroscopic techniques. Their N-4(3H)-oxo nature of compounds was confirmed by the 
presence of the N-3 proton signal that is significantly downfield at about δ 12.35 ppm. Their 
amide nature was also confirmed by the presence of IR bands in the region ν
max 
1660−1680 cm-
1 and ν
max 
1550−1595 cm-1 corresponding to C=O and C-N, respectively. The accurate calculated 
m/z values in each case are consistent with the observed molecular weight of the assigned 
structure. 
 
211         212a, b         213a, b 
Scheme 65: Iodine-promoted cyclocondensation-dehydrogenation to yield quinazolin-4(3H)-
ones 213 
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Table 14: Substitution pattern, percentage yields and melting points of compounds 213a–b. 
Compounds Ar % Yield Mp. (°C) 
213a 4-FC6H4- 91 278–280 °C 
213b 4-ClC6H4 93 342–344 °C 
 
The quinazolin-4(3H)-one scaffold has been employed extensively for the synthesis of the 4-
heteroatom and 4-carbo substituted quinazoline derivatives via initial aromatization with 
phosphoryl chloride or thionyl chloride and subsequent nucleophilic displacement of chlorine 
with nucleophilic reagents or cross-coupling reactions.138 In this investigation, we subjected 2-
aryl-6-dibromoquinolin-4(3H)-ones 213a, b to phosphoryl chloride under reflux for 2 h to yield 
the corresponding substituted 4-chloroquinazolines 214a, b (Scheme 66). The 4-
chloroquinazoline nature of compounds 214a, b was confirmed by the absence of an N-H signal 
in their 1H NMR spectra. Moreover, the IR spectra of products 214 are characterized by the 
absence of the C=O stretch found in the spectra of the corresponding substrates and the molecular 
ion region of the mass spectra of these substituted derivatives reveal the presence of the M+ and 
M+2 peaks in the ratio 3:1 typical for molecules containing the 35Cl and 37Cl isotopes. 
 
 
                    213a, b                              214a, b 
Scheme 66: POCl3–promoted aromatization of 213a, b. 
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Table 15: Substitution pattern, percentage yields and melting points of compounds 214a–b. 
Compounds Ar % Yield Mp. (°C) 
214a 4-FC6H4- 85 208−210 °C 
214b 4-ClC6H4- 91 244–246  °C 
 
The C(4)–Cl position of the 4-chloroquinazoline is highly activated than other positions due to 
the α-nitrogen effect, which makes this position more electrophilic than any other position on 
the quinazoline scaffold.129 This encouraged us to merge compounds 214 with the 7-amino-2-
aryl-5-bromobenzofurans 210a–e as described in the next section. 
 
2.4.3 Reactions of the 5-bromo-2-arylbenzofuran-7-amines and the 4-chloroquinazolines 
 
We subjected the electrophilic 4-chloroquinazoline derivatives 214a and 214b to the amino-
dechlorination with the nucleophilic 7-aminobenzofurans 210a–e in the presence of 5% HCl in 
isopropanol (iPrOH) under reflux (Scheme 67). We isolated after 4 h by aqueous work-up and 
recrystallization, compounds characterized using a combination of NMR and IR spectroscopic 
techniques as well as mass spectrometry as the quinazoline-benzofuran hybrids 215a–j. The 1H 
NMR spectra of compounds 215 revealed the presence of an increased number of signals in the 
aromatic region due to incorporated aryl rings as well as a singlet around 11.4 ppm which 
correspond to the nitrogen bridge (4-amino group). The calculated m/z values for the molecular 
hybrids 215a–h, on the other hand, were found to be consistent with the molecular ions of the 
assigned structures. The structure of these compounds was distinctly confirmed by single crystal 
X-ray diffraction (XRD) analysis of compound 215i (Figure 29; CCDC 1815109). The crystal 
structure reveals the presence of intramolecular hydrogen bonding between the amine proton and 
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endocyclic oxygen atom. The crystallographic data of compound 215i is presented in Table 17 
below. 
 
 210a–e        X = F (214a); Cl (214b)          215a–j 
Scheme 67: Amination of 4-chloroquinazolines 214a, b with the 7-aminobenzofurans 210a–e  
Table 16: Substitution pattern and percentage yields of compounds 215a–j. 
Compound Ar X %Yield of 215 
215a C6H5- F 75 
215b 3-FC6H4- F 82 
215c 4-FC6H4- F 87 
215d 3-ClC6H4- F 78 
215e 4-CF3OC6H4- F 82 
215f C6H5- Cl 83 
215g 3-FC6H4- Cl 81 
215h 4-FC6H4- Cl 78 
215i 3-ClC6H4- Cl 67 
215j 4-CF3OC6H4- Cl 82 
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Figure 29: Oak Ridge Thermal Ellipsoid Plot (ORTEP) diagram of 215i. Displacement ellipsoids 
are drawn at the 50% probability level and H atoms are shown as small spheres of arbitrary radii. 
 
Table 17: Crystallographic data of compound 215i (CCDC deposition number: 1815109).  
Formula C28H15Br2Cl2N3O 
Mr 640.15 
Temperature/K 173(2) 
Wavelength/Å 0.71073 
Crystal size/mm3 0.2 x 0.1 x 0.1 
Crystal system Monoclinic 
Space group P21/c 
a/Å 3.7696(18) 
b/Å 52.52(2) 
c/Å 12.732(6) 
α/° 90 
β/° 90.044(6) 
γ/° 90 
V/Å3 2521(2) 
Z 4 
ρ (calcd)/Mg m-3 1.687 
μ/mm-1 3.456 
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Table 17 continues 
F(000) 1264 
ϴ Range for data 
collection/° 
3.103 to 25.493 
Reflections collected 8866 
No. of unique data [R(int)] 4187 [0.0909] 
   No. data with I ≥ 2σ(I) 2354 
Final R(I ≥ 2σ(I)) 0.1150 
Final wR2 (all data) 0.3234 
CCDC deposition number 1815109 
 
The molecular framework of compounds 215a–j resembles that of the biologically important 4-
anilinoquinazolines such as the EGFR-TK inhibitor, Gefitinib. This encouraged us to evaluate 
these quinazoline-appended benzofuran hybrids for potential in vitro anti-proliferative properties 
as described in the next section. 
 
2.5 Biological activity of the benzofuran-chalcones and benzofuran-aminoquinazolines 
 
The benzofuran-appended chalcone hybrids 203a–y and the benzofuran-aminoquinazoline 
hybrids 215a–j were evaluated for potential antiproliferative properties in vitro. Their modes of 
cancer cell death were evaluated experimemntally complemented with molecular docking 
studies as described in the next sections. 
 
2.5.1 Evaluation of the benzofuran-chalcone hybrids for antiproliferative properties 
 
All the synthesized benzofuran-chalcone hybrids 203a–y were evaluated for their anti-
proliferative activity against human breast cancer cell line (MCF-7) using 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) method.155 Actinomycin D, 
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which is a known antibiotic drug with antibacterial and antitumour activities was used as a 
positive control in this investigation.156 The results were expressed as median growth inhibitory 
concentration (IC50) values, which represent the compound concentration required to produce a 
50% inhibition of cell growth after 48 h of incubation and are summarized in Table 18. It is 
observed that all the synthesized compounds showed significant anti-proliferative activity with 
IC50 values ranging from 3.55×10
-4 to 69.0 μM  while the positive control, actinomycin D 
demonstrated the IC50 at 36.7 µM. Compounds 203b, 203d and 203e substituted with a phenyl 
ring on the benzofuran moiety and  electron withdrawing groups such as a 4-fluorophenyl, 4-
methoxyphenyl or 4-trifluoromethoxyphenyl group on the chalcone functionality exhibited more 
significant cytotoxicity against the MCF-7 cells than the reference standard (IC50 = 37.82 µM) 
with the IC50 values of 0.55, 22.78 and 0.59 µM, respectively. However, cytotoxicity decreased 
within the series 203f–j substituted with a 2-(4-fluorophenyl) group on the benzofuran ring. A 
combination of 4-fluorophenyl ring on the benzofuran moiety and a 4-methoxyphenyl or 4-
trifluoromethoxyphenyl group on the chalcone framework in compounds 203i and 203j resulted 
in increased cytotoxicity against the MCF-7 cell line for these compounds with the IC50 values 
of 3.55 ×10-4 µM and 16.00 µM, respectively. Similarly, compound 203l substituted with a 2-
(3-fluorophenyl) ring on the benzofuran moiety and a 4-fluorophenyl group on the chalcone arm 
displayed low activity. Moreover, compounds 203k, 203m, and 203o replaced with a phenyl, 4-
chlorophenyl and 4-trifluoromethoxyphenyl group on the chalcone fragment were found to 
exhibit increased cytotoxicity when compared to actinomycin D with IC50 values of 23.01, 14.75 
and 7.87 µM, respectively. The derivative 203n substituted with 4-methoxyphenyl on the 
benzofuran moiety exhibited cytotoxic activity comparable to actinomycin D. The 3-
chlorophenyl group substitution at the 2-position of the benzofuran framework in compounds 
203p, 203q, 203s and 203t and a phenyl, 4-fluorophenyl, 4-methoxyphenyl and 4-
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trifluoromethoxy group on the chalcone fragment, on the other hand, resulted in significant 
cytotoxicity with IC50 values of 12.63, 23.82, 2.69 and 26.62 µM, respectively. 
Table 18: Cytotoxic effects of 203a–y against MCF-7 cell line. The results are presented as IC50 
(μM) ± standard deviation (SD) from three individual experiments.  
Compounds  IC50 (μM) ± SD 
203a 47.96 ± 2.10 
203b 0.55 ± 0.24 
203c    >100 
203d 22.78 ± 0.86 
203e 0.59 ± 0.21 
203g 48.59 ± 2.10 
203h 54.16 ± 0.40 
203i 3.55×10-4 ± 0.07 
203j 16.00 ± 0.62 
203k 23.01 ± 0.38 
203l >100 
203m 14.75 ± 0.33 
203n 39.25 ± 0.42 
203o 7.87 ± 0.25 
203p 12.63 ± 0.23 
203q 23.82 ± 0.29 
203r 66.75 ± 0.84 
203s 2.69 ± 0.23 
203t 26.62 ± 0.27 
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Table 18 continues 
203u 48.96 ± 0.30 
203v 28.43 ± 0.46 
203w 30.62 ± 0.35 
203x 69.09 ± 0.76 
203y 43.17 ± 0.28 
Actinomycin D 37.82 ± 1.30 
 
Many anticancer compounds exert their growth inhibitory effect either by arresting the cell or by 
inducing apoptosis or a combined effect of both cycle arrest and apoptosis.154 Moreover, 
regulation of the cell cycle and apoptosis are effective approaches in the development of cancer 
therapeutics. 
 
2.5.2 Mode of cancer cell death (apoptosis vs necrosis) 
 
Syam and coworkers previously synthesized a (E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one 
derivative which was found to exhibit significant antiproliferative activity against breast cancer 
cell line (MCF-7) and to induce apoptosis through the intrinsic and extrinsic pathways.157 Based 
on this literature, we performed dual Annexin V-Cy3 and SYTOX staining to assess the 
apoptosis status of MCF-7 cells after 48 h of treatment with the most cytotoxic compounds, 203b 
and 203i through flow cytometry (Figure 30). Annexin V-Cy3 can detect the externalisation of 
phosphatidylserine of the cell membrane, which is one of the mode of actions of apoptosis, 
whereas SYTOX checks the integrity of the cell membrane.158 Analysis proved that the tested 
compounds significantly induced programmed cell death in MCF-7 cells in comparison with the 
control (untreated cells) and the reference standard (Actinomycin D). The highest pro-apoptotic 
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potential was observed after 48 h of incubation with the compounds 203b and 203i in breast 
cancer cells, where we observed 23.3% and 32.2% viable cells; and 73.5% and 64.8% apoptotic 
cells, respectively (Table 19)  
 
Figure 30: Annexin V staining of MCF-7 cells treated with 203b, 203i and actinomycin D at 1 
µM concentration for 48 h, respectively. 
             203b             203i       Actinomycin D 
   
Table 19: Quantitive apoptosis assay of MCF-7 using Annexin V SYTOX staining 
Compound %Viable 
cells (Q3) 
%Early 
apoptosis (Q4) 
%Late 
apoptosis (Q2) 
%Necrosis 
(Q1) 
203b 23.3 1.5 72 3.2 
203i 32.2 3.1 61.7 3.1 
Actinomycin D 30.7 3.4 61.4 4.5 
 
Caspases (cysteinyl-directed aspartate-specific proteases) are cysteine proteases that play a 
central role in propagating the process of programmed cell death (apoptosis) in response to 
proapoptotic signals.159 While some caspases primarily act to initiate intracellular event cascade, 
other caspases that are called effector caspases act further downstream and direct cellular 
breakdown through cleavage of structural proteins (Caspase-3, and Caspase-7). 160Activation of 
Caspase-3/7 is thus a mode of actin of apoptosis. We performed a caspase activation assay to 
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further understand the role of compounds 203b and 203i plays in promoting cancerous cell death 
in MCF-7 cells. It was observed that MCF-7 cells treated with compounds 203b and 203i 
experienced a moderate caspase-3 activity when compared with actinomycin D. The results from 
caspase-3 activation (Figure 31) indicate that compound 203b, which induced increased 
apoptosis according to the Annexin staining, does not induce significant caspase activation when 
compared to 203i and actinomycin D. Since the breast cancer cell line MCF-7 lacks a functional 
caspase-3 gene product,161 apoptosis induction in these cells by these compounds may be through 
other molecular pathways that do not involve caspase activation. 
 
Figure 31. Effects of compounds 203b, 203i, and actinomycin D (Act. D) at 1 µM on human 
Caspase-3 (Asp175) activity in MCF-7 cells, respectively. 
 
Inhibition of tubulin polymerization activity is regarded as the other approach for innovative 
therapeutic strategies in cancer treatment and the chalcone derivatives are known to produce their 
anticancer activity through inhibition of tubulin polymerization by binding to colchicine-binding 
site.162 Compounds that bind to the colchicine binding site are defined as inhibitors of tubulin 
assembly and considered as microtubule destabilizing agents. Replacement of the A-ring of the 
chalcone framework with different aryl and heteroaryl moieties has previously been found to 
result in derivatives with potent anti-tubulin activity. The anologous (E)-3-(6-chloro-2H-
chromen-3-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one, for example, was found to bind 
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directly to tubulin and disturb microtubule stability and the function of the spindle apparatus, 
which causes cancer cells to undergo apoptosis.163 Based on this literature precedence, we then 
decided to investigate the effect on tubulin polymerization of the benzofuran-chalcones 203. 
 
2.5.3 Inhibition of tubulin polymerisation of compound 203 complemented with 
molecular docking 
 
To determine the effect of compounds 203 on tubulin polymerization, a fluorescence-enhanced 
tubulin polymerization assay kit was used. The benzofuran-chalcone hybrids 203a–y were 
evaluated for their ability to inhibit tubulin polymerization using actinomycin D and colchicine 
as reference standards in a cell-free in vitro assay. The IC50 values for these compounds were 
also determined and these are listed in Table 20. Although moderately cytotoxic against the 
MCF-7 cells, the parent compound 203a was found to inhibit tubulin polymerization more so 
than the other derivatives bearing substituents at the 4-position of the phenyl ring on the 
benzofuran framework. Compounds 203f, 203i and 203j were found to exhibit increased 
inhibitory effect against tubulin polymerization and the observed trend in IC50 values: 203f (23.3 
µM) < 203j (8.85 × 10-3 µM) < 203i (5.51 × 10-5 µM) compares well with their antiproliferative 
effect against the MCF-7 cell line. A combination of a 2-(3-fluorophenyl) group on the chalcone 
arm and a 2-(4-trifluoromethoxyphenyl) group on the benzofuran scaffold in compound 203o 
resulted in increased inhibitory effect against tubulin polymerization (IC50 = 1.76 × 10
-3 µM) 
than the analogous compounds within the series 203k–o. Moderate activity was observed for 
compound 203n substituted with a 4-methoxyphenyl group on the benzufuran framework. A 
combination of a 2-(3-chlorophenyl) group on the chalcone moiety and a phenyl ring (203p) or 
4-methoxyphenyl group (203s) on the benzofuran framework resulted in significant inhibitory 
effect against tubulin polymerization compared to the other derivatives within the series 203p–
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t. A combination of the 2-(4-fluorophenyl) group on the benzofuran framework and a 2-(4-
methoxyphenyl) substituent on the chalcone arm in compound 203v resulted in significant 
inhibitory effect (IC50 = 1.62 × 10
-2 µM) against tubulin polymerization compared to the other 
derivatives within the series 203u–y. The benzofuran-chalcone hybrids described in this 
investigation significantly interfere with tubulin polymerization by lowering the rate of assembly 
(Table 20), which suggests that the molecular target of these chalcone derivatives might be 
tubulin. However, the strong anti-tubulin polymerization activity among other series does not 
necessarily correspond well with the poor or lack of cytotoxicity for the other derivatives. 
Nonlinearity between antiproliferative activity and the effect on tubulin polymerization has been 
observed for some inhibitors before where highly cytotoxic compounds were not necessarily 
potent inhibitors of tubulin polymerization and vice versa.162-163 In addition to induction of 
apoptosis and/or tubulin inhibition, chalcones have also been found to exhibit anticancer activity 
through other mechanisms of action.164 
 
Table 20. IC50 values of 203a-y against tubulin using colchicine as a positive control 
      
         203a–y    
Compounds  R1 R2 IC50 (µM) 
203a H H 15.6 ± 0.06 
203b F H 26.5± 0.17 
203c Cl H 26.6± 0.27 
 103 
 
                      Table 20 continues   
203d CH3O- H 34.5± 0.22 
203e CF3O- H 25.4
 ± 0.24 
203f H 4-F 23.3± 0.11 
203g F 4-F 13.2 ± 0.17 
203h Cl 4-F 1.33 ± 0.38 
203i CH3O- 4-F 5.51 × 10
-5 ± 0.39 
203j CF3O- 4-F 8.85 × 10
-3 ± 0.42 
203k H 3-F 77.0 ± 0.21 
203l F 3-F 3.98 ± 0.07 
203m Cl 3-F 10.2 ± 0.19 
203n CH3O- 3-F 0.80± 0.37 
203o CF3O- 3-F 1.76 × 10
-3 ± 0.11 
203p H 3-Cl 9.37 × 10-2 ± 0.21 
203q F 3-Cl 51.3 × 10-2 ± 0.22 
203r Cl 3-Cl 345.0± 0.16 
203s CH3O- 3-Cl 0.71
 ± 0.30 
203t CF3O- 3-Cl 2.83± 0.07 
203u H 4-OCH3 18.3
 ± 0.16 
203v F 4-OCH3 1.62 × 10
-3 ± 0.12 
203w Cl 4-OCH3 48.4 ± 0.11 
203x CH3O- 4-OCH3 67.4 ± 0.14 
203y CF3O- 4-OCH3 7.80 ± 0.07 
Colchicine   9.88 × 10-2 ± 0.17 
 
 104 
 
To help us understand the anticancer activity of compounds 203a–y and guide further structure 
activity relationship (SAR) studies, we selected compounds 203i and 203o and docked them into 
tubulin. Compounds 203i and 203o, which exhibited increased inhibitory effects against tubulin 
polymerization and colchicine, were docked into tubulin (PDB ID: 1SAO) and their docked 
poses are represented in Figure 32 below. The docking poses of colchicine (Figure 32) and the 
benzofuran-chalcones 203i (Figure 32) and 203o (Figure 32) revealed that the hybrids occupy 
the hydrophobic pocket of the colchicine-binding site at the interface between the α and β-chains. 
Increased hydrophobic (alkyl, pi-alkyl, pi-sigma, amide-pi) interactions exist between the most 
active compound 203i with the side chains of tubulin residues Ala180, Ala316, Ala354, Val318, 
Lys352, and Leu248 (Figure 32). The hydrogen atoms of the methoxy group are involved in 
carbon hydrogen bonding with Val315 (Hb distances = 2.71 and 2.54 Å) and van der Waals 
interaction with Met259. The bromine atom, on the other hand, is involved in halogen bond 
interaction with the protein residue Ala317. The docking pose of 203o (Figure 32) also revealed 
the presence of several hydrophobic interactions between the benzofuran moiety and the 4-
trifluoromethoxyphenyl group of the chalcone arm with the protein residues Ala250, Ala354, 
Leu255, and Lys352. There are also pi-sulfur bond interactions between the 3-fluorophenyl and 
4-trifluoromethoxyphenyl groups with Cys241 and Met259, respectively. The trifluoromethoxy 
group is involved in a hydrogen bond interaction with Lys352 (Hb distance = 2.73 Å) and Thr314 
(Hb distance = 2.73 Å). The fluorine atom of the 3-fluorophenyl ring interacts with Val238 via 
halogen bonding while the fluorine atoms of the trifluoromethoxy group are involved in halogen 
bond interaction with Asn350, Asn358, Val238, and Val315. The modeling studies against 
tubulin suggest that the hydrophobic interactions and hydrogen and/or halogen bonding with the 
protein residues helps to stabilize the binding of these compounds in the colchicine-binding 
domain of α,β-tubulin interface. This probably accounts for the observed significant tubulin 
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polymerization inhibitory effect and the increased cytotoxicity of these compounds against the 
MCF-7 cell line. 
 
Colchicine 
  
                             203i                                                     203o 
Figure 32. (a) 2D interaction diagrams for the binding of tubulin (PDB code: 1SAO) with 
colchicine, 203i and 203o. Residues are annotated with their three-letter amino acid code. 
 
The chalcone-based compounds were found to exhibit anticancer activity via several 
mechanisms of action, including tyrosine kinase inhibition,164 we decided to evaluate the most 
cytotoxic compounds from against the MCF-7 cell line for their potential to inhibit EGFR-TK 
phosphorylation. 
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2.5.4 Inhibition of EGFR-TK phosphorylation of 203 complemented with molecular 
docking  
 
The most cytotoxic benzofuran-appended hybrids namely, 203b, 203j, 203o, 203p and 203v, 
and evaluated them for their potential to inhibit EGFR-tyrosine kinase phosphorylation against 
actinomycin D and gefitinib. The treatment of NIH3T3 (SAA) and B104-1-1 (neuroblast-
transformed NIH3T3) cells with actinomycin D has previously been found to block Shc/Grb2 
interaction for the treatment of specific tumors caused by EGFR.165 Gefitinib, on the other hand, 
is a selective inhibitor of the EGFR-TK and it inhibits tumour pathogenesis, metastasis, and 
angiogenesis, and also promotes apoptosis.48 The test compounds and the two reference 
standards were evaluated for inhibitory effects against EGFR-tyrosine kinase phosphorylation 
and the corresponding IC50 values are represented in Table 21. The results of this assay revealed 
that the title compounds also exhibit significant inhibitory effect against EGFR-TK 
phosphorylation when compared to gefitinib. Compound 203b exhibited an increased 
cytotoxicity and apoptotic effect but poor anti-tubulin activity was also found to exhibit 
significant inhibitory activity against EGFR with an IC50 value of 0.17 µM. The most cytotoxic 
compound 203i against the MCF-7 cells seems to exhibit inhibitory effects against tubulin 
polymerization and EGFR-TK phosphorylation. Moderate inhibitory effects against the EGFR 
were also observed for compounds 203o, 203p, and 203v with IC50 values of 0.12, 0.17 and 0.15 
µM, respectively. 
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Table 21: IC50 values (in µM) of EGFR-TK by 203b, 203i, 203o, 203p, and 203v against 
actinomycin D and gefitinib. 
Compound IC50 (μM) 
203b 0.17 ± 0.03 
203i 0.09 ± 0.03 
203o 0.12 ± 0.04 
203p 0.17 ± 0.06 
203v 0.15 ± 0.02 
Actinomycin D 0.04 ± 0.03 
Gefitinib 0.03 ± 0.02 
 
An in silico docking of the most potent compounds 203i and 203o in the active site of the EGFR 
complexed with the reversible ATP competitive drug Gefitinib (PDB ID: 1M17) predicted that 
the compounds might exhibit a binding conformation similar to that of Gefitinib (Figure 33). The 
important protein residues in the hydrophobic pocket of the ATP-competitive site that interacts 
with 203i are Leu694, Leu820, Arg817, and Val702 (Figure 33). The benzofuran moiety is also 
involved in pi-sulfur interaction with Cyst773 and pi-sulfur interaction also exists between the 
methoxyphenyl group on the chalcone arm with Met743. The Lys721 residue establishes a 
cation-interaction with the 4-methoxyphenyl ring of 203i. There is also a pi-anion interaction 
between the benzofuran core of 203i and carboxylic side chain of Asp831 located on the 
phosphate-binding region along the sugar pocket. Carbon-hydrogen bond interactions, which are 
the most common kinase-inhibitor interactions exist between Leu764 (Hb distance = 2.66 Å), 
Ala719 (Hb distance = 2.52 Å) and Thr766 (Hb distance = 2.43 Å) with the methoxy group of 
203i. The fluorine atom on the 2-phenyl ring of the benzofuran scaffold is involved in hydrogen 
bonding with the NH backbone of Met769 (Met769-NH…F distance = 2.18 Å), which is known 
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to hydrogen bond to N-1 of the adenine ring of ATP and help to fix it in the binding pocket. This 
interaction, in our view, would account for the increased inhibitory effect of this compound 
against the EGFR and therefore its increased cytotoxicity against the EGFR-positive MCF-7 cell 
line. The docking pose of compound 203o (Figure 33) reveals the presence of hydrophobic 
(alkyl, pi-alkyl and pi-sigma) interactions with the protein residues Leu764, Leu694, Cys773, 
Lys721, Val702, and Leu820. Val702, Leu820, and Ala719 are located near the gatekeeper 
residue, Thr766, and its location is envisaged to control the access of an inhibitor to the 
hydrophobic pocket of the ATP-competitive site.166 The Lys721 in the ATP-binding site of 
EGFR is considered to be one of the key residues to decide the biological activity of the EGFR. 
The fluorine atom on the 4-fluorophenyl group is involved in halogen bonding with Ala719 and 
Leu764 and additional halogen bonding exists between the trifluoromethoxy group and the 
protein residue Pro770. Halogen-bonds are known to confer the specificity of inhibitors against 
protein kinases.167 Moreover, fluorine-containing groups have been found to enhance the 
efficacy of the molecule by promoting electrostatic interactions with targets, improving cellular 
membrane permeability due to its lipophilicity, and increasing strength toward oxidative 
metabolism of the drug.168 Compounds 203i and 203o exhibit increased interactions with the 
protein residues in the binding pocket of EGFR and a better binding affinity in line with their 
strong EGFR binding activity in addition to its significant cytotoxicity against the MCF-7 cells. 
The results of the synthesis and biological activity studies of the benzofuran-chalcone hybrids 
prepared in this investigation have since been published.169 
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A 
                    
                                   203i                                                                            203o 
Figure 33. 2D interaction diagrams for the binding of EGFR (PDB code 1M17) with gefitinib 
(A), 203i and 203o. Residues are annotated with their three-letter amino acid code. 
 
2.5.6 Evaluation of the benzofuran-quinazoline hybrids for antiproliferative properties 
 
The in vitro anti-proliferative activity of the benzofuran-quinazolines 215a-j was examined 
against four EGFR-expressing cancer cell lines; the A549 (lung cancer), Caco-2 (colon 
carcinoma), HeLa (cervical cancer) and C3A (Hepatocellular carcinoma) cell lines using the 3-
(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay.155 
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Gefitinib was used as a reference drug. The results were expressed as median growth inhibitory 
concentration (IC50) values, which represent the compound concentration required to produce a 
50% inhibition of cell growth after 72 h of incubation, compared to untreated controls and 
standard (Gefitinib) (Table 22). Investigations of the anti-proliferative activity against A549 
indicated that compound 215j (IC50 47.4 ± 0.07 µM) was found to be the most potent derivative, 
being significantly more active than Gefitinib (IC50 51.3 ± 0.17). Also, compound 215f possessed 
slightly higher anti-proliferative activities than the reference drug (IC50 48.0 ± 0.10 and 51.3 ± 
0.17 µM, respectively). Compounds 215b and 215c were almost equipotent to Gefitinib (IC50 
54.3 ± 0.19 and 52.6 ±0.20 µM, respectively). The evaluation of the anti-proliferative activity in 
Caco-2 cell line, on the other hand, revealed that compound 215j (IC50 18.4 ± 0.07 µM) was the 
most potent counterpart when compared to gefitinib (IC50 27.9 ± 1.05 µM). The presence of a 4-
trifluoromethoxyphenyl group on the benzofuran framework in compound 215j led to significant 
cytotoxicity against the A549 (IC50 = 47.4 µM) and HeLa (IC50 = 28.1 µM) and more so against 
the Caco-2 cell line (IC50 = 18.4 µM) with no activity against the C3A cells when compared with 
Gefitinib. The incorporation of 3-Cl substituent to the benzofuran moiety in 215d enhanced the 
anti-proliferative activity against C3A (IC50 = 9.0 µM) and the HeLa (IC50 = 22.1 µM) cell lines, 
especially when accompanied with 4-flourophenyl moiety on the quinazoline core at 2-position 
and resulted in reduced cytotoxicity against the A549 and Caco-2 cell lines. Also, incorporation 
of electron withdrawing groups at 4-position is not favorable for the anti-proliferative activity, 
except for the 4-Cl substituent which is well tolerated with a 4-chlorophenyl group on the 
quinazoline framework seems to be more desirable for cytotoxicity than with a 2-(4-
fluorophenyl) ring, which resulted in diminished cytotoxicity for 215e. 
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Table 22: Cytotoxic effects of 215a–j and Gefitinib against A549, Caco-2, C3A and HeLa cell 
lines 
N
N
Br
NH
X
O
Br
R
 
     215a–e (X = F) & 215f–j (X = Cl)  
 
  Cancer cells IC50 (µM) 
Compound R A549 Caco-2 C3A HeLa 
215a H 64.7 ± 0.11 96.3 ± 0.10 81.0 ± 0.03 17.6 ± 0.39 
215b 3-F 54.3 ± 0.19 83.9 ± 0.07 90.1 ± 0.02 47.0 ± 0.38 
215c 4-F 52.6 ±0.20 98.8 ± 0.02 > 100 11.4 ± 0.56 
215d 3-Cl 65.1 ± 0.12 47.7 ± 0.01 9.0 ± 0.01 22.1 ± 1.10 
215e 4-OCF3 97.6 ± 0.07 65.2 ± 0.10 > 100 23.4 ± 0.49 
215f H 48.0 ± 0.10 75.0 ± 0.02 73.9 ± 0.02 15.4 ± 0.45 
215g 3-F 78.5 ± 0.15 94.4 ± 0.02 79.1 ± 0.01 53.5 ± 4.46 
215h 4-F 74.1 ± 0.21 49.1 ± 0.01 > 100 28.6 ± 1.12 
215i 3-Cl 86.6 ± 0.16 33.5 ± 0.10 68.2 ± 0.02 75.1 ± 5.25 
215j 4-OCF3 47.4 ± 0.07 18.4 ± 0.07 > 100 28.1 ± 0.79 
Gefitinib  51.3 ± 0.17 27.9 ± 1.05 5.0 ± 0.04 98.8 ± 0.56 
 
The 4-anilinoquinazolines48-50 and benzofuran derivatives30 are known to be cytotoxic to cancer 
cells by inducing apoptosis. In this study, to confirm that compounds 215d and 215j which 
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showed the strongest cytotoxic effect, induced apoptosis, the Annexin-V FITC test was 
performed as an indicator of early apoptosis. 
 
2.5.7 Mode of cancer cell death (apoptosis vs necrosis) 
 
To elucidate the molecular mechanism of the cytotoxic effects of 215d and 215j, we investigated 
whether these compounds induced the morphological changes characteristic of apoptotic cell 
death in the C3A and Caco-2 cell lines against doxorubicin hydrochloride as a reference standard, 
respectively. The population of apoptotic cells was determined by means of Annexin-V and 
propium iodide (PI) double staining by flow cytometry, which is a useful tool for evaluation of 
molecular and morphological events that take place during cell death and cell proliferation. It 
was determined that compounds 215d and 215j showed an apoptotic effect from 5 µM onwards 
and as the dose increased, so did the apoptotic effect figure (34). The highest pro-apoptotic 
potential was observed after 24 h of incubation with compounds 215d in hepatocellular 
carcinoma cells, where we observed 82.4% viable cells and 17.7% apoptotic cells. In the case of 
compound 215j in colon cancer cells most of the apoptotic effect was at the stage of early 
apoptosis (19.8%–21.1%) and the cell death rate (11%–23.9%) was determined to be increased 
with the increasing concentration. 
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(a) Compound 215d asgainst C3A cell line 
Doxorubuxin       215d (5 µM)   215d (12.5 µM) 
 
(b) Compound 215j against Caco-2 cell line 
Doxorubucin          215j (5 µM)  215j (12.5 µM) 
     
Figure 34: Effects of compounds 215d and 215j on the induction of apoptosis in C3A (a) and 
Caco-2 cells (b) as determined by Annexin V/PI staining. Data represent the percentage of 
apoptotic cells for the control and compounds 215d and 215j at 5 and 12.5 µM after 24 h. 
 
Apoptosis may start through intrinsic or extrinsic pathways. To better identify the initial pathway 
of apoptosis, the caspase activation assay for apoptosis regulators was applied. The presence of 
cleaved caspase-3 was investigated to determine by which route cellular apoptosis had occurred. 
Consequently, we evaluated compounds 215d and 215j for potential to induce caspase-3 
activation in C3A and Caco-2 cells using Gefitinib as a reference standard (Figure 35). The 
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results of this study indicate that these compounds induce apoptosis through activation of 
caspase-3 that subsequently leads to cell membrane alterations.  
   
Figure 35: Effects of compounds 215d and 215j on Human Caspase-3 (Asp175) activity in 
C3A and Caco-2 cells against Gefinitib (Gef), respectively. 
 
The hepatocellular carcinoma and the colorectal adenocarcinoma cell lines have been found to 
express high levels of EGFR and sensitivity to Gefitinib.170,171 Inhibition of EGFR-TK activity 
is regarded as the most promising approach for innovative therapeutic strategies in cancer 
treatment.172 
 
2.5.8 Inhibition of EGFR-TK phosphorylation complemented with molecular docking 
 
The benzofuran-based 4-aminoquinazolines 215a-j were tested for their inhibitory potency 
against human EGFR against Gefitinib as the reference standard (Table 23). Compound 215j 
was found to exhibit significant cytotoxicity against the A549, Caco-2 and Hela cells showed 
moderate EGFR inhibitory activity (IC50 = 61.46 nM) compared to the reference standard. The 
most cytotoxic compound 215d against the C3A cell line and compound 215e were found to 
inhibit the EGFR IC50 = 29.26 nM and 31.1 nM more so than the reference drug. Based on the 
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observed results, we can conclude that the EGFR-TK inhibitory activity of the benzofuran-
aminoquinazolines 215 is correlated to their antiproliferative activities. 
 
Table 23: Percentage inhibition and IC50 values (in nM) of EGFR-TK by 215a-j against 
Gefitinib 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular docking studies in were also performed performed using AutoDock to validate 
whether compounds 215 have comparable binding mode to that of gefitinib for EGFR. A crystal 
structure of EGFR that previously co-crystalized with Erlotinib (an inhibitor of EGFR) was 
obtained from the protein data bank (PDB ID: 1M17). The control (Gefitinib) docked on 
Erlotinib binding site produced root mean square deviation (RMSD) of 1.6 Å with the crystal 
structure (Figure 36). Binding free energy calculation showed that Gefitinib is more favourable 
Compound IC50 (nM) 
215a 111.3 ± 0.42 
215b 122.5 ± 0.50 
215c 52.2 ± 0.18 
215d 29.3 ± 0.02 
215e 31.1 ± 0.12 
215f 40.4 ± 0.16 
215g 132.9 ± 0.55 
215h 125.7 ± 0.52 
215i 90.2 ± 0.34 
215j 61.5 ± 0.01 
Gefitinib 33.1 ± 0.02 
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for the inhibition towards EGFR compared with Erlotinib. The binding conformation of Gefitinib 
might explain the better binding affinity compared with Erlotinib. The morpholine region of 
Gefitinib was positioned as anti-parallel with Phe699 side chain, but no such orientation was 
observed in Erlotinib. In addition, the 3-chloro-4-fluorophenyl moiety of Gefitinib also docked 
deeper into the EGFR binding pocket compared with Erlotinib. Compound 215i has the highest 
binding affinity among the 2-arylbenzofuran-appended 4-aminoquinazoline hybrids 215a–j with 
the binding free energy of -11.54 kcal/mol.  
 
 
Figure 36: Docked conformation of Erlotinib (as docking control), Gefitinib and 4-
aminoquinazoline–appended 2-arylbenzofurans (compound 215; stick representation) in the 
binding pocket of epidermal growth factor receptor (EGFR) kinase domain (surface and ribbon 
representation). Blue dotted lines are the direct hydrogen bonding formed between docked 
ligands and EGFR. The results for the synthesis and biological evaluation of the 4-
aminoquinazoline–appended 2-arylbenzofurans have since been published.173 
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Chapter 3: Conclusions 
 
In summary, the 2-amino-3-halogenochalcone and 2-hydroxy-3-halogenochalcone moieties 
represent suitable scaffolds for sequential alkynylation and heteroannulation for the construction 
of the five-membered heterocyclic ring onto the 1,3-diaryl-2-propen-1-one framework to afford 
novel indole-and benzofuran-chalcones, respectively. The indole-chalcones were found to 
undergo site-selective acetylation with triflouroacetic anhydride (TFAA) in the absence of a 
catalyst or additive to afford the corresponding 3-trifluoroacetylindole-chalcones without traces 
of the isomeric N-1 acetylated derivatives. The ambident electrophilic C=C–C=O framework of 
the indole- and benzofuran-chalcones, in turn, facilitated one-pot nucleophilic attack on the 
carbonyl group (1,2-addition) and subsequent conjugate addition at the β-carbon (1,4- or Michael 
addition) with 2-aminothiophenol to afford indole- and benzofuran-benzothiezapine hybrids. A 
simple method for linking the 2-arylbenzofuran and quinazoline scaffolds through an amino 
bridge to comprise analogues of the medicinally important 4-anilinoquinazolines or Cediranib 
(12) has also been developed. 
 
Most of benzofuran-chalcone hybrids exhibited moderate to significant antigrowth effects in 
vitro against the MCF-7 cell line when compared to the reference standard actinomycin D. The 
presence of a 2-phenyl substituent on the benzofuran moiety and a 4-fluorophenyl group in 
compound 203b or a combination of a 2-phenyl group on the benzofuran moiety and a 4-
(trifluoromethoxy)phenyl group on the chalcone arm of 203e increased cytotoxicity against the 
MCF-7 cell line. The presence of a 4-methoxyphenyl group on the chalcone and 4-fluorophenyl 
group (203i) or 3-chlorophenyl group (203s) on the benzofuran framework of the benzofuran-
chalcone hybrids The most cytotoxic benzofuran-chalcone hybrids 203b and 203i, have been 
evaluated for apoptosis by Annexin V-Cy3 SYTOX staining and caspase-3 activation The 
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experimental and molecular docking results suggest that the title compounds have potential to 
inhibit tubulin polymerization and epidermal growth factor receptor tyrosine kinase (EGFR-TK) 
phosphorylation. The modeled structures of representative compounds displayed hydrophobic 
interactions as well as hydrogen and/or halogen bonding with the protein residues in the 
colchicine binding site of tubulin or ATP binding pocket of the EGFR. These interactions 
presumably account for the observed increased binding affinity of these compounds against the 
two receptors and their significant antigrowth effect against the MCF-7 cell line. 
 
The benzofuran-aminoquinazoline hybrids 215a–j were found to exhibit moderate to significant 
cytotoxicity against the HeLa cells with the exception of 215b, 215g and 215i substituted with a 
fluorine or chlorine atom on the 3-position of the phenyl substituent on the benzofuran arm. 
Although most of these compounds are less active against the Caco-2 and C3A cell lines, a 
combination of a 2-(3-chlorophenyl) group on the benzofuran moiety and a 2-(4-fluorophenyl) 
group on the quinazoline framework of 215d resulted in significant cytotoxicity against the C3A 
cell line (IC50 = 9.0 µM) when compared to Gefitinib (IC50 = 5.01 µM). Likewise, compound 
215j substituted with a 4-chlorophenyl group at the 2-position of the quinazoline moiety and 4-
trifluoromethoxyphenyl group at the 2-position of the benzofuran framework was found to 
exhibit increased cytotoxicity against the Caco-2 cells (IC50 = 18.4 µM) more so than Gefitinib 
(IC50 = 27.9 µM). Compounds 215d and 215j, which were selected for further evaluation of the 
mode of cell death were able to trigger apoptosis in C3A and Caco-2 cells, respectively. This 
demonstrates that the benzofuran-aminoquinazoline hybrids exhibit cytotoxicity and pro-
apoptotic properties. Compounds 215d and 215j not only demonstrated strong antiproliferation 
activities against some of the tested cancer cell lines, but also showed significant inhibitory 
activity towards EGFR (IC50 = 29.3 nM and 61.5 nM, respectively) compared to the medicinally 
important EGFR inhibitor, Gefitinib (IC50 = 33.1 nM). Molecular docking of compounds 215 
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into EGFR-TK active site suggests that they bind to the region of EGFR like Gefitinib does. The 
benzofuran-aminoquinazoline and their derivatives may also target other protein kinases. 
Therefore, future studies will be extended to other types of protein kinases to explore their 
mechanism of action and selectivity. 
 
The Csp2–Br bond of the compounds prepared in this investigation could be transformed via 
other transition metal catalysed cross-coupling reactions to afford polycarbosubstitued 
derivatives. The reactions may include Kumada cross-coupling with organomagnesium 
compounds174, Suzuki cross-coupling with organoboronic acids175, Negishi cross-coupling with 
organozinc reagents176, Heck cross-coupling with alkenes177, Sonogashira cross-coupling with 
terminal alkynes129, Stille cross-coupling with organostannane compounds174 or Buchwald-
Hartwig reaction which represents an important example for the carbon-heteroatom bond 
formation between aryl/heteroarylhalides with amines178 to afford poly-substituted derivatives. 
 
Future research extending from this study will include the following: 
 
i. Synthesis of polysubstituted pyrroloquinolinones 217 via initial epoxidation of the indole-
appended chalcones 201 followed by base-mediated cyclization of the incipient epoxide 
derivatives 216. The pyrroloquinoline-based compounds, for example, are antimitotic agents179 
capable of disruption of tubulin polymerization180,181 Microtubule targeting agents are effective 
anti-cancer drugs and have also been instrumental as biological probes to identify the nature of 
tubulin and the role of tubulin dynamics in mitosis182-183 Some pyrroloquinolinones have also 
been found to induce cell cycle arrest184,185 and act as dual topoisomerase I and II inhibitors.186 
Compounds 217 would then be  evaluated for their capability to serve as dual inhibitors of 
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tubulin polymerization and DNA topoisomerase I/II activity complemented with molecular 
docking. 
 
    201           216           217 
ii. To effect the site-selective tandem Sonogashira cross-coupling and cyclization of 3-bromo-
2,4-dihydroxy-5-iodobenzophenone 218 with terminal acetylenes followed by Claisen-
Schmidt aldol condensation of the intermediate 5-acetyl-2-aryl-7-bromo-6-
hydroxybenzofurans 219 with benzaldehyde derivatives to afford the corresponding linear 
benzofuran-chalcone hybrids 220. Further cclization of the ortho-hydroxy chalcone moiety 
would afford furoflavanones, furoflavones, furoisoflavones or furofavanols with potential 
biological activity. Moreover, tandem Sonogashira cross-coupling and cyclization of 220 with 
terminal acetyls would afford diarylbenzodifuranyl-chalcone hybrids 222 with potential 
biological or photophysical properties. 
 
 
iii. Transformation of 2-amino-5-bromo-3-iodoacetophenone 197a via Vilsmeier-Haack reaction 
with POCl3-DMF mixture followed by acid-mediated hydrolysis of the intermediate 6-bromo-
4-chloro-8-iodoquinoline-3-carbaldehyde to afford 6-bromo-8-iodo-4-oxo-1,4-
dihydroquinoline-3-carbaldehyde. One-pot palladium catalysed tandem Sonogashira cross-
218                               219                                       220 
221 
222 
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coupling and cycloisomerization of 223 with terminal acetylenes, for example, would afford 
the corresponding 2-aryl-8-bromo-6-oxo-6H-pyrrolo[3,2,1-ij]quinoline-5-carbaldehydes. 
Compound 224 has several reactive centres, anmely the electrophilic unsaturated dicarbonyl 
framework, Csp2–Br and Csp2–H bonds for further transformation with nucleophilic reagents 
and transition metal mediated C–C and/or C–N bond formation. The Schiff bases 225 of 224, 
on the other hand, could be complexed with Zn(II) metal, for example, to afford complexes 
226 with potential biological and photophysical properties. 
 
                                                                                                                                     226 
 
 
  
223                                                           224                                                  225 
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Chapter 4: Experimental 
 
4.0  General  
 
Commercially available solvents and reagents were used as supplied or purified by conventional 
methods before use. Melting points were recorded on a Thermocouple digital melting point 
apparatus (Mettler Toledo LLC, Columbus, OH, USA) and are uncorrected. IR spectra (Bruker 
Optics, Billerica, MA, USA) were recorded as powders using a Bruker VERTEX 70 FT-IR 
Spectrometer (Bruker Optics, Billerica, MA, USA) with a diamond ATR (attenuated total 
reflectance) accessory by using the thin-film method. For column chromatography, Merck 
kieselgel 60 (0.063–0.200 mm) (Merck KGaA, Frankfurt, Germany) was used as stationary 
phase. NMR spectra were obtained as CDCl3 or DMSO-d6 solutions using Varian 300 MHz 
(Varian Inc., Palo Alto, CA, USA) or Agilent 500 MHz NMR (Agilent Technologies, Oxford, 
UK) spectrometers and the chemical shifts are quoted relative to the TMS peak. High-resolution 
mass spectra were recorded using Synapt G2 Quadrupole Time-of-flight Mass Spectrometer 
(Waters Corp., Milford, MA, USA) at the University of Stellenbosch Mass Spectrometry Unit. 
The following abbreviations are used throughout for NMR spectroscopy: 
 ppm = parts per million 
J = coupling constant in Hz 
δ = chemical shift values in ppm 
s = singlet, br s = broad singlet 
d = doublet, dd = doublet of doublets 
t = triplet, q = quartet,   
m = multiplet; qt = quintet 
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4.1 Halogenation of 2-aminoacetophenone (195a) and 2-hydroxyacetophenone (195b) 
 
4.1.1 Synthesis of 2-amino-5-bromo-3-iodoacetophenone (196a) 
 
 
A stirred solution of 2-aminoacetophenone 195a (5.00 g, 36.99 mmol) in CH2Cl2 (500 mL) at 0 
℃ was treated slowly with pyridinium tribromide (11.83 g, 36.9 mmol). The reaction mixture 
was allowed to warm up to room temperature (RT) and then stirred at this temperature for 3 h. 
The resultant precipitate was filtered and recrystalized from hexane to afford 196a as a yellow 
solid (6.02 g, 76%), mp. 79–81 ℃ (lit.142 82–83 ℃); νmax (ATR) 3453, 3316, 1653, 1609, 1563, 
1540, 1464, 1360, 1287, 1217, 1160, 956, 888, 822, 738, 671, 623, 517 cm-1; 1H NMR (500 
MHz, CDCl3) 2.65 (3H, s, CH3), 6.29 (2H, br s, NH2), 6.56 (1H, d, J = 8.5 Hz, H-3), 7.34 (1H, 
dd, J = 2.5 and 8.5 Hz, H-4), 7.80 (1H, d, J = 2.5 Hz, H-6); 13C NMR (125 MHz, CDCl3) 27.7, 
106.5, 118.9, 119.2, 134.0, 136.9, 149.0, 199.6. 
 
4.1.2 Synthesis of 5-bromo-2-hydroxyacetophenone (196b) 
  
 
A stirred solution of 2-hydroxyacetophenone 195b (5.26 g, 38.7 mmol) in acetic acid (400 mL) 
was treated with N-bromosuccinimide (18.02 g, 38.7 mmol) at RT. The mixture was stirred under 
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reflux for 1.5 h and then quenched with an ice-cold water. The resulting precipitate was filtered 
and recrystallized to afford 5-bromo-2-hydroxyacetophenone 196b (4.92 g, 59%); mp. 74‒75 °C 
(lit.143 82–83 ℃) (hexane); νmax (ATR) 491, 516, 624, 735, 879, 1081, 1195, 1285, 1346, 1473, 
1559, 1640, 3280 cm-1; 1H NMR (CDCl3) 2.63 (3H, s, CH3), 6.87 (1H, d, J = 8.5 Hz, H-3), 7.53 
(1H, dd, J = 2.4 and 8.5 Hz, H-4), 7.81 (1H, d, J = 2.4 Hz, H-6), 12.14 (1H, s, OH); 13C NMR 
(CDCl3) 26.6, 87.6, 106.7, 118.9, 134.7, 145.7, 148.5, 203.02.  
 
4.1.3 Synthesis of 2-amino-5-bromo-3-iodocetophenone (197a) 
  
 
A stirred solution of 196a (5.00 g, 23.36 mmol) in acetic acid (400 mL) was treated with N-
iodosuccinimide (5.78 g, 25.69 mmol) at RT. The mixture was stirred at RT for 2 h and then 
quenched with an ice-cold water. The resulting precipitate was filtered and recrystallized from 
ethanol to afford 197a (5.88 g, 74%); mp 95–97 ℃ (EtOH); νmax (ATR) 3453, 3383, 1637, 1590, 
1558, 1510, 1425, 1353, 1226, 949, 862, 741, 675, 625, 535, 443 cm-1; 1H NMR (500 MHz, 
CDCl3) 2.58 (3H, s, CH3), 6.97 (2H, br s, NH2), 7.83 (1H, d, J = 2.0 Hz, H-4), 7.88 (1H, d, J = 
2.0 Hz, H-6); 13C NMR (125 MHz, CDCl3) 27.7, 87.6, 106.7, 118.9, 134.7, 145.7, 148.5, 199.0; 
HRMS (ES): MH+, found 339.8838. C8H8NO
79BrI+ requires: 339.8834. 
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4.1.4  Synthesis of 5-bromo-2-hydroxy-3-iodoacetophenone (197b) 
 
A mixture of 5-bromo-2-hydroxyacetophenone 196b (3.23 g, 15.0 mmol) and N-
iodosuccinimide (5.78 g, 18,0 mmol) in acetic acid (400 mL) was treated as for 197a above. 
Work-up and recrystallization afforded 197b as a brown solid (4.78 g, 93%), mp. 111‒112 °C 
(Lit.146 104–105 °C); νmax (ATR) 441, 539, 670, 779, 862, 968, 1077, 1190, 1233, 1362, 1420, 
1581, 1650, 3259 cm-1; 1H NMR (CDCl3) 2.65 (3H, s, CH3), 7.83 (1H, d, J = 2.1 Hz, H-4), 8.04 
(1H, d, J = 2.1 Hz, H-6), 13.07 (1H, s, OH); 13C NMR (CDCl3) 26.4, 87.6, 111.1, 120.2, 133.1, 
147.1, 160.2, 203.2; HRMS (ES): MH+, found.  C8H7O2
79BrI+ requires: 341.8575. 
 
4.2  Synthesis of the (E)-2-amino-5-bromo-3-iodochalcones 198a–d 
 
      198a–d  
 
(E)-1-(2-Amino-5-bromo-3-iodophenyl)-3-phenylprop-2-en-1-one (198a); X = NH, R = H  
 
A mixture of 2-amino-5-bromo-3-iodocetophenone 197a (3.00 g, 8.84 mmol), benzaldehyde 
(0.98 g, 8.84 mmol) and potasium hydroxide (4 pellets, ca 0.8 g) in ethanol (30 mL) was stirred 
for 6 hours at room temperature. The mixture was quenched with ice cold water (120 mL) and 
the precipitate was filtered to afford 198a as a yellow solid (3.20 g, 86%), mp. 103–105 °C 
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(EtOH); νmax (ATR) 453, 581, 676, 889, 976, 1070, 1173, 1281, 1335, 1581, 1642, 3278, 3432 
cm-1; δH (500 MHz, CDCl3) ; δC (125 MHz, CDCl3) 7.01 (2H, br s, NH2), 7.41–7.44 (3H, m, 
ArH), 7.50 (1H, d, Jtrans = 15.5 Hz, α-H), 7.64 (1H, d, J = 2.0 Hz, 4-H), 7.65 (2H, d, J = 6.5 Hz, 
ArH), 7.76 (1H, d, Jtrans = 15.5 Hz, β-H), 7.91 (1H, d, J 2.0 Hz, 6-H); δC (125 MHz, CDCl3) 99.0, 
105.6, 111.3, 119.7, 122.0, 128.4, 130.6, 133.7, 134.8, 139.3, 144.4, 150.3, 190.3; HRMS (ES): 
MH+, found. 427.9144. C15H12NO
79BrI+ requires: 427.9147. 
 
(E)-1-(2-Amino-5-bromo-3-iodophenyl)-3-(4′-fluorophenyl)prop-2-en-1-one (198b); X = 
NH, R = F 
 
A mixture of 2-amino-5-bromo-3-iodocetophenone 197a (3.00 g, 8.84 mmol), 4-
fluorobenzaldehyde (1.09 g, 8.84 mmol) and potasium hydroxide (4 pellets, ca 0.8 g) in ethanol 
(30 mL) was treated as described for 198a. Work-up afforded 198b as a yellow solid (3.50 g, 
89%), mp. 146–149 °C (EtOH); νmax (ATR) 454, 542, 674. 825, 975, 1155, 1190, 1504, 1550, 
1643, 3302, 3447 cm-1; δH (500 MHz, CDCl3) 7.00 (2H, br s, NH2), 7.12 (2H, J = 8.7 Hz, 3′,5′-
H), 7.41 (1H, d, Jtrans = 15.5 Hz, α-H), 7.64 (2H, t, J = 8.7 Hz, 2′,6′-H), 7.73 (1H, d, Jtrans = 15.5 
Hz, β-H), 7.92 (1H, d, J = 2.1 Hz, 4-H), 7.94 (1H, d, J 2.1 Hz, 6-H); δC (125 MHz, CDCl3) 87.7, 
106.9, 116.1 (d, 2JCF = 21.8 Hz), 119.8, 121.4, 130.4 (d, 
3JCF = 8.5 Hz), 130.9 (d, 
4JCF = 3.3 Hz), 
133.5, 143.4, 145.6, 149.0, 164.1 (d, 1JCF = 250.2 Hz), 189.9; HRMS (ES): MH
+, found  
445.9050. C15H11NO
79BrIF+ requires: 445.9053. 
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(E)-1-(2-Amino-5-bromo-3-iodophenyl)-3-(4′-chlorophenyl)prop-2-en-1-one (198c); X = 
NH, R = Cl) 
 
A mixture of 2-amino-5-bromo-3-iodocetophenone 197a (3.00 g, 8.84 mmol), 4-
chlorobenzaldehyde (1.24 g, 8.84 mmol) and potasium hydroxide (4 pellets, ca 0.8 g) in ethanol 
(30 mL) was treated as described for 198a. Work-up afforded 198c. as a yellow solid (3.71 g, 
93%), mp. 142–144°C (EtOH); νmax (ATR) 460, 675, 821, 1013, 1091, 1189, 1488, 1506, 154, 
1584, 1641, 3314, 3456 cm-1; δH (500 MHz, CDCl3) 7.00 (2H, br s, NH2), 7.12 (2H, J = 8.7 Hz, 
3′,5′-H), 7.41 (1H, d, Jtrans = 15.5 Hz, α-H), 7.64 (2H, t, J = 8.7 Hz, 2′,6′-H), 7.73 (1H, d, Jtrans = 
15.5 Hz, β-H), 7.92 (1H, d, J = 2.1 Hz, 4-H), 7.94 (1H, d, J 2.1 Hz, 6-H); δC (125 MHz, CDCl3) 
87.7, 106.9, 119.7, 122.2, 129.3, 129.7, 135.5, 136.5, 143.2, 143.2, 145.6, 149.1, 189.7; HRMS 
(ES): MH+, found 461.8745. C15H11NO
79Br35ClI+ requires: 461.8757. 
 
(E)-1-(2-Amino-5-bromo-3-iodophenyl)-3-(4′-methoxyphenyl)prop-2-en-1-one (198d); X = 
NH, R = OCH3 
 
A mixture of 2-amino-5-bromo-3-iodocetophenone 197a (3.00 g, 8.84 mmol), 4-
methoxybenzaldehyde (1.20 g, 8.84 mmol) and potasium hydroxide (4 pellets, ca 0.8 g) in 
ethanol (30 mL) was treated as described for 198a. Work-up afforded 198d as a yellow solid 
(3.64 g, 91%), mp. 139–142 °C (EtOH); νmax (ATR) 537, 673, 824, 985, 1166, 1259, 1506, 1548, 
1634, 3276, 3448 cm-1; δH (500 MHz, CDCl3) 3.86 (3H, s, OCH3), 6.92 (2H, br s, NH2), 6.94 
(2H, J = 8.0 Hz, 3′,5′-H), 7.36 (1H, d, Jtrans = 15.5 Hz, α-H), 7.60 (2H, t, J = 8.0 Hz, 2′,6′-H), 
7.74 (1H, d, Jtrans = 15.5 Hz, β-H), 7.90 (1H, d, J = 1.5 Hz, 4-H), 7.94 (1H, d, J 1.5 Hz, 6-H); δC 
(125 MHz, CDCl3) 55.4, 87.6, 106.9, 114.4, 119.4, 120.2, 127.5, 130.3, 135.4, 144.7, 145.2, 
148.9, 161.7, 190.1; HRMS (ES): MH+, Found 457.9251. C16H14NO2
79BrI+ requires: 457.9253. 
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(E)-1-(5-Bromo-2-hydroxy-3-iodophenyl)-3-phenylprop-2-en-1-one (197e); X = O, R = H 
 
A mixture of 197b (2.90 g, 8.33 mmol), benzaldehyde (1.05 g, 9.99 mmol) and KOH (2.74 g, 
48.9 mmol) in methanol (100 mL) was treated as described for 198a to afford 198e as an orange 
solid (2.57 g, 72%), mp. 152–154 °C (EtOH); νmax (ATR) 581, 676, 889, 976, 1070, 1173, 1281, 
1335, 1581, 1642, 3278 cm-1; δH (500 MHz, CDCl3) 7.47 (1H, t, J = 7.0, Ar), 7.50 (1H, d, Jtrans 
= 15.5 Hz, α-H), 7.68 (2H, d, J = 8.0 Hz, Ar), 7.65 (2H, d, J = 7.5 Hz, Ar), 8.00 (1H, d, Jtrans = 
15.5 Hz, β-H), 8.01 (1H, d, J 2.0 Hz, H-4), 8.07 (1H, d, J 2.0 Hz, H-6), 13.5 (1H, br s, OH); δC 
(125 MHz, CDCl3) 110.9, 114.5, 115,9, 120.8, 126.9, 130.1, 130.9, 131.2, 131.9, 142.6, 147.5, 
160.3, 190.7; HRMS (ES): found 428.8997. C15H11O2
79BrI+ requires 428.8987. Anal calcd for 
C15H10O2BrI: C, 41.99; H, 2.35. Found: C, 41.96; H, 2.32. 
 
(E)-1-(5-Bromo-2-hydroxy-3-iodophenyl)-3-(4′-fluorophenyl)prop-2-en-1-one (198f); X = 
O, R = F 
 
A mixture of 197b (3.78 g, 11.08 mmol), 4-flourobenzaldehyde (1.86 g, 13.30 mmol) and KOH 
(3.44 g, 61.3 mmol) in methanol (100 mL) was treated as described for 198a to afford 198f as 
an orange solid (4.11 g, 80%), mp. 177–179 °C (EtOH); νmax (ATR) 542, 674, 825, 975, 1155, 
1190, 1504, 1550, 1643, 3202 cm-1; δH (500 MHz, CDCl3) 7.15 (2H, t, J = 8.5 Hz) 7.46 (1H, d, 
Jtrans = 16.0 Hz, α-H), 7.69 (2H, t, J = 8.0 Hz), 7.95 (1H, d, Jtrans = 16.0 Hz, β-H), 8.00 (1H, d, J 
1.5 Hz. H-4), 8.07 (1H, d, J 2.5 Hz, H-6), 13.7 (1H, br s, OH); δC (125 MHz, CDCl3) 87.7, 106.9, 
116.1 (d, 2JCF = 21.8 Hz), 119.8, 121.4, 130.4 (d, 
3JCF = 8.5 Hz), 130.9 (d, 
4JCF = 3.3 Hz), 133.5, 
143.4, 145.6, 149.0, 164.1 (d, 1JCF = 250.2 Hz), 189.3; HRMS (ES): found 446.8815. 
C15H10O2F
79BrI+ requires 446.9053. Anal calcd for C15H9O2FBrI: C, 40.30; H, 2.03. Found: C, 
40.19; H, 1.98. 
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(E)-1-(5-Bromo-2-hydroxy-3-iodophenyl)-3-(4-chlorophenyl)prop-2-en-1-one (198g); X = 
O, R = Cl 
 
A mixture of 197b (3.78 g, 11.08 mmol), 4-chlorobenzaldehyde (1.86 g, 13.30 mmol) and KOH 
(3.44 g, 61.3 mmol) in methanol (100 mL) was treated as described for 198a to afford 198g as 
an orange solid (4.11 g, 80%), mp. 184–186 °C (EtOH); νmax (ATR) 675, 821, 1013, 1091, 1189, 
1488, 1506, 154, 1584, 1641, 3249 cm-1; δH (500 MHz, CDCl3) 1.58 (1H, br s, OH) 7.03 (1H, d, 
Jtrans = 16.0 Hz, α-H), 7.39 (2H, d, J = 8.5 Hz, H-2',6'), 7.55 (2H, d, J = 8.5 Hz, H-3',5'), 7.67 (1H, 
d, Jtrans = 16.0 Hz, β-H), 7.84 (1H, d, J 2.5 Hz. H-4), 8.05 (1H, d, J 2.5 Hz, H-6); δC (125 MHz, 
CDCl3) 87.7, 111.1, 120.2, 125.7, 129.3, 129.5, 133.1, 133.2, 136.5, 142.1, 147.4, 160.2, 188.3 
(C=O); HRMS (ES): found 462.8519. C15H10O2
35Cl79BrI+ requires 462.8499. Anal calcd for 
C15H9O2ClBrI: C, 38.87; H, 1.96. Found: C, 38.77; H, 2.04. 
 
(E)-1-(5-Bromo-2-hydroxy-3-iodophenyl)-3-(4ʹ-methoxyphenyl)prop-2-en-1-one (198h); X 
= O, R = OCH3 
 
A mixture of 197b (4.08 g, 11.96 mmol), 4-methoxybenzaldehyde (1.95 g, 14.35 mmol) and 
KOH (3.34 g, 59.80 mmol) in methanol (100 mL) was treated as described for 198a to afford 
198h as an orange solid (3.83 g, 69%), mp. 173–175 °C (EtOH); νmax (ATR) 537, 673, 824, 985, 
1166, 1259, 1506, 1548, 1634, 3276 cm-1; δH (500 MHz, CDCl3) 3.88 (3H, s, OCH3) 6.96 (2H, 
d, J = 8.5 Hz, H-3',5'), 7.42 (1H, d, Jtrans = 16.0 Hz, α-H), 7.65 (2H, d, J = 8.5 Hz, H-2',6'), 7.96 
(1H, d, Jtrans = 16.0 Hz, β-H), 8.01 (1H, d, J 2.0 Hz, H-4), 8.05 (1H, d, J 2.0 Hz, H-6), 13.5 (1H, 
br s, OH); δC (125 MHz, CDCl3) 55.6, 114.3, 115.9, 126.8, 129.9, 130.0, 130.9, 131.0, 131.9, 
140.9, 147.5, 162.5, 164.6, 190.7; HRMS (ES): MH+, found 458.9095. C16H13O3
79BrI+ requires 
458.9093. Anal calcd for C16H12O3BrI: C, 41.86; H, 2.63. Found: C, 41.93; H, 2.75. 
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(E)-1-(5-Bromo-2-hydroxy-3-iodophenyl)-3-(4ʹ-(trifluoromethoxy)phenyl)prop-2-en-1-
one (185i); X = O, R = OCF3 
 
A mixture of 197b (2.98 g, 8.79 mmol), 4-trifluoromethoxybenzaldehyde (2.15 g, 10.54 mmol) 
and KOH (2.46 g, 43.95 mmol) in methanol (100 mL) was treated as described for 198a to afford 
198i as an orange solid (3.33 g, 74%), mp. 106–107 ºC; νmax (ATR) 542, 691, 869, 1033, 1140, 
1259, 1343, 1447, 1573, 1642, 3283 cm-1; δH (500 MHz, CDCl3) 7.33 (1H, d, J = 8.0 Hz, H-3'), 
7.50 (2H, d, J = 8.5 Hz, H-2',6'), 7.54 (1H, d, Jtrans = 16.0 Hz, α-H), 7.61 (1H, d, J = 8.0 Hz, H-
5'), 7.94 (1H, d, Jtrans = 16.0 Hz, β-H), 8.01 (1H, d, J 2.0 Hz, H-4), 8.10 (1H, d, J 2.0 Hz, H-6), 
13.6 (1H, br s, OH); δC (125 MHz, CDCl3) 112, 120.2 (t, JCF = 256.0 Hz), 123.8, 127.2, 129.9, 
130.6, 132.0, 133.1, 136.1, 145.5, 147.3, 147.5,  161.4, 191.9; HRMS (ES): MH+, found 
510.8633 C16H9O3
79BrIF3
+ requires 510.8654. Anal calcd for C16H12O3BrI: C, 41.86; H, 2.63. 
Found: C, 41.93; H, 2.75. 
 
4.3 Sonogashira cross-coupling of compounds 198a–f 
 
 
      198a–f 
 
 
 
α 
β 
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(E)-1-(2-Amino-5-bromo-3-(phenylethynyl)phenyl)-3-phenylprop-2-en-1-one (200a); R1 = 
H, R2 = H 
 
A mixture of 198a (2.00 g, 4.67 mmol), phenylacetylene (0.57 g, 5.60 mmol), PdCl2(PPh3)2 (0.16 
g, 0.23 mmol), Cs2CO3 (1.82 g, 5.60 mmol) and CuI (0.09 g, 0.46 mmol) in ethanol (40 mL) was 
placed in a two-necked round bottom flask equipped with a stirrer bar, rubber septum and a 
condenser. The mixture was flushed with argon gas for 5 min. and a balloon filled with argon 
gas was connected to the top of the condenser. The mixture was stirred at 70 °C for 4 h, cooled 
to r.t. and then quenched with an ice-cold water. The mixture was extracted with chloroform (3 
x 30 mL) and the combined organic layers were dried over anhydrous MgSO4. The salt was 
filtered off and the solvent was evaporated under reduced pressure on a rotary evaporator. The 
residue was purified by column chromatography on silica gel to afford 200a as a solid (1.44 g, 
76%); Rf (toluene) 0.37, mp. 106–108 °C; νmax (ATR) 535, 728, 850, 922, 1019, 1113, 1202, 
1308, 1440, 1587, 1644, 3300, 3331, 3470 cm-1; δH (500 MHz, CDCl3) 7.12 (2H, br s, NH2), 
7.38–7.40 (3H, m. PhH), 7.42–7.45 (3H, m, PhH), 7.42 (1H, d, Jtrans = 16.0 Hz, α-H), 7.54–7.56 
(2H, m, PhH), 7.65 (1H, J = 2.5 Hz, 6-H), 7.66–7.68 (2H, m, Ph), 7.80 (1H, d, Jtrans = 16.0 Hz, 
β-H), 7.95 (1H, d, J 2.5 Hz, 6-H); δC (125 MHz, CDCl3) 97.2, 105.7, 112.1, 119.7, 122.1, 122.4, 
128.4, 128.5, 128.8, 129.0, 130.5, 131.6, 133.5, 134.9, 139.0, 144.0, 144.3, 150.3, 190.4; HRMS 
(ES): MH+, found 402.0490. C23H17NO
79Br+ requires: 402.0494. 
 
(E)-1-(2-Amino-5-bromo-3-(phenylethynyl)phenyl)-3-(4′-fluorophenyl)prop-2-en-1-one 
(200b); R1 = F, R2 = H 
 
A mixture of 198b (2.00 g, 4.50 mmol), phenylacetylene (0.52 g, 5.40 mmol), PdCl2(PPh3)2 (0.16 
g, 0.23 mmol), Cs2CO3 (1.80 g, 5.40 mmol) and CuI (0.08 g, 0.45 mmol) in ethanol-water (40 
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mL) was treated as described for 200a; work up and column chromatography on silica gel 
afforded 200b as a solid (1.52 g, 81%); Rf (toluene) 0.35, mp. 121–123 °C; νmax (ATR) 536, 638, 
753, 850, 948, 1028, 1131, 1250, 1302, 1441, 1508, 1585, 1643, 3294, 3340, 3469 cm-1; δH (300 
MHz, CDCl3) 7.11 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.12 (2H, br s, NH2), 7.36–7.38 (3H, m, PhH), 
7.43 (1H, d, Jtrans = 16.0 Hz, α-H), 7.51–7.54 (2H, m, PhH), 7.62 (1H, d, J = 2.5 Hz, 4-H), 7.64 
(2H, t, J = 8.7 Hz, 2′,6′-H), 7.72 (1H, d, Jtrans = 16.0 Hz, β-H), 7.91 (1H, d, J = 2.4 Hz, 6-H); δC 
(75 MHz, CDCl3) 83.3, 97.2, 105.7, 112.1, 116.0 (d, 
2JCF = 21.8 Hz), 119.5, 121.6, 121.7, 122.3, 
128.4, 128.9, 130.4 (d, 3JCF = 8.6 Hz), 131.0 (d, 
4JCF = 3.4 Hz), 131.6, 133.4, 143.0, 150.3, 164.0 
(d, 1JCF = 250.5 Hz), 190.1; δF (470 MHz, CDCl3) -109.0; HRMS (ES): MH+, found 420.0394. 
C23H16NO
79BrF+ requires: 420.0399. 
 
(E)-1-(2-Amino-5-bromo-3-(phenylethynyl)phenyl)-3-(4ʹ-chlorophenyl)prop-2-en-1-one 
(200c); R1 = 4, R2 = H 
 
A mixture of 198c (2.00 g, 4.35 mmol), phenylacetylene (0.53 g, 5.21 mmol), PdCl2(PPh3)2 (0.15 
g, 0.22 mmol), Cs2CO3 (1.69 g, 5.21 mmol) and CuI (0.08 g, 0.44 mmol) in ethanol (40 mL) was 
treated as described for 200a; work up and column chromatography on silica gel afforded 200c 
as a solid (1.32, 71%); Rf (toluene) 0.37, mp. 110–113 °C; νmax (ATR) 484, 688, 751, 817, 98, 
1011, 1089, 1196, 1483, 1532, 1585, 1644, 3330, 3462 cm-1; δH (500 MHz, CDCl3) 7.12 (2H, br 
s, NH2), 7.40 (1H, t, J = 8.0 Hz, 4"-H), 7.44 (2H, t, J = 8.0 Hz, 3",5"-H), 7.49 (2H, d, J = 8.5 Hz, 
3',5'-H), 7.65 (2H, d, J = 8.5 Hz), 7.68 (1H, d, Jtrans = 16.0 Hz, α-H), 7.72 (2H, d, J = 8.0, 2",6"-
H), 7.87 (1H, Jtrans = 16.0 Hz, β-H), 7.97 (1H, d, J = 1.5 Hz, 4-H), 8.00 (1H, d, J = 1.5 Hz, 6-H); 
δC (125 MHz, CDCl3) 87.5, 97.3, 106.7, 122.0, 128.3, 128.7, 129.1, 129.4, 129.5, 131.4, 133.0, 
133.2, 133.2, 136.3, 138.9, 142.6, 145.6, 148.9, 189.5; HRMS (ES): MH+, found 436.0106. 
C23H16NO
35Cl79Br+ requires: 436.0104. 
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(E)-1-(2-Amino-5-bromo-3-(phenylethynyl)phenyl)-3-(4ʹ-methoxyphenyl)prop-2-en-1-one 
(200d); R1 = OCH3, R2 = H 
 
A mixture of 198d (2.00 g, 4.36 mmol), phenylacetylene (0.53 g, 5.20 mmol), PdCl2(PPh3)2 (0.15 
g, 0.22 mmol), Cs2CO3 (1.70 g, 5.23 mmol) and CuI (0.08 g, 0.436 mmol) in ethanol (40 mL) 
was treated as described for 200a; work up and column chromatography on silica gel afforded 
200d as a solid (1.17 g, 62%); Rf (toluene) 0.32, mp. 108–110 °C; νmax (ATR) 497, 535, 687, 
752, 822, 984, 1027, 1171, 1197, 1582, 1584, 1643, 2852, 3342, 3469 cm-1; δH (500 MHz, 
CDCl3) 3.86 (3H, s, OCH3), 6.93 (2H, J = 8.7 Hz, 3′,5′-H), 7.08 (2H, br s, NH2), 7.36–7.40 (3H, 
m, PhH), 7.42 (1H, d, Jtrans = 15.5 Hz, α-H), 7.51–7.53 (2H, m, PhH), 7.60 (2H, d, J = 8.7 Hz, 
2′,6′-H), 7.62 (1H, d, J = 2.1 Hz, 4-H), 7.73 (1H, d, Jtrans = 15.5 Hz, β-H), 7.92 (1H, d, J = 2.1 
Hz, 4-H), 7.93 (1H, d, J 2.1 Hz, 6-H); δC (125 MHz, CDCl3) 55.4, 83.5, 97.1, 105.7, 112.0, 114.4, 
119.6, 119.9, 122.4, 127.6, 128.5, 128.8, 130.2, 131.6, 133.4, 138.8, 144.2, 161.6, 190.4; HRMS 
(ES): MH+, found 432.0602. C24H19NO2
79Br+ requires: 432.0599. 
 
(E)-3-(2-Amino-5-bromo-3-((4ʹʹ-(trifluoromethoxy)phenyl)ethynyl)phenyl)-3-(4ʹ-
chlorophenyl)prop-2-en-1-one (200e); R1 = Cl, R2 = OCF3 
 
A mixture of 198c (2.00 g, 4.35 mmol), trifluoromethoxyphenylacetylene (0.97 g, 5.21 mmol), 
PdCl2(PPh3)2 (0.15 g, 0.22 mmol), Cs2CO3 (1.69 g, 5.21 mmol) and CuI (0.08 g, 0.44 mmol) in 
ethanol (40 mL) was treated as described for 200a; work up and column chromatography on 
silica gel afforded 200e as a solid (1.76 g, 78%); Rf (toluene) 0.44, mp. 120–123 °C; νmax (ATR) 
486, 654, 778, 843, 1090, 1156, 1291, 1344, 1566, 1646, 3346, 3463 cm -1; δH (500 MHz, CDCl3) 
7.10 (2H, br s, NH2), 7.15 (2H, d, J = 8.0 Hz, 3",5"-H), 7.40 (2H, d, J = 8.0 Hz, 3',5'-H), 7.49 
(1H, d, Jtrans = 15.5 Hz, α-H), 7.56 (2H, d, J 8.5 Hz, 2",6"-H ), 7.58 (2H, d, J 8.5 Hz, 2',6'-H), 
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7.63 (1H, d, J 2.0 Hz, 4-H), 7.72 (1H, d, Jtrans = 15.5 Hz, β-H), 7.93 (1H, d, J 2.0 Hz, 6-H); δC 
(125 MHz, CDCl3) 84.1, 95.6, 105.7, 111.6, 119.5, 120.9, 121.0, 122.2, 122.3 129.2, 129.6, 
133.1, 133.2, 133.7, 136.4, 139.2, 142.8, 149.2, 150.2, 189.9; δF (470 MHz, CDCl3) -57.8; 
HRMS (ES): MH+, found 519.9913. C24H15NO2
35Cl79BrF3
+ requires: 519.9927. 
 
(E)-3-(2-Amino-5-bromo-3-((4ʹʹ-(trifluoromethoxy)phenyl)ethynyl)phenyl)-1-(4ʹ-
methoxyphenyl)prop-2-en-1-one (200f); R1 = OCH3, R2 = OCF3 
 
A mixture of 198d (2.00 g, 4.36 mmol), trifluoromethoxyphenylacetylene (0.97 g, 5.20 mmol), 
PdCl2(PPh3)2 (0.15 g, 0.22 mmol), Cs2CO3 (1.70 g, 5.23 mmol) and CuI (0.08 g, 0.44 mmol) in 
ethanol (40 mL) was treated as described for 200a; work up and column chromatography on 
silica gel afforded 200f as a solid (1.83 g, 82%); Rf (toluene) 0.44, mp. 125–127 °C (EtOH); νmax 
(ATR) 556, 791, 886, 1034, 1170, 1202, 1249, 1350, 1422, 1507, 1644, 3331, 3470 cm-1; δH (500 
MHz, CDCl3) 3.86 (3H, s, OCH3), 6.78 (2H, s, NH2), 6.98 (2H, d, J = 8.5 Hz, 3",5"-H), 7.33 
(2H, d, J = 7.5 Hz, 3',5'-H), 7.59 (1H, d, Jtrans = 15.5 Hz, α-H), 7.67 (2H, d, J 7.0 Hz, 2",6"-H ), 
7.75 (2H, d, J 2.5 Hz, 4-H), 7.72 (1H, d, Jtrans = 15.5 Hz, β-H), 7.95 (2H, d, J 2.0 Hz, 6-H); δC 
(125 MHz, CDCl3) 55.2, 84.4, 95.5, 105.8, 111.5, 114.4, 119.5, 120.0, 121.0, 121.2, 127.5, 127.9, 
130.3, 133.1, 133.4, 133.8, 138.9, 144.3, 150.2, 161.7, 190.3; δF (470 MHz, CDCl3) -57.8; 
HRMS (ES): MH+, found 516.0419. C25H18NO3
79BrF3
+
 requires: 516.0419. 
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4.4 PdCl2-mediated cyclization of compounds 200a–f. 
 
 
      200a–f 
 
(E)-1-(5-Bromo-2-phenyl-1H-indol-7-yl)-3-phenylprop-2-en-1-one (201a); R1 = H, R2 = H 
 
A mixture of 200a (1.20 g, 2.99 mmol) and PdCl2 (0.11 g, 0.60 mmol) in acetonitrile (20 mL) 
was heated at 90 °C for 3 h. The solvent was evaporated under reduced pressure and the residue 
was quenched with saturated sodium thiosulfate. The resultant precipitate was washed 
thoroughly with cold water and then recrystallized to afford 201a as a solid (0.90 g, 75%), mp. 
197–199 °C (EtOH); νmax (ATR) 568, 685, 707, 758, 841, 889, 1128, 1448, 1576, 1649, 3419 
cm-1; δH (500 MHz, CDCl3) 6.82 (1H, d, J = 2.5 Hz, 3-H), 7.17 (1H, d, J = 7.0 Hz, ArH), 7.26 
(1H, t, J = 8.0 Hz, ArH), 7.39 (1H, t, J = 7.5 Hz, ArH), 7.46–7.50 (4H, m, ArH), 7.71–7.76 (4H, 
m, ArH), 7.92 (1H, d, Jtrans = 16.0 Hz, β-H), 7.99 (2H, d, J 2.0 Hz, 4-H and 6-H), 10.90 (1H, s, 
NH); δC (125 MHz, CDCl3) 98.7, 112.0, 120.5, 121.4, 125.5, 126.3, 126.5, 128.7, 129.0, 129.1, 
129.2, 130.8, 131.3, 132.5, 134.8, 135.3, 140.8, 144.7, 189.8; HRMS (ES): MH+, found 
402.0483. C23H17NO
79Br+ requires: 402.0494. 
 
 
 
α 
β 
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(E)-1-(5-Bromo-2-phenyl-1H-indol-7-yl)-3-(4ʹ-fluorophenyl)prop-2-en-1-one (201b); R1 = 
F; R2 = H 
 
A mixture of 200b (1.36 g, 3.10 mmol) and PdCl2 (0.109 g, 0.62 mmol) in acetonitrile (20 mL) 
was treated as for 201a to afford 201b as a solid (0.83 g, 63%), mp. 237–239 °C (EtOH); νmax 
(ATR) 575, 886, 754, 821, 973, 1128, 1229, 1505, 1572, 1597, 1645, 3426 cm-1; δH (500 MHz, 
CDCl3) 6.83 (1H, d, J = 2.5 Hz, 3-H), 7.17 (2H, t, J = 8.5 Hz, ArH), 7.40 (1H, t, J = 7.5 Hz, 
ArH), 7.50 (2H, t, J = 7.5 Hz, ArH), 7.69 (1H, d, Jtrans = 15.0 Hz, α-H), 7.71–7.77 (4H, m, ArH), 
7.89 (1H, d, Jtrans = 15.5 Hz, β-H), 8.00 (2H, d, J 2.0 Hz, 4-H and 6-H), 10.90 (1H, s, NH); δC 
(125 MHz, CDCl3) 98.7, 112.0, 116.2 (d, 
2JCF = 21.8 Hz), 120.3, 121.3, 125.5, 126.3, 128.5, 
129.1, 129.2, 130.6 (d, 3JCF = 8.5 Hz), 131.0 (d, 
4JCF =
 2.8 Hz), 131.3, 132.5, 135.3, 140.8, 143.3, 
163.4 (d, 1JCF = 246.7 Hz), 189.5; δF (470 MHz, CDCl3) -106.2; HRMS (ES): MH+, found 
420.0399. C23H16NO
79BrF+ requires: 420.0394. 
 
(E)-1-(5-Bromo-2-phenyl-1H-indol-7-yl)-3-(4ʹ-chlorophenyl)prop-2-en-1-one (201c); R1 = 
Cl, R2 = H 
 
A mixture of 200c (1.10 g, 2.52 mmol) and PdCl2 (0.09 g, 0.51 mmol) in acetonitrile (20 mL) 
was was treated as for 201a to to afford 201c as a solid (0.79 g, 71%), mp. 184–186 °C (EtOH); 
νmax (ATR) 577, 685, 753, 815, 890, 1011, 1087, 1130, 1301, 1449, 1487, 1601, 1647, 3429 cm-
1; δH (500 MHz, CDCl3) 6.82 (1H, s, J = 2.0 Hz, 3-H), 7.40 (1H, t, J = 8.0 Hz, 4"-H), 7.44 (2H, 
t, J = 8.0 Hz, 3",5"-H), 7.49 (2H, d, J = 8.5 Hz, 3',5'-H), 7.65 (2H, d, J = 8.5 Hz), 7.68 (1H, d, 
Jtrans = 16.0 Hz, α-H), 7.72 (2H, d, J = 8.0, 2",6"-H), 7.87 (1H, Jtrans = 15.5 Hz, β-H), 7.97 (1H, 
d, J = 1.5 Hz, 4-H), 8.00 (1H, d, J = 1.5 Hz, 6-H), 10.88 (1H, s, NH); δC (125 MHz, CDCl3) 98.7, 
112.0, 121.0, 121.3, 125.6, 126.3, 128.6, 129.1, 129.2, 129.3, 129.8, 131.3, 132.5, 133.3, 135.3, 
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136.7, 140.9, 143.1, 189.5; HRMS (ES): MH+, found 436.0092. C23H16NO
35Cl79Br+ requires: 
436.0104. 
 
(E)-1-(5-Bromo-2-phenyl-1H-indol-7-yl)-3-(4ʹ-methoxyphenyl)prop-2-en-1-one (201d); R1 
= OCH3, R2 = H 
 
A mixture of 200d (1.00 g, 2.32 mmol) and PdCl2 (0.08 g, 0.46 mmol) in acetonitrile (20 mL) 
was treated as for 201a to to afford 201d as a solid (0.53 g, 53%), mp. 176–179 °C (EtOH); νmax 
(ATR) 578, 688, 822, 972, 1034, 1128, 1176, 1292, 1448, 1569, 1641, 3411 cm-1; δH (500 MHz, 
CDCl3) 3.90 (3H, s, OCH3), 6.83 (1H, s, J = 2.0 Hz, 3-H), 7.00 (2H, d, J = 9.0 Hz, 2',6'-H), 7.39 
(2H, t, J = 8.0 Hz, 4"-H), 7.49 (2H, t, J = 8.0 Hz, 3",5"-H), 7.63 (1H, d, Jtrans = 15.0 Hz, α-H), 
7.70 (2H, d, J = 9.0 Hz, 3',5'-H), 7.76 (1H, dd, J = 1.0 and 8.0 Hz, 2",6"-H), 7.91 (1H, Jtrans = 
15.0 Hz, β-H), 7.99 (1H, d, J = 1.5 Hz, 4-H), 8.00 (1H, d, J = 1.5 Hz, 6-H), 10.93 (1H, br s, NH), 
NH); δC (125 MHz, CDCl3) 55.5, 89.6, 112.0, 114.5, 118.2, 121.7, 125.5, 126.1, 127.5, 128.5, 
128.8, 129.1, 130.5, 131.4, 132.4, 135.3, 140.7, 144.5, 161.9, 189.7; HRMS (ES): MH+, found 
431.0511C24H18NO2
79Br requires 431.0521. 
 
(E)-3-(5-Bromo-2-(4ʹʹ-(trifluoromethoxy)phenyl)-1H-indol-7-yl)-1-(4ʹ-chlorophenyl)-
prop-2-en-1-one (201e); R1 = Cl, R2 = OCF3 
 
A mixture of 200e (1.30 g, 2.51 mmol) and PdCl2 (0.09 g, 0.50 mmol) in acetonitrile (20 mL) 
was treated as for 201a to 201e as a solid (0.83 g, 63%) mp. 252–254 °C °C (EtOH); νmax (ATR) 
572, 685, 762, 846, 967, 1086, 1157, 1256, 1350, 1456, 1566, 1648, 3426 cm-1; δH (500 MHz, 
CDCl3) 6.81 (1H, d, J = 2.5 Hz, 3-H), 7.15 (1H, t, J = 8.0 Hz, 3",5"-H), 7.38 (1H, t, J = 8.0 Hz, 
3',5'-H), 7.48 (2H, d, J = 8.0 Hz, 2",6"-H), 7.65 (1H, d, Jtrans = 15.0 Hz, α-H), 7.71 (2H, d, J 8.5 
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Hz,), 7.74 (2H, d, J 8.0 Hz, 2',6'-H), 7.87 (1H, d, Jtrans = 16.0 Hz, β-H), 7.97 (1H, d, J 2.0 Hz, 4-
H), 7.99 (1H, d, J 2.0 Hz, 6-H), 10.88 (1H, br s, NH); δC (125 MHz, CDCl3) 99.2, 112.2, 114.5, 
117.9, 121.4, 121.5, 121.7, 126.4, 126.8, 127.4, 128.9, 130.1, 130.5, 132.2, 135.4, 139.1, 144.6, 
149.1, 161.9, 189.6; δF (470 MHz, CDCl3) -58.2; HRMS (ES): MH+ found 519.9944. 
C24H15NO2F3
35Cl79Br+ requires: 519.9927. 
 
(E)-3-(5-Bromo-2-(4ʹʹ-(trifluoromethoxy)phenyl)-1H-indol-7-yl)-1-(4ʹ-methoxyphenyl)-
prop-2-en-1-one (201f); R1 = OCH3, R2 = OCF3 
 
A mixture of 200f (0.90 g, 1.75 mmol) and PdCl2 (0.06 g, 0.35 mmol) in acetonitrile (20 mL) 
was treated as for 201a to 201f as a solid (0.49 g, 54%), mp. 197–198 °C (EtOH); νmax (ATR) 
573, 692, 760, 889, 919, 1032, 1158, 1276, 1351, 1460, 1509, 1644, 3421 cm-1;  δH (500 MHz, 
CDCl3) 3.88 (3H, s, OCH3) 6.80 (1H, d, J = 2.5 Hz, 3-H), 6.98 (2H, d, J = 8.5 Hz, 3',5'-H), 7.32 
(2H, d, J = 8.0 Hz, 3",5"-H), 7.61 (1H, d, Jtrans = 15.5 Hz, α-H), 7.68 (2H, d, J = 8.0 Hz, 2",6"-H 
), 7.76 (2H, d, J 8.5 Hz, 2',6'-H), 7.87 (1H, d, Jtrans = 15.5 Hz, β-H), 7.97 (1H, d, J 2.0 Hz, 4-H), 
7.99 (1H, d, J 2.0 Hz, 6-H), 10.90 (1H, s, NH); δC (75 MHz, CDCl3); δC (125 MHz, CDCl3) 55.4, 
99.2, 112.2, 114.4, 117.9, 121.4, 121.5, 121.7, 126.4, 126.8, 127.4, 128.9, 130.1, 130.5, 132.2, 
135.4, 139.1, 144.6, 149.0, 161.9, 189.6; δF (470 MHz, CDCl3) -57.8; HRMS (ES): MH+, found 
516.0408. C25H18NO3F3
79Br+ requires: 516.0422. 
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4.5 Synthesis of benzofuran-chalcone hydrids 203a–y. 
 
 
      203a–y 
 
(E)-1-(5-Bromo-2-phenylbenzofuran-7-yl)-3-phenylprop-2-en-1-one (203a); R1 = 4-H, R2 
= H 
 
To a three-necked round-bottom flask equipped with a stirrer bar, condenser and rubber septa 
compound 198d (1.02 g, 2.38 mmol), phenylacetylene (0.29 g, 2.85 mmol), PdCl2(PPh3)2 (0.08 
g, 0.12 mmol), Cs2CO3 (0.93 g, 2.85 mmol) and CuI (0.05 g, 0.24 mmol) and aqueous DMF (20 
mL) were added in sequence. The mixture was purged with nitrogen gas for 20 min. and a balloon 
filled with nitrogen gas was connected to the top of the condenser and the mixture was heated at 
80 °C for 2 h. The mixture was quenched with an ice-cold water and the product was extracted 
with chloroform. The combined organic solutions were washed with brine and dried over 
anhydrous MgSO4. The salt was filtered off and the solvent was evaporated under reduced 
pressure. The residue was purified by recrystallization from acetone to afford 203a as a solid 
(0.63 g, 66%); mp. 197–195 °C; νmax  (ATR) 567, 680, 758, 853, 972, 1097, 1176, 1283, 1365, 
1491, 1574, 1596, 1656 cm-1; δH (500 MHz, CDCl3) 7.06 (1H, s, =CH), 7.15 (1H, t, J = 7.5 Hz), 
7.42 (2H, d, J =7.0 Hz), 7.54–7.49 (3H, m, Ar), 7.56 (2H, d, J = 8.0 Hz, Ar), 7.65 (1H, J = 2.5 
Hz, H-4), 7.68 (2H, d, J = 8.0 Hz, Ar), 7.74 (1H, d, Jtrans = 16.0 Hz, α-H), 7.80 (1H, d, Jtrans = 16.0 
Hz, β-H), 7.95 (1H, d, J 2.5 Hz, H-6); δC (125 MHz, CDCl3) 88.6, 88.9, 100.9, 118.5, 122.0, 
α 
β 
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123.1, 125.1, 128.3, 128.4, 128.6, 128.8, 129.0, 129.3, 129.4, 131.1, 131.6, 152.8, 157.8, 195.2; 
HRMS (ES): found 403.0325. C23H16O2
79Br requires 403.0334. Anal calcd for C23H15O2Br: C, 
68.50; H, 3.75. Found: C, 68.38; H, 3.73. 
 
(E)-1-(5-Bromo-2-phenylbenzofuran-7-yl)-3-(4ʹ-fluorophenyl)prop-2-en-1-one (203b); R1 
= 4-F, R2 = H 
 
A mixture of 198b (0.98 g, 2.20 mmol), phenylacetylene (0.269 g, 2.64 mmol), PdCl2(PPh3)2 
(0.08 g, 0.11 mmol), Cs2CO3 (0.86 g, 2.64 mmol) and CuI (0.04 g, 0.22 mmol) in aqueous DMF 
(20 mL) was treated as for the preparation of 203a to afford 203b as a solid (0.73 g, 79%); mp. 
220–223 °C; νmax (ATR) 579, 690, 798, 835, 997, 1098, 1155, 1278, 1363, 1433, 1502, 1585, 
1673 cm-1; δH (300 MHz, CDCl3) 7.07 (1H, s, =CH), 7.15 (2H, t, J = 8.5 Hz, Ar), 7.43 (2H, d, J 
= 8.5 Hz, Ar ), 7.48 (2H, t, J = 8.0 Hz, Ar), 7.73 (1H, t, J = 8.0 Hz, Ar), 7.88 (2H, d, J = 7.5 Hz, 
Ar), 7.91 (1H, d J = 1.5 Hz, H-4), 7.93 (1H, d, Jtrans = 16.0 Hz, α-H), 7.95 (1H, d, Jtrans = 16.0 Hz, 
β-H), 8.03 (1H, d, J = 2.4 Hz, H-6); δC (75 MHz, CDCl3) 100.5, 116.3 (d, 2JCF = 21.8 Hz), 116.5, 
124.1, 124.6, 125.1, 127.8, 128.1, 129.1, 129.3, 129.5, 130.5 (d, 3JCF = 8.5 Hz), 131.2 (d, 
4JCF = 
2.9 Hz), 132.8, 143.5, 151.6, 157.7, 164.2 (d, 1JCF = 239.0 Hz), 186.5; HRMS (ES): found 
421.0254. C23H15O2F
79Br+ requires 421.0239. Anal calcd for C23H14O2FBr: C, 65.58; H, 3.35. 
Found: C, 65.42; H, 3.41. 
 
(E)-1-(5-Bromo-2-phenylbenzofuran-7-yl)-3-(4ʹ-chlorophenyl)prop-2-en-1-one (203c); R1 
= 4-Cl, R2 = H 
 
A mixture of 198c (1.07 g, 2.32 mmol), phenylacetylene (0.28 g, 2.78 mmol), PdCl2(PPh3)2 (0.08 
g, 0.12 mmol), Cs2CO3 (0.90 g, 0.78 mmol) and CuI (0.04 g, 0.23 mmol) in aqueous DMF (20 
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mL) was treated as for the preparation of 203a to afford 203c as a solid (0.79, 78%); mp. 242–
245 °C; νmax (ATR) 524, 685, 751, 814, 974, 1090, 1217, 1317, 1365, 1489, 1588, 1592, 1659 
cm-1; δH (500 MHz, CDCl3) 7.06 (1H, s, =CH), 7.42 (2H, d, J = 8.5 Hz, Ar), 7.49 (1H, t, J = 8.5 
Hz, Ar ), 7.67 (2H, d, J = 8.7 Hz, Ar), 7.84 (2H, d, J = 8.0 Hz, Ar), 7.86 (1H, d, Jtrans = 16.0 Hz, 
α-H), 7.88 (1H, d, J = 1.5 Hz, H-4), 7.91 (1H, d, J = 2.5 Hz, 6-H), 8.02 (1H, d, Jtrans = 16.0 Hz, 
β-H), 8.04 (2H, d, J = 7.0 Hz, Ar); δC (125 MHz, CDCl3) 116.5, 125.1, 125.2, 125.3, 127.9, 
128.1, 128.3, 129.0, 129.3, 129.6, 129.7, 131.1, 132.8, 133.4, 136.7, 143.2, 151.6, 157.7, 186.4; 
HRMS (ES): found 436.9937. C23H15O2ClBr
+ requires 436.9944. Anal calcd for C23H14O2ClBr: 
C, 63.11; H, 3.22. Found: C, 63.08; H, 3.17. 
 
(E)-1-(5-Bromo-2-phenylbenzofuran-7-yl)-3-(4ʹ-methoxyphenyl)prop-2-en-1-one (203d); 
R1 = 4-OCH3, R2 = H  
 
A mixture of 198d (0.96 g, 2.10 mmol), phenylacetylene (0.26 g, 2.52 mmol), PdCl2(PPh3)2 (0.07 
g, 0.11 mmol), Cs2CO3 (0.82 g, 2.52 mmol) and CuI (0.04 g, 0.21 mmol) in aqueous DMF was 
treated as for the preparation of 203a to afford 203d as a solid (0.65 g, 72%); mp. 206–208 °C; 
νmax (ATR) 531, 672, 766, 870, 991, 1023, 1170, 1256, 1365, 1422, 1509, 1558, 1654 cm-1; δH 
(500 MHz, CDCl3) 3.86 (3H, s, OCH3), 6.98 (2H, d, J = 8.5 Hz, Ar), 7.14 (1H, s, =CH), 7.19 
(1H, t, J = 8.0 Hz, Ar), 7.44 (2H, d, J = 8.7 Hz, Ar), 7.81 (2H, d, J = 8.0 Hz, Ar), 7.83 (1H, d, 
Jtrans = 16.0 Hz, α-H), 7.88 (1H, d, Jtrans = 16.0 Hz, β-H), 7.92 (2H, d, J = 8.5 Hz, Ar), 8.00 (1H, 
d, J = 2.5 Hz, 4-H), 8.02 (1H, d, J = 2.5 Hz, 6-H); δC (125 MHz, CDCl3) 55.4, 83.5, 97.1, 105.7, 
112.0, 114.4, 119.6, 119.9, 122.4, 127.6, 128.5, 128.8, 129.4, 130.2, 131.6, 133.4, 138.8, 144.2, 
161.6, 186.7; HRMS MH+, found 433.0364. C24H18O3
79Br+ requires 433.0361. Anal calcd for 
C24H17O3Br: C, 66.53; H, 3.95. Found: C, 66.59; H, 3.93. 
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(E)-1-(5-Bromo-2-phenylbenzofuran-7-yl)-3-(4ʹ-(trifluoromethoxy)phenyl)prop-2-en-1-
one (203e); R1 = 4-OCF3, R2 = H 
 
A mixture of 198e (0.52 g, 1.02 mmol), phenylacetylene (0.12 g, 1.22 mmol), PdCl2(PPh3)2 (0.04 
g, 0.05 mmol), Cs2CO3 (0.37 g, 1.22 mmol) and CuI (0.02 g, 0.12 mmol) in aqueous DMF (20 
mL) was treated as for the preparation of 203a to afford 203e as a solid (0.33 g, 67%); 177–178 
°C; νmax (ATR) 568, 685, 790, 866, 969, 1036, 1147, 1253, 1409, 1492, 1600, 1658 cm-1; δH (500 
MHz, CDCl3) 7.07 (1H, s, =CH), 7.31 (1H, d, J = 8.0 Hz, Ar), 7.43 (1H, t, J =8.0 Hz, Ar), 7.47 
(2H, d, J = 8.0 Hz, Ar), 7.49 (2H, J = 7.5 Hz, Ar), 7.62 (2H, d, J = 8.7 Hz, Ar), 7.88 (1H, d, J = 
8.7 Hz, Ar), 7.91 (1H, d, Jtrans = 16.0 Hz, α-H), 7.92 (1H, d, J 2.0 Hz, H-4), 8.06 (1H, d, J 2.0 Hz, 
H-6), 8.09 (1H, d, Jtrans = 16.0 Hz, β-H); δC (125 MHz, CDCl3) 100.5, 116.6, 119.9 (t, JCF = 256.0 
Hz), 122.8, 123.6, 125.1, 126.2, 129.6, 128.1, 129.0, 129.2, 129.6, 130.5, 132.9, 137.1, 142.8, 
149.7, 151.8, 157.9, 186.1; HRMS (ES): found 487.0157. C24H15O3
79BrF3 requires 487.0157. 
Anal calcd for C24H14O3BrF3: C, 59.16; H, 2.90. Found: C, 59.13; H, 3.01. 
 
(E)-1-(5-Bromo-2-(4ʹʹ-fluorophenyl)benzofuran-7-yl)-3-phenylprop-2-en-1-one (203f); R1 
= 4-H, R2 = F 
 
A mixture of 198a (0.96 g, 2.35 mmol), 4-flourophenylacetylene (0.32 g, 2.70 mmol), 
PdCl2(PPh3)2 (0.11 g, 0.16 mmol), Cs2CO3 (0.88 g, 2.70 mmol) and CuI (0.04 g, 0.24 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203f as a solid (0.69 g, 70%); 
mp. 224–226 °C; νmax (ATR) 575, 682, 751, 826, 976, 1099, 1172, 1217, 1366, 1432, 1508, 1587, 
1656 cm-1; δH (500 MHz, CDCl3) 6.97 (1H, s, =CH), 7.18 (1H, t, J = 8.5 Hz, Ar), 7.44–7.46 (4H, 
m, Ar), 7.51 (2H, t, J = 8.0 Hz, Ar), 7.72 (1H, d, Jtrans = 16.0 Hz, α-H), 7.74 (1H, d, Jtrans = 16.0 
Hz, β-H), 7.84 (2H, t, J = 8.5 Hz, Ar), 7.86 (1H, d, J = 2.0 Hz, H-4), 7.87 (1H, d, J = 2.0 Hz, H-
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6); δC (125 MHz, CDCl3) 100.5, 116.2 (d, 2JCF = 21.9 Hz), 116.5, 124.0, 124.5, 125.1, 127.9, 
128.1, 129.0, 129.3, 129.5, 130.4 (d, 3JCF = 8.5 Hz), 131.2, 132.4 (d, 
4JCF = 3.8 Hz), 143.5, 151.5, 
157.8, 161.2 (d, 1JCF = 245.0 Hz), 186.5; HRMS (ES): found: 421.0161. C23H15FO2
79Br+ requires 
421.0141. Anal calcd for C23H14FO2Br: C, 65.58; H, 3.35. Found: C, 68.49; H, 3.33. 
 
(E)-1-(5-Bromo-2-(4ʹʹ-fluorophenyl)benzofuran-7-yl)-3-(4ʹ-fluorophenyl)prop-2-en-1-one 
(203g); R1 = F, R2 = F  
 
A mixture of 198b (1.18 g, 2.65 mmol), 4-flourophenylacetylene (0.38 g, 3.18 mmol), 
PdCl2(PPh3)2 (0.09 g, 0.13 mmol), Cs2CO3 (1.03 g, 3.18 mmol) and CuI (0.05 g, 0.27 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203g as a solid (0.88 g, 76%); 
mp. 239–242 °C; νmax (ATR) 575, 645, 755, 860, 977, 1096, 1157, 1285, 1365, 1414, 1598, 1658, 
1678 cm-1; δH (500 MHz, CDCl3) 6.99 (1H, s, =CH), 7.17 (2H, t, J = 8.5 Hz, Ar), 7.46 (2H, t, J 
= 8.5 Hz, Ar), 7.73 (2H, t, J = 8.7 Hz, Ar), 7.86 (2H, t, J = 8.5 Hz, Ar), 7.89 (1H, d, J = 2.0 Hz, 
H-4), 7.94 (1H, d, Jtrans = 16.0 Hz, α-H), 8.00 (1H, d, Jtrans = 16.0 Hz, β-H), 8.02 (1H, d, J = 2.5 
Hz, H-6); δC (125 MHz, CDCl3) 100.5, 115.1 (d, 2JCF = 21.9 Hz), 116.2 (d, 2JCF = 21.9 Hz), 
124.1, 124.6, 125.1, 127.9, 128.1, 129.0, 129.6 (d, 4JCF = 3.8 Hz), 130.4 (d, 
3JCF = 8.5 Hz), 132.0 
(d, 3JCF = 8.5 Hz), 132.7 (d, 
4JCF = 3.8 Hz), 143.4, 151.6, 157.3, 162.1 (d, 
1JCF = 248.0 Hz), 162.9 
(d, 1JCF = 267.3 Hz), 186.5; HRMS (ES): found 439.0132. C23H14O2F2
79Br+ requires 439.0145. 
Anal calcd for C23H13O2F2Br: C, 62.89; H, 2.98. Found: C, 62.87; H, 2.93. 
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(E)-1-(5-Bromo-2-(4ʹʹ-fluorophenyl)benzofuran-7-yl)-3-(4ʹ-chlorophenyl)prop-2-en-1-one 
(203h); R1 = 4-Cl, R2 = F  
 
A mixture of 198c (0.92 g, 2.00 mmol), 4-flourophenylacetylene (0.29 g, 2.40 mmol), 
PdCl2(PPh3)2 (0.07 g, 0.10 mmol), Cs2CO3 (0.78 g, 2.40 mmol) and CuI (0.04 g, 0.20 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203h as a solid (0.69 g, 77%); 
mp. 231–233 °C; νmax (ATR) 579, 666, 741, 891, 987, 1097, 1145, 1248, 1337, 1447, 1502, 1598, 
1674 cm-1; δH (500 MHz, CDCl3) 7.06 (1H, s, =CH), 7.15 (2H, t, J = 8.0 Hz, Ar), 7.46 (2H, d, J 
= 8.0 Hz, Ar), 7.72 (2H, t, J = 8.5 Hz, Ar), 7.87 (2H, d, J = 7.5 Hz, Ar), 7.91 (1H, d, J = 2.0 Hz, 
H-4), 7.93 (1H, d, Jtrans = 16.0 Hz, α-H), 7.98 (1H, d, Jtrans = 16.0 Hz, β-H), 8.03 (1H, d, J = 2.0 
Hz, H-6); δC (125 MHz, CDCl3) 100.5, 116.3 (d, 2JCF = 21.9 Hz), 120.2, 124.1, 124.3, 124.4, 
125.6, 129.3, 129.5, 130.4 (d, 3JCF = 8.7 Hz), 131.2, 132.4 (d, 
4JCF = 3.8 Hz), 142,1, 143.6, 147.3, 
151.5, 156.8, 161.3 (d, 1JCF = 245.0 Hz), 188.4; HRMS (ES): found 454.9873. 
C23H14O2F
35Cl79Br+ requires 454.9850. Anal calcd for C23H13O2FClBr: C, 60.62; H, 2.88. Found: 
C, 60.68; H, 2.85. 
 
(E)-1-(5-Bromo-2-(4ʹʹ-fluorophenyl)benzofuran-7-yl)-3-(4ʹ-methoxyphenyl)prop-2-en-1-
one (203i); R1 = 4-OCH3, R2 = F  
 
A mixture of 198d (1.05 g, 2.30 mmol), 4-flourophenylacetylene (0.33 g, 2.76 mmol), 
PdCl2(PPh3)2 (0.08 g, 0.12 mmol), Cs2CO3 (0.89 g, 2.76 mmol) and CuI (0.04 g, 0.23 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203i as a solid (0.65 g, 72%); 
mp. 252–254 °C; νmax (ATR) 526, 654, 791, 878, 976, 1099, 1159, 1287, 1364, 1455, 1572, 1589, 
1655 cm-1; δH (500 MHz, CDCl3) 3.86 (3H, s, OCH3), 6.98 (2H, d, J = 8.5 Hz, Ar), 7.14 (1H, s, 
=CH), 7.19 (1H, t, J = 8.0 Hz, Ar), 7.44 (2H, d, J = 8.7 Hz, Ar), 7.81 (1H, d, J = 8.0 Hz, Ar), 
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7.83 (1H, d, Jtrans = 16.0 Hz, α-H), 7.88 (1H, d, Jtrans = 16.0 Hz, β-H), 7.92 (2H, d, J = 8.5 Hz, 
Ar), 8.00 (1H, d, J = 2.5 Hz, H-4), 8.02 (1H, d, J = 2.5 Hz, H-6); δC (125 MHz, CDCl3) 55.5, 
100.2, 114.6, 116.3 (d, 2JCF = 21.9 Hz), 124.1, 124.3, 124.4, 125.8, 127.0, 127.6, 128.8, 130.4 
(d, 3JCF = 8.7 Hz), 131.2, 132.4 (d, 
4JCF = 3.8 Hz), 143.6, 144.9, 151.5, 156.8, 161.6 (d, 
1JCF = 
245.0 Hz), 186.8; HRMS (ES): found 451.0327. C24H17O3
79Br+ requires 451.0345. Anal calcd 
for C24H16O3Br: C, 63.87; H, 3.57. Found: C, 68.83; H, 3.62. 
 
(E)-1-(5-Bromo-2-(4ʹʹ-fluorophenyl)benzofuran-7-yl)-3-(4ʹ(trifluoromethoxy)phenyl)- 
prop-2-en-1-one (203j); R1 = 4-OCF3, R2 = F  
 
A mixture of 198e (0.76 g, 1.49 mmol), 4-flourophenylacetylene (2.14 g, 1.78 mmol), 
PdCl2(PPh3)2 (0.05 g, 0.07 mmol), Cs2CO3 (0.58 g, 1.78 mmol) and CuI (0.03 g, 0.15 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203j as a solid (0.48 g, 64%); 
mp. 203–204 °C; νmax (ATR) 580, 695, 789, 892, 978, 1094, 1169, 1262, 1345, 1577, 1601, 1660 
cm-1; 7.01 (1H, s, =CH), 7.17 (1H, t, J = 8.5 Hz, Ar), 7.31 (2H, d, J = 7.5 Hz, Ar), 7.49 (1H, t, 
J = 8.0 Hz, Ar) 7.60 (2H, d, J = 7.5 Hz, Ar), 7.96 (2H, t, J = 8.5 Hz, Ar),  7.90 (1H, d, Jtrans = 
16.0 Hz, α-H), 7.92 (1H, d, J = 2.0 Hz, H-4), 8.00 (1H, d, Jtrans = 16.0 Hz, β-H), 8.05 (1H, d, J = 
2.0 Hz, H-6); δC (125 MHz, CDCl3) 100.3, 116.3 (d, 2JCF = 21.9 Hz), 116.7, 119.8 (t, JCF = 256.0 
Hz), 123.7, 124.3, 125.5, 126.1, 127.0 (d, 3JCF = 8.7 Hz), 127.5, 128.1 (d, 
4JCF = 3.8 Hz), 130.5, 
132.8, 136.9, 142.9, 149.8, 151.6, 156.9, 163.4 (d, 1JCF = 245.0 Hz), 186.1; HRMS (ES): found 
504.0044. C24H14O3
79BrF4
+ requires 504.0066. Anal calcd for C24H13O3BrF4: C, 57.05; H, 2.59. 
Found: C, 57.08; H, 2.64. 
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(E)-1-(5-Bromo-2-(3ʹʹ-fluorophenyl)benzofuran-7-yl)-3-phenylprop-2-en-1-one (203k); R1 
= 4-H, R2 = 3-F  
 
A mixture of 198a (1.05 g, 2.50 mmol), 3-flourophenylacetylene (0.36 g, 3.00 mmol), 
PdCl2(PPh3)2 (0.09 g, 0.13 mmol), Cs2CO3 (0.98 g, 3.00 mmol) and CuI (0.05 g, 0.25 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203k as a solid (0.73 g, 70%); 
mp. 243–245°C; νmax (ATR) 503, 664, 765, 854, 939, 1039, 1159, 1220, 1325, 1448, 1588, 1655 
cm-1; δH (500 MHz, CDCl3) 7.08 (1H, s, =CH), 7.11 (1H, t, J = 8.0 Hz, Ar), 7.43 (1H, t, J = 8.0 
Hz, Ar), 7.46 (1H, d, J = 8.0 Hz, Ar), 7.47 (1H, d, J = 8.0 Hz, Ar), 7.59 (1H, dt, J = 8.0 and 2.0 
Hz, Ar), 7.65 (1H, d, J = 8.0 Hz, Ar), 7.73-7.75 (3H, m, Ar), 7.91 (1H, d, J = 2.0 Hz, H-4), 7.93 
(1H, d, Jtrans = 16.0 Hz, α-H), 8.02 (1H, d, Jtrans = 16.0 Hz, β-H), 8.06 (1H, d, J = 2.0 Hz, H-6); δC 
(125 MHz, CDCl3) 101.5, 112.2 (d, 
3JCF = 23.7 Hz), 116.3 (d, 
2JCF = 21.9 Hz), 116.7, 120.8, 
120.9, 124.2, 124.6, 128.1, 128.6, 129.1, 130.7, 130.8 (d, 6JCF = 1.8 Hz), 131.4 (d, 
4JCF = 8.6 
Hz), 132.5, 134.8, 145.1, 151.6, 156.3 (d, 5JCF = 2.8 Hz), 163.1 (d, 
1JCF = 245.0 Hz), 186.4; 
HRMS (ES): found: 421.0243. C23H15FO2
79Br+ requires 421.0239. Anal calcd for C23H14FO2Br: 
C, 65.52; H, 3.35. Found: C, 65.80; H, 3.41. 
 
(E)-1-(5-Bromo-2-(3ʹʹ-fluorophenyl)benzofuran-7-yl)-3-(4ʹ-fluorophenyl)prop-2-en-1-one 
(203l); R1 = F, R2 = 3-F  
 
A mixture of 198b (0.89 g, 2.00 mmol), 3-flourophenylacetylene (0.29 g, 2.40 mmol), 
PdCl2(PPh3)2 (0.07 g, 0.10 mmol), Cs2CO3 (0.78 g, 2.40 mmol) and CuI (0.04 g, 0.20 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203l as a solid (0.67 g, 77%); 
mp. 266–267 °C; νmax (ATR) 572, 680, 779, 891, 976, 1171, 1281, 1346, 1488, 1597, 1660 cm-
1; δH (500 MHz, CDCl3) 7.08 (1H, s, =CH), 7.12 (1H, t, J = 8.5 Hz, Ar), 7.42 (1H, d, J = 8.0 Hz, 
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Ar), 7.45 (2H, d, J = 7.5 Hz, Ar), 7.59 (1H, dt, J = 8.5 and 2.0 Hz, Ar), 7.64 (1H, d, J = 8.0 Hz, 
Ar), 7.73 (2H, t, J = 8.5 Hz, Ar), 7.90 (1H, d, Jtrans = 16.0 Hz, α-H), 7.92 (1H, d, J = 2.5 Hz, H-
4), 7.95 (1H, d, Jtrans = 16.0 Hz, β-H), 8.05 (1H, d, J = 2.5 Hz, H-6);  δC (125 MHz, CDCl3) 100.5, 
112.0 (d, 2JCF = 23.9 Hz), 116.3 (d, 
2JCF = 21.9 Hz), 116.9 (d, 
2JCF = 21.9 Hz), 120.8 (d, 
2JCF = 
2.9 Hz), 124.1, 124.3, 124.4, 128.1, 128.5, 130.4 (d, 4JCF = 8.6 Hz), 130.7 (d, 
3JCF = 8.5 Hz), 
131.2 (d, 3JCF = 2.9 Hz), 131.4 (d, 
4JCF = 8.5 Hz), 132.4, 143.7, 151.6, 156.3 (d, 
2JCF = 2.7 Hz), 
163.1 (d, 1JCF = 245.6 Hz), 164.3 (d, 
1JCF = 251.2 Hz), 186.3; HRMS (ES): found 438.0028. 
C23H14O2F2
79Br+ requires 439.0067. Anal calcd for C23H13O2F2Br: C, 62.89; H, 2.98. Found: C, 
62.91; H, 3.01. 
 
(E)-1-(5-Bromo-2-(3ʹʹ-fluorophenyl)benzofuran-7-yl)-3-(4ʹ-chlorophenyl)prop-2-en-1-
one (203m); R1 = Cl, R2 = 3-F  
 
A mixture of 198c (0.87 g, 1.89 mmol), 3-flourophenylacetylene (0.27 g, 2.26 mmol), 
PdCl2(PPh3)2 (0.07 g, 0.09 mmol), Cs2CO3 (0.73 g, 2.26 mmol) and CuI (0.04 g, 0.19 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203m as a solid (0.58 g, 68%); 
mp. 234–235°C; νmax (ATR) 515, 662, 728, 880, 1036, 1169, 1219, 1315, 1448, 1571, 1655 cm-
1; δH (500 MHz, CDCl3) 7.09 (1H, s, =CH), 7.14 (1H, t, J = 8.0 Hz, Ar), 7.45 (2H, d, J = 8.5 Hz, 
Ar), 7.58 (1H, d, J = 8.5 Hz, Ar), 7.63-7.68 (4H, d, J = 7.5 Hz, Ar), 7.89 (1H, d, Jtrans = 16.0 Hz, 
α-H), 7.92 (1H, d, J = 2.0 Hz, H-4), 7.99 (1H, d, Jtrans = 16.0 Hz, β-H), 8.05 (1H, d, J = 2.0 Hz, 
H-6); δC (125 MHz, CDCl3) 101.5, 112.9 (d, 3JCF = 23.7 Hz), 116.4 (d, 2JCF = 21.9 Hz), 116.7, 
120.8 (d, 2JCF = 2.87 Hz), 124.0, 124.9, 128.2, 128.6, 129.4, 129.7, 130.8 (d, 
6JCF = 8.5 Hz), 
131.4 (d, 4JCF = 8.6 Hz), 132.5, 133.3, 136.8, 143.5, 151.6, 156.3 163.1 (d, 
1JCF = 245.0 Hz), 
186.2; HRMS (ES): found 454.9931 C23H14O2F
35Cl79Br+ requires 454.9771. Anal calcd for 
C23H13O2FClBr: C, 60.62; H, 2.88. Found: C, 60.59; H, 2.90. 
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(E)-1-(5-Bromo-2-(3ʹʹ-fluorophenyl)benzofuran-7-yl)-3-(4ʹ-methoxyphenyl)prop-2-en-1-
one (203n); R1 = OCF3, R2 = 3-F  
 
A mixture of 198d (1.10 g, 2.40 mmol), 3-flourophenylacetylene (0.35 g, 2.88 mmol), 
PdCl2(PPh3)2 (0.08 g, 0.12 mmol), Cs2CO3 (0.94 g, 2.88 mmol) and CuI (0.05 g, 0.24 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203n as a solid (0.79 g, 73%); 
mp. 221–222 °C; νmax (ATR)  562, 683, 778, 893, 973, 1076, 1194, 1257, 1348, 1487, 1591, 
1655 cm-1; δH (500 MHz, CDCl3) 3.88 (3H, s, OCH3), 6.98 (2H, d, J = 8.5 Hz, Ar), 7.08 (1H, s, 
=CH), 7.11 (1H, t, J = 8.5 Hz, Ar), 7.45 (1H, d, J = 7.5 Hz, Ar), 7.69 (1H, d, J = 8.5 Hz, Ar), 
7.65 (1H, d, J = 8.0 Hz, Ar), 7.69 (2H, d, J = 8.5 Hz, Ar), 7.87 (1H, d, Jtrans = 16.0 Hz, α-H), 7.89 
(1H, d, J = 1.5 Hz, H-4), 7.92 (1H, d, Jtrans = 16.0 Hz, β-H), 8.04 (1H, d, J = 2.5 Hz, H-6); δC 
(125 MHz, CDCl3) 55.4, 112,2 (d, 
3JCF = 23.7 Hz), 114.6, 116.3 (d, 
2JCF = 20.9 Hz), 116.7, 121.0 
(d, 4JCF = 2.8 Hz), 122.4, 123.7, 124.5, 127.5, 127.7, 128.5, 129.9, 130.4, (d, 
3JCF = 7.5 Hz),130.7, 
131.4 (d, 3JCF = 7.6 Hz), 132.4, 145.0, 151.6, 156.2 (d, 
4JCF = 2.9 Hz),163.1 (d, 
1JCF = 263.6 Hz), 
186.4; HRMS (ES): found 451.0327. C24H17O3
79Br+ requires 451.0345. Anal calcd for 
C24H16O3Br: C, 63.87; H, 3.57. Found: C, 63.92; H, 3.64. 
 
(E)-1-(5-Bromo-2-(3ʹʹ-fluorophenyl)benzofuran-7-yl)-3-(4ʹ-(trifluoromethoxy)phenyl)- 
prop-2-en-1-one (203o); R1 = OCF3, R2 = 3-F  
 
A mixture of 198e (1.03 g, 2.01 mmol), 3-flourophenylacetylene (2.90 g, 2.42 mmol), 
PdCl2(PPh3)2 (0.07 g, 0.10 mmol), Cs2CO3 (0.79 g, 2.42 mmol) and CuI (0.04 g, 0.20 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203o as a solid (0.88 g, 87%); 
mp. 186–187 °C; νmax (ATR) 575, 696, 779, 892, 978, 1075, 1160, 1256, 1346, 1487, 1573, 1656 
cm-1; δH (500 MHz, CDCl3)  7.09 (1H, s, =CH), 7.14 (1H, t, J = 8.0 Hz, Ar), 7.31 (1H, d, J = 8.7 
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Hz, Ar), 7.43 (1H, d, J = 8.5 Hz, Ar), 7.45 (1H, d, J = 8.5 Hz, Ar), 7.50 (1H, t, J = 8.0 Hz, Ar), 
7.55 (1H, dt, J = 8.5 and 2.5 Hz, Ar), 7.59 (1H, d, J = 8.0 Hz, Ar), 7.65 (1H, t, J = 8.5 Hz, Ar), 
7.91 (1H, d, Jtrans = 16.0 Hz, α-H), 7.93 (1H, d, J = 2.5 Hz, H-4) 8.04 (1H, d, Jtrans = 16.0 Hz, β-
H), 8.08 (1H, d, J = 1.5 Hz, H-6); δC (125 MHz, CDCl3) 100.5, 112.0 (d, 2JCF = 23.9 Hz), 116.5 
(d, 2JCF = 21.9 Hz), 116.8, 120.2 (q, JCF = 256.0 Hz), 122.9, 123.7, 125.9, 127.2, 128.4, 128.7, 
130.5, 130.6 (d, 4JCF = 7.5 Hz),  131.2 (d, 
3JCF = 8.5 Hz), 132.5, 136.9, 143.1, 149.8 (d, 
2JCF = 
1.9 Hz), 151.7, 156.4 (d, 2JCF = 3.8 Hz), 163.1 (d, 
1JCF = 245.6 Hz), 198.9; HRMS (ES): found 
505.0085. C24H14O3
79BrF4
+ requires 505.0062. Anal calcd for C24H13O3BrF4: C, 57.05; H, 2.59. 
Found: C, 57.12; H, 2.61. 
 
(E)-1-(5-Bromo-2-(3ʹʹ-chlorophenyl)benzofuran-7-yl)-3-phenylprop-2-en-1-one (203p); R1 
= H, R2 = 3-Cl  
 
A mixture of 198a (0.99 g, 2.32 mmol), 3-chlorophenylacetylene (0.38 g, 2.78 mmol), 
PdCl2(PPh3)2 (0.08 g, 0.12 mmol), Cs2CO3 (0.90 g, 2.78 mmol) and CuI (0.04 g, 0.23 mmol) in 
aqueous DMF (20 mL) was treated as for the preparation of 203a to afford 203p as a solid (0.75 
g, 75%); mp. 218–219 °C; νmax  (ATR) 575, 663, 780, 893, 944, 1012, 1194, 1279, 1345, 1488, 
1585, 1602, 1657 cm-1; δH (500 MHz, CDCl3)  7.09 (1H, s, =CH), 7.40 (2H, d, J = 8.0 Hz, Ar), 
7.47 (2H, d, J = 8.0 Hz, Ar), 7.73-7.77 (5H, m, Ar), 7.90 (1H, d, J = 2.5 Hz, H-4), 7.92 (1H, d, 
J = 1.5 Hz, H-6), 7.96 (1H, d, Jtrans = 16.0 Hz, α-H), 8.06 (1H, d, Jtrans = 16.0 Hz, β-H); δC (125 
MHz, CDCl3) 101.3, 116.4, 123.2, 124.0, 124.5, 125.1, 128.1, 128.6, 128.7, 129.2, 129.4, 130.4, 
130.9, 131.0, 132.4, 134.8, 135.2, 145.1, 151.7, 156.0, 186.2; HRMS (ES): found 436.9942. 
C23H15O2Cl
79Br requires 436.9942. Anal calcd for C23H14O2ClBr: C, 63.11; H, 3.22. Found: C, 
63.08; H, 3.16. 
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(E)-1-(5-Bromo-2-(3ʹʹ-chlorophenyl)benzofuran-7-yl)-3-(4ʹ-fluorophenyl)prop-2-en-1-one 
(203q); R1 = F, R2 = 3-Cl  
 
A mixture of 198b (0.96g, 2.16 mmol), 3-chlorophenylacetylene (0.35 g, 2.59 mmol), 
PdCl2(PPh3)2 (0.08 g, 0.11 mmol), Cs2CO3 (0.84 g, 2.59 mmol) and CuI (0.04 g, 0.22 mmol) in 
aqueous DMF (20 mL) was treated as for the preparation of 203a to afford 203q as a solid (0.67 
g, 69%); mp. 232–233 °C; νmax (ATR)  570, 630, 781, 891, 973, 1078, 1102, 1221, 1376, 1494, 
1584, 1596, 1655 cm-1; δH (300 MHz, CDCl3)  7.09 (1H, s, =CH), 7.17 (2H, t, J = 8.5 Hz, Ar), 
7.41 (2H, t, J = 8.5 Hz, Ar ), 7.21-7.76 (3H, m, Ar), 7.91 (1H, d, J = 8.0 Hz, Ar), 7.92 (1H, d J 
= 2.0 Hz, H-4), 7.95 (1H, d, Jtrans = 16.0 Hz, α-H), 7.98 (1H, d, Jtrans = 16.0 Hz, β-H), 8.08 (1H, 
d, J = 2.0 Hz, H-6); δC (75 MHz, CDCl3) 100.2, 116.3 (d, 2JCF = 21.8 Hz), 116.5, 124.1, 124.3, 
124.4, 125.6, 125.7, 127.1, 127.8, 128.0, 129.8, 130.4 (d, 3JCF = 8.5 Hz), 131.1 (d, 
4JCF = 2.8 
Hz), 132.7, 136.9, 143.6, 151.6, 156.8, 164.4 (d, 1JCF = 239.0 Hz), 186.6; HRMS (ES): found 
454.9851. C23H14O2F
79BrCl+ requires 454.9850. Anal calcd for C23H13O2FBrCl: C, 60.62; H, 
2.88. Found: C, 60.64; H, 2.90. 
 
(E)-1-(5-Bromo-2-(3ʹʹ-chlorophenyl)benzofuran-7-yl)-3-(4ʹ-chlorophenyl)prop-2-en-1-one 
(203r); R1 = Cl, R2 = 3-Cl  
 
A mixture of 198c (1.00 g, 2.17 mmol), 3-chlorophenylacetylene (0.35 g, 2.60 mmol), 
PdCl2(PPh3)2 (0.08 g, 0.11 mmol), Cs2CO3 (0.85 g, 2.60 mmol) and CuI (0.04 g, 0.22 mmol) in 
aqueous DMF (20 mL) was treated as for the preparation of 203a to afford 203r as a solid (0.79, 
77%); mp. 257–258 °C; νmax (ATR) 574, 639, 776, 859, 980, 1077, 1192, 1238, 1346, 1476, 
1507, 1562, 1656 cm-1; δH (500 MHz, CDCl3) 7.08 (1H, s, =CH), 7.41 (2H, d, J = 7.5 Hz, Ar), 
7.46-7.48 (3H, m, Ar ), 7.73-7.77 (2H, m, Ar), 7.91 (1H, d, J = 2.0 Hz, H-4), 7.94 (1H, d, J = 
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8.0 Hz, Ar), 7.96 (1H, d, Jtrans = 16.0 Hz, α-H),  8.06 (1H, d, Jtrans = 16.0 Hz, β-H), 8.08 (1H, d, J 
= 7.0 Hz, H-6); δC (125 MHz, CDCl3) 101.6, 116.8, 123.2, 124.0, 124.5, 125.1, 128.1, 128.6, 
128.7, 129.1, 129.4, 130.3, 130.9, 131.0, 132.4, 134.8, 135.2, 145.1, 151.7, 156.0, 186.2; HRMS 
(ES): found 470.9995. C23H14O2Cl2Br
+ requires 470.9476. Anal calcd for C23H13O2Cl2Br: C, 
58.51; H, 2.78. Found: C, 58.60; H, 2.82. 
 
(E)-1-(5-Bromo-2-(3ʹʹ-chlorophenyl)benzofuran-7-yl)-3-(4ʹ-methoxyphenyl)prop-2-en-1-
one (203s); R1 = OCH3, R2 = 3-Cl  
 
A mixture of 198d (0.89 g, 1.95 mmol), 3-chlorophenylacetylene (0.32 g, 2.34 mmol), 
PdCl2(PPh3)2 (0.07 g, 0.10 mmol), Cs2CO3 (0.76 g, 2.34 mmol) and CuI (0.04 g, 0.20 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203s as a solid (0.65 g, 71%); 
mp. 214–215 °C; νmax (ATR) 551, 695, 772, 893, 1076, 1169, 1255, 1346, 1474, 1508, 1585, 
1654 cm-1; δH (500 MHz, CDCl3) 3.88 (3H, s, OCH3), 6.99 (2H, d, J = 8.5 Hz, Ar), 7.09 (1H, s, 
=CH), 7.40 (2H, t, J = 8.0 Hz, Ar), 7.71 (2H, d, J = 9.0 Hz, Ar), 7.74 (2H, d, J = 7.5 Hz, Ar), 
7.90 (1H, d, J = 2.5 Hz, 4-H), 8.00 (1H, d, Jtrans = 16.0 Hz, α-H), 8.04 (1H, d, Jtrans = 16.0 Hz, β-
H), 8.06 (1H, d, J = 2.5 Hz, 6-H); δC (125 MHz, CDCl3) 55.4, 101.5, 113.5, 114.6, 116.7, 122.3, 
124.4, 125.1, 127.8, 128.6, 129.3, 130.3, 130.4, 131.1, 132.2, 132.4, 135.1, 145.0, 151.7, 156.0, 
162.0, 186.2; HRMS MH+, found 467.0046. C24H17O3
79BrCl+ requires 467.0050. Anal calcd for 
C24H16O3BrCl: C, 61.63; H, 3.45. Found: C, 61.58; H, 3.48. 
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(E)-1-(5-Bromo-2-(3ʹʹ-chlorophenyl)benzofuran-7-yl)-3-(4ʹ-(trifluoromethoxy)phenyl)- 
prop-2-en-1-one (203t); R1 = OCF3, R2 = 3-Cl  
 
A mixture of 198e (1.02 g, 2.00 mmol), 3-chlorophenylacetylene (0.33 g, 2.40 mmol), 
PdCl2(PPh3)2 (0.07 g, 0.10 mmol), Cs2CO3 (0.78 g, 2.40 mmol) and CuI (0.04 g, 0.20 mmol) in 
aqueous DMF (20 mL) was treated as for the preparation of 203a to afford 203t as a solid (0.73 
g, 71%); mp. 196–197 °C; νmax  (ATR) 575, 695, 776, 893, 997, 1076, 1172, 1260, 1344, 1490, 
1561, 1599, 1656 cm-1; δH (500 MHz, CDCl3) 7.03 (1H, s, =CH), 7.31 (1H, d, J = 7.5 Hz, Ar), 
7.40 (2H, d, J =7.0 Hz, Ar), 7.51 (1H, t, J = 8.0 Hz, Ar), 7.56 (1H, d, J = 8.0 Hz, Ar), 7.68 (1H, 
d, J =7.5 Hz, Ar). 7.75 (1H, dt, J = 2.0 and 8.0 Hz, Ar), 7.78 (1H, d, J =8.0 Hz, Ar), 7.90 (1H, d, 
Jtrans = 16.0 Hz, α-H), 7.93 (1H, d, J 2.0 Hz, H-4), 8.05 (1H, d, Jtrans = 16.0 Hz, β-H), 8.09 (1H, d, 
J 2.0 Hz, H-6); δC (125 MHz, CDCl3) 101.3, 116.4, 119.5 (t, JCF = 256.0 Hz), 123.2, 124.0, 
124.5, 125.1, 128.1, 128.6, 128.7, 129.2, 129.4, 130.4, 130.9, 131.0, 132.4, 134.8, 135.2, 145.1, 
151.7, 156.0, 186.2; HRMS (ES): found 520.9930. C24H14O3
79BrF3Cl requires 520.9923. Anal 
calcd for C24H13O3BrF3Cl: C, 55.25; H, 2.51. Found: C, 55.30; H, 2.54. 
 
(E)-1-(5-Bromo-2-(4ʹʹ-methoxyphenyl)benzofuran-7-yl)-3-phenylprop-2-en-1-one (203u); 
R1 = H, R2 = 4-OCH3  
 
A mixture of 198a (0.93 g, 2.18 mmol), 4-methoxyphenylacetylene (0.34 g, 2.61 mmol), 
PdCl2(PPh3)2 (0.08 g, 0.11 mmol), Cs2CO3 (0.84 g, 2.61 mmol) and CuI (0.04 g, 0.22 mmol) in 
aqueous DMF (20 mL) was treated as for the preparation of 203a to afford 203u as a solid (0.68 
g, 72%); mp. 255–256 °C; νmax  (ATR) 571, 680, 765, 889, 979, 1098, 1156, 1254, 1347, 1435, 
1580, 1596, 1657 cm-1; δH (500 MHz, CDCl3) 3.87 (3H, s, OCH3), 6.92 (1H, s, =CH), 6.98 (2H, 
d, J = 9.0 Hz, Ar), 7.45-7.46 (3H, m, Ar ), 7.74 (2H, d, J = 8.0 Hz, Ar), 7.81 (2H, d, J = 9.0 Hz, 
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Ar), 7.85 (1H, J = 1.5 Hz, H-4), 7.92 (1H, d, Jtrans = 16.0 Hz, α-H), 7.98 (1H, d, J 2.5 Hz, H-6), 
8.02 (1H, d, Jtrans = 16.0 Hz, β-H); δC (125 MHz, CDCl3) 55.4, 98.8, 114.4, 116.4, 122.1, 123.9, 
124.9, 126.7, 127.4, 128.6, 129.1, 130.7, 133.1 (2C), 134.9, 144.7, 151.5, 157.9, 160.5, 186.8; 
HRMS (ES): found 433.0439. C24H18O3
79Br requires 433.0439 Anal calcd for C24H17O3Br: C, 
66.53; H, 3.95. Found: C, 66.54; H, 3.95. 
 
(E)-1-(5-Bromo-2-(4ʹʹ-methoxyphenyl)benzofuran-7-yl)-3-(4ʹ-fluorophenyl)prop-2-en-1-
one (203v); R1 = F, R2 = 4-OCH3  
 
A mixture of 198b (0.94 g, 2.11 mmol), 4-methoxyphenylacetylene (0.33 g, 2.53 mmol), 
PdCl2(PPh3)2 (0.08 g, 0.11 mmol), Cs2CO3 (0.82 g, 2.53 mmol) and CuI (0.04 g, 0.21 mmol) in 
aqueous DMF (20 mL) was treated as for the preparation of 203a to afford 203v as a solid (0.78 
g, 82%); mp. 241–242 °C; νmax (ATR)  575, 695, 776, 893, 997, 1076, 1172, 1260, 1344, 1490, 
1561, 1599, 1656 cm-1; δH (500 MHz, CDCl3) 6.91 (1H, s, =CH), 6.98 (2H, d, J = 9.0 Hz, Ar), 
7.14 (2H, t, J = 8.5 Hz, Ar ), 7.72 (2H, t, J = 8.5 Hz, Ar), 7.79 (2H, d, J = 9.0 Hz, Ar), 7.85 (1H, 
d J = 1.5 Hz, H-4), 7.90 (1H, d, Jtrans = 16.0 Hz, α-H), 7.93 (1H, d, Jtrans = 16.0 Hz, β-H), 7.98 
(1H, d, J = 2.4 Hz, H-6); δC (125 MHz, CDCl3) 55.5, 100.2, 114.6, 116.3 (d, 2JCF = 21.9 Hz), 
124.1, 124.3, 124.4, 125.8, 127.0, 127.6, 128.8, 130.4 (d, 3JCF = 8.7 Hz), 131.2, 132.4 (d, 
4JCF = 
3.8 Hz), 143.6, 144.9, 151.5, 156.8, 161.6 (d, 1JCF = 245.0 Hz), 186.8; HRMS (ES): found 
451.0333. C24H17O3F
79Br+ requires 451.0345. Anal calcd for C24H16O3FBr: C, 63.87; H, 3.57. 
Found: C, 63.89; H, 3.62. 
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(E)-1-(5-Bromo-2-(4ʹʹ-methoxyphenyl)benzofuran-7-yl)-3-(4ʹ-chlorophenyl)prop-2-en-1-
one (203w); R1 = Cl, R2 = 4-OCH3  
 
A mixture of 198c (1.04 g, 2.26 mmol), 4-methoxyphenylacetylene (0.36 g, 2.71 mmol), 
PdCl2(PPh3)2 (0.08 g, 0.11 mmol), Cs2CO3 (0.88 g, 2.71 mmol) and CuI (0.04 g, 0.23 mmol) in 
aqueous DMF (20 mL) was treated as for the preparation of 203a to afford 203w as a solid (0.83, 
79%); mp. 209–210 °C; νmax (ATR) 550, 646, 784, 982, 1098, 1173, 1254, 1346, 1436, 1579, 
1657 cm-1; δH (500 MHz, CDCl3) 3.88 (3H, s, OCH3), 6.98 (2H, d, J = 9.0 Hz, Ar), 7.08 (1H, s, 
=CH), 7.40 (2H, d, J = 8.0 Hz, Ar), 7.72 (2H, d, J = 9.0 Hz, Ar), 7.75 (2H, d, J = 8.5 Hz, Ar), 
7.90 (1H, d, J = 2.5 Hz, 4-H), 7.92 (1H, d, Jtrans = 16.0 Hz, α-H), 7.97 (1H, d, Jtrans = 16.0 Hz, β-
H), 8.08 (1H, d, J = 2.5 Hz, 6-H); δC (125 MHz, CDCl3) 55.4, 101.6, 114.6, 116.7, 122.3, 123.2, 
124.4, 125.1, 127.6, 129.4, 130.3, 130.4, 131.0, 132.3, 135.1, 145.0, 151.7, 155.9, 162.0, 186.2; 
HRMS (ES): found 466.381. C24H17O3ClBr
+ requires 466.0377. Anal calcd for C24H16O3ClBr: 
C, 61.63; H, 3.45. Found: C, 61.65; H, 3.47. 
 
(E)-1-(5-Bromo-2-(4ʹʹ-methoxyphenyl)benzofuran-7-yl)-3-(4ʹ-methoxyphenyl)prop-2-en-
1-one (203x); R1 = OCH3, R2 = 4-OCH3  
 
A mixture of 198d (0.95 g, 2.00 mmol), 4-methoxyphenylacetylene (0.32 g, 2.40 mmol), 
PdCl2(PPh3)2 (0.07 g, 0.10 mmol), Cs2CO3 (0.78 g, 2.40 mmol) and CuI (0.04 g, 0.20 mmol) in 
aqueous DMF was treated as for the preparation of 203a to afford 203x as a solid (0.64 g, 69%); 
mp. 216–217 °C; νmax (ATR) 550, 699, 783, 980, 1093, 1213, 1346, 1506, 1585, 1657 cm-1; δH 
(500 MHz, CDCl3) 3.87 (6H, s, 2xOCH3), 6.91 (1H, s, =CH), 6.97 (2H, d, J = 9.0 Hz, Ar), 6.98 
(2H, d, J = 9.0 Hz, Ar), 7.68 (2H, d, J = 8.0 Hz, Ar), 7.81 (2H, d, J = 8.5 Hz, Ar), 7.83 (1H, d, 
J = 8.0 Hz, Ar), 7.84 (1H, d, Jtrans = 16.0 Hz, α-H), 7.87 (1H, d, Jtrans = 16.0 Hz, β-H), 7.89 (1H, 
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d, J = 2.5 Hz, 4-H), 7.97 (1H, d, J = 2.5 Hz, 6-H); δC (125 MHz, CDCl3) 55.4, 55.5, 98.8, 114.4, 
114.5,116.3, 122.2, 122.6, 124.3, 126.7, 127.1, 127.3, 130.4, 133.0, 144.6, 151.5, 157.8, 160,7, 
161.9, 186.8; HRMS MH+, found 463.0532. C25H20O4
79Br+ requires 463.0545. Anal calcd for 
C25H19O4Br: C, 64.81; H, 4.13. Found: C, 64.78; H, 4.20. 
 
(E)-1-(5-Bromo-2-(4ʹʹ-methoxyphenyl)benzofuran-7-yl)-3-(4ʹ-(trifluoromethoxy) phenyl) 
prop-2-en-1-one (203y); R1 = OCF3, R2 = 4-OCH3  
 
A mixture of 198e (0.87 g, 1.70 mmol), 4-methoxyphenylacetylene (0.27 g, 2.04 mmol), 
PdCl2(PPh3)2 (0.06 g, 0.01 mmol), Cs2CO3 (0.66 g, 2.04 mmol) and CuI (0.03 g, 0.17 mmol) in 
aqueous DMF (20 mL) was treated as for the preparation of 203a to afford 203y as a solid (0.59 
g, 67%); mp. 187–188 °C; νmax  (ATR) 549, 694, 797, 866, 999, 1023, 1171, 1248, 1349, 1481, 
1569, 1598, 1655 cm-1; δH (500 MHz, CDCl3) 3.87 (3H, s, OCH3), 6.93 (1H, s, =CH), 7.00 (2H, 
d, J = 8.5 Hz), 7.31 (1H, d, J =8.0 Hz), 7.49 (1H, t, J = 8.0 Hz, Ar), 7.61 (1H, d, J = 8.0 Hz, Ar), 
7.65 (1H, d, J = 8.0 Hz, Ar), 7.81 (2H, d, J = 8.5 Hz, Ar), 7.87 (1H, J = 2.0 Hz, H-4), 7.91 (1H, 
d, Jtrans = 16.0 Hz, α-H), 8.03 (1H, d, J 2.0 Hz, H-6), 8.11 (1H, d, Jtrans = 16.0 Hz, β-H); δC (125 
MHz, CDCl3) 55.4, 98.9, 114.5, 116.5, 119.5 (t, JCF = 256.0 Hz), 119.8, 121.9, 122.8, 123.4, 
126.3, 126.6, 127.5, 127.7, 127.8, 130.5, 133.2, 139.4, 142.7, 158.0, 160.8, 186.2; HRMS (ES): 
found 517.0262. C25H17O4
79BrF3 requires 517.0262. Anal calcd for C25H16O4BrF3: C, 58.05; H, 
3.12. Found: C, 58.06; H, 3.13. 
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4.6 C-3 Trifluoroacetylation of compounds 201a–f with TFAA in THF 
 
 
      201a–f 
 
(E)-1-(5-Bromo-2-phenyl-3-(trifluoroacetyl)-1H-indol-7-yl)-3-phenylprop-2-en-1-one 
(204a); R1 = H, R2 = H 
 
A mixture of 201a (1.00 g, 2.48 mmol) and TFAA (0.78 g, 3.72 mmol) in THF (20 mL) was 
heated at 60 °C for 5 h. The mixture was allowed to cool to RT and then quenched with an ice-
cold water. The resultant precipitate was filtered, washed thoroughly with cold water and then 
recrystallized to afford 204a as a solid (1.09 g, 88%), mp. 195–197 °C (EtOH); νmax (ATR) 527, 
678, 775, 846, 971, 1099, 1193, 1285, 1339, 1478, 1599, 1647, 1666, 3388 cm-1; δH (500 MHz, 
CDCl3) 7.47–7.61 (10H, m, ArH), 7.70 (1H, d, Jtrans = 16.0 Hz, α-H), 7.92 (1H, d, Jtrans = 16.0 Hz, 
β-H), 8.16 (1H, d, J 2.0 Hz, 4-H), 8.68 (1H, d, J 2.0 Hz, 6-H), 11.15 (1H, s, NH); δC (125 MHz, 
CDCl3) 107.5, 112.5, 115.9 (q, 
1JCF 286.4 Hz, CF3), 119.6, 121.8, 128.2, 128.4, 128.6, 128.7, 
129.0, 129.4, 130.2, 130.4, 130.5, 131.1, 133.5, 134.2, 145.9, 149.5, 176.9 (q, 2JCF 37.0 Hz, 
CF3C=O), 189.3 (C=O); δF (470 MHz, CDCl3) -77.1; HRMS (ES): MH+, found: 498.0315. 
C25H16NO2F3
79Br+ requires: 498.0317. 
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(E)-1-(5-Bromo-2-phenyl-3-(trifluoroacetyl)-1H-indol-7-yl)-3-(4ʹ-fluorophenyl) prop-2-
en-1-one (204b); R1 = F, R2 = H 
 
A mixture of 201b (0.42 g, 0.99 mmol) and TFAA (0.31 g, 1.49 mmol) in THF (10 mL) was 
treated as for the preparation of 204a to afford 204b as a solid (0.39 g, 76%), mp. 164–166 °C 
(EtOH); νmax (ATR) 584, 665, 759, 831, 980, 1092, 1198, 1225, 1351, 1478, 1598, 1646, 1665, 
3391 cm-1; δH (500 MHz, CDCl3) 7.15 (2H, t, J = 8.5 Hz, 3',5'-H), 7.52–7.59 (5H, m, PhH), 7.61 
(1H, d, Jtrans = 15.5 Hz, α-H), 7.72 (2H, t, J 8.0 Hz, 2',6'-H), 7.87 (1H, d, Jtrans = 16.0 Hz, β-H), 
8.14 (1H, d, J 1.8 Hz, 4-H), 8.67 (1H, d, J 1.8 Hz, 6-H), 11.14 (1H, s, NH); δC (125 MHz, DMSO-
d6) 107.6, 115.6 (q, 
1JCF 288.2 Hz, CF3), 116.2 (d, 
2JCF = 21.8 Hz), 120.3, 121.3, 125.5, 126.3, 
128.5, 129.1, 129.2, 130.6 (d, 3JCF = 8.5 Hz), 131.0 (d, 
4JCF =
 2.8 Hz), 131.3, 132.5, 135.3, 140.8, 
143.3, 157.4 163.4 (d, 1JCF = 246.7 Hz), 177.1 (q, 
2JCF 37.0 Hz, CF3C=O), 189.2 (C=O); δF (470 
MHz, CDCl3) -75.1, -72.3; HRMS (ES): MH
+, found 516.0228. C25H15NO2F4
79Br+ requires: 
516.0222. 
 
(E)-1-(5-Bromo-2-phenyl-3-(trifluoroacetyl)-1H-indol-7-yl)-3-(4ʹ-chlorophenyl)prop-2-en-
1-one (204c); R1 = Cl, R2 = H 
 
A mixture of 201c (0.37 g, 0.84 mmol) and TFAA (0.27 g, 1.28 mmol) in THF (10 mL) was 
treated as for the preparation of 204a to afford 204c as a solid (0.41 g, 91%), mp. 180–183 °C; 
νmax (ATR) 573, 693, 799, 889, 971, 1083, 1159, 1299, 1351, 1495, 1571, 1644, 1696, 3421 cm-
1; δH (500 MHz, CDCl3) 7.43 (2H, d, J = 8.5 Hz), 7.52–7.63 (7H, m, PhH), 7.66 (1H, d, Jtrans = 
15.5 Hz, α-H), 7.87 (1H, d, Jtrans = 15.5 Hz, β-H), 8.15 (1H, d, J 2.0 Hz, 4-H), 8.67 (1H, d, J 2.0 
Hz, 6-H), 11.12 (1H, s, NH); δC (125 MHz, CDCl3) 107.6, 116.1 (q, 1JCF 288.2 Hz, CF3), 120.2, 
121.8, 128.3, 128.5, 129.4, 129.5, 129.9, 130.3, 130.4, 130.5, 130.5, 130.6, 132.8, 133.6, 137.2, 
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144.4, 149.7, 177.1 (q, 2JCF 37.0 Hz, CF3C=O) 189.1 (C=O); δF (470 MHz, CDCl3) -72.4; HRMS 
(ES): MH+, found 531.9919. C25H15NO2F3
35Cl79Br+ requires: 531.9927. 
 
(E)-1-(5-Bromo-2-phenyl-3-(trifluoroacetyl)-1H-indol-7-yl)-3-(methoxyphenyl)prop -2-en-
1-one (204d); R1 = OCH3, R2 = H 
 
A mixture of 201d (0.21 g, 0.49 mmol) and TFAA (0.15 g, 0.73 mmol) in THF (10 mL) was 
treated as for the preparation of 204a to afford 204d as a solid (0.16 g, 62%), mp. 173–175 °C 
(EtOH); νmax (ATR) 561, 665, 761, 846, 935, 1040, 1130, 1257, 1350, 1426, 1545, 1603, 1648, 
3426 cm-1; δH (500 MHz, CDCl3) 3.89 (3H, s, OCH3), 6.98 (2H, d, J = 8.5 Hz), 7.51–7.60 (6H, 
m, ArH), 7.69 (2H, d, J 8.5 Hz, ArH), 7.90 (1H, d, Jtrans = 15.0 Hz, β-H), 8.14 (1H, d, J 2.0 Hz, 
4-H), 8.65 (1H, d, J 2.0 Hz, 6-H), 11.20 (1H, s, NH); δC (125 MHz, CDCl3) 55.5, 107, 116.1 (q, 
1JCF 288.2 Hz, CF3) 119.3, 120.1, 120.7, 122.2, 127.1, 128.2, 128.5, 129.6, 130.1, 130.3, 130.5, 
130.8, 133.7,  145.9, 149.6, 151.1, 162.3, 177.3 (q, 2JCF 37.0 Hz, CF3C=O) 189.3 (C=O); δF (470 
MHz, CDCl3) -72.3; HRMS (ES): MH
+, found 528.0425. C26H18NO3F3
79Br+ requires: 528.0422.  
 
(E)-3-(5-Bromo-3-(trifluoroacetyl)-2-(4ʹʹ-(trifluoromethoxy)phenyl)-1H-indol-7-yl)-3-(4ʹ-
chlorophenyl)prop-2-en-1-one (204e); R1 = Cl, R2 = OCF3 
 
A mixture of 201e (0.27 g, 0.52 mmol) and TFAA (0.16 g, 0.78 mmol) in THF (10 mL) was 
treated as for the preparation of 204a to afford 204e as a solid (0.29 g, 90%), mp. 266–269 °C 
(EtOH); νmax (ATR) 578, 695, 796, 853, 978, 1090, 1195, 1278, 1339, 1195, 1278, 1339, 1489, 
1586, 1652, 1681 cm-1; δH (500 MHz, CDCl3) 7.38 (2H, d, J = 7.5 Hz), 7.4 (2H, d, J = 7.0 Hz), 
7.64-7.67 (4H, s, ArH), 7.66 (1H, d, Jtrans = 15.5 Hz, α-H), 7.87 (1H, d, Jtrans = 15.5 Hz, β-H), 8.15 
(1H, d, J 2.0 Hz, 4-H), 8.65 (1H, d, J 2.0 Hz), 11.18 (1H, s, NH); δC (125 MHz, CDCl3) 107, 
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116.3 (q, 1JCF 288.2 Hz, CF3) 119.3, 120.1, 120.7, 121.9, 128.6, 128.9, 129.4, 129.9, 130.0, 130.5, 
130.9, 131.4, 132.7, 133.6, 137.3, 144.8, 148.1, 150.8, 176.8 (q, 2JCF 37.0 Hz, CF3C=O) 189.3 
(C=O); δF (470 MHz, CDCl3) -75.9, -72.6, -57.7; HRMS (ES): MH+ found 614.0261. 
C26H14NO3F6
35Cl79Br+ requires: 614. 9651. 
 
(E)-3-(5-Bromo-3-(trifluoroacetyl)-2-(4ʹʹ-(trifluoromethoxy)phenyl)-1H-indol-7-yl)-3-(4ʹ-
methoxyphenyl)prop-2-en-1-one (204f); R1 = OCH3, R2 = OCF3  
 
A mixture of 201f (0.42 g, 0.82 mmol) and TFAA (0.26 g, 1.22 mmol) in THF (10 mL) was 
treated as for the preparation of 204a to afford 204f as a solid (0.44 g, 88%), mp. 200–203 °C 
(EtOH); νmax (ATR) 564, 694, 745, 859, 972, 1096, 1199, 1261, 1342, 1484, 1596, 1641, 1674 
cm-1; δH (500 MHz, CDCl3) 3.89 (3H, s, OCH3), 6.98 (2H, d, J = 8.5 Hz, 2',6'-H), 7.38 (2H, d, J 
= 8.0 Hz, 2",6"-H), 7.58 (1H, d, Jtrans = 15.5 Hz, α-H), 7.65 (2H, d, J 8.5 Hz, 3',5'-H ), 7.69 (2H, 
d, J 8.0 Hz, 3",5"-H ), 7.90 (1H, d, Jtrans = 15.0 Hz, β-H), 8.16 (1H, d, J 2.0 Hz, 4-H), 8.63 (1H, 
d, J 2.0 Hz, 6-H), 11.25 (1H, s, NH); δC (125 MHz, CDCl3) 55.5, 88.9, 107, 116.3 (q, 1JCF 288.2 
Hz, -CF3) 119.3, 120.7, 121.4, 122.3, 127.0, 128.4, 129.0, 129.8, 130.1, 131.4, 133.7, 146.1, 
147.9, 150.7, 162.3 176.8 (q, 2JCF 37.0 Hz, CF3C=O) 189.3 (C=O); δF (470 MHz, CDCl3) -57.7, 
-72.7; HRMS (ES): MH+, found 612.0262. C27H17NO4F6
79Br+ requires: 612.0245. 
 
 
 
 
 
 
 
 
 160 
 
4.7 Typical procedure for the synthesis of benzothiazepine derivatives 205a–g. 
 
205a–g 
 
4-(5-Bromo-2-phenyl-1H-indol-7-yl)-2-phenyl-2,3-dihydrobenzo[b][1,4]thiazepine (205a); 
X = NH, R1 = H, R2 = H 
 
A stirred mixture of 201a (0.41 g, 1.02 mmol) and 2-aminothiophenol (0.15g ,1.26 mmol) in 
glacial acetic acid (10 mL) was heated at 120 °C for 2 h and then allowed to cool to RT. The 
mixture was quenched with an ice-cold water and the resulting precipitate was filtered and 
recrystallized from ethanol to afford 205 as a green solid. (0.38 g, 92%), mp.225–227 ℃ (EtOH); 
νmax (ATR) 568.1, 685.4, 707.4, 758.0, 841.2, 889.1, 1128.6, 1448.3, 16.06, 3418.8 cm-1; δH (500 
MHz, CDCl3) 3.05 (1H, dd, J = 13.0 and 12.5 Hz, HA), 3.45 (1H, dd, J = 12.5 and 4.5 Hz, 
HM),6.85 (1H, d, J = 2.5 Hz, 3-H), 7.17 (1H, t, J = 7.0 Hz, Ar), 7.26 (2H, d, J = 8.0 Hz, Ar), 7.39 
(2H, d, J = 7.5 Hz, ArH), 7.46–7.50 (9H, m, ArH),7.93 (1H, d, J = 2.0 Hz, H-4), 7.99 (1H, d, J 
2.0 Hz, 6-H), 11.60 (1H, s, NH); δC (125 MHz, CDCl3) 38.5, 53.9, 111.3, 111.8, 120.3, 122.6, 
122.9, 123.6, 125.3, 125.5, 125.9, 127.1, 127.7, 128.8, 129.8, 130.4, 130.9, 134.9, 140.8, 144.7, 
151.5, 153.1,155.1, 155.2, 160.3 HRMS (ES): MH+, found . 510.0588 C29H21N2S
79Br+ requires 
510.0609. 
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4-(5-Bromo-2-phenyl-1H-indol-7-yl)-2-(4-fluorophenyl)-2,3-dihydrobenzo[b][1,4]- 
thiazepine (205b); X= NH, R1 = H, R2 = F 
 
A mixture of 201b (0.45 g, 1.07 mmol) and 2-aminothiophenol (0.16 g, 1.28 mmol) in acetic 
acid (10 mL) was treated as described for 201a to afford 205b as a green solid (0.40 g, 90%), 
mp.228–230 ℃ (EtOH); νmax (ATR) 575.2, 885.9, 754.4, 821.1, 972.6, 1128.0, 1229.6, 1505.4, 
1572.0, 16.03, 3426.4 cm-1; δH (500 MHz, CDCl3) 3.02 (1H, dd, J = 13.0 and 12.5 Hz, HA), 3.76 
(1H, dd, J = 12.5 and 4.5 Hz, HM), 5.54 (1H, dd, J = 12.5 and 4.5 Hz, HX), 7.21 (2H, t, J = 8.5 
Hz, Ar) 7.31 (1H, t, J = 8.5 Hz, Ar), 7.34–7.38 (6H, m, Ar), 7.50 (1H, s, =CH), 7.56 (1H, d, J = 
8.5 Hz, Ar), 7.80 (2H, t, J = 8.5 Hz, Ar), 8.05 (1H, dd, J = 1.5, 12.0 Hz, Ar), 8.24 (1H, d, J = 2.0 
Hz, H-4), 8.30 (1H, d, J = 2.0 Hz, H-6), 10.90 (1H, s, NH); δC (125 MHz, CDCl3) 39.8, 
59.5,102.0, 112.2,116.2 (d, 2JCF = 21.8 Hz), 120.3, 121.3,122.5, 125.5, 125.8, 125.9, 126.3, 
128.5, 129.1, 129.2, 129.6,129.9, 130.6 (d, 3JCF = 8.5 Hz), 131.0 (d, 
4JCF =
 2.8 Hz), 131.3, 132.5, 
135.3, 140.8, 143.3, 163.4 (d, 1JCF = 246.7 Hz); HRMS (ES): MH
+, found .528.0494 
C29H20N2S
79BrF+ requires 528.0515. 
 
4-(5-Bromo-2-phenyl-1H-indol-7-yl)-2-(4-chlorophenyl)-2,3 -dihydrobenzo[b][1,4]- 
thiazepine (205c); X = NH, R1 = H, R2 = 4-Cl 
 
A mixture of 201c (0.35 g, 0.84 mmol) and 2-aminothiophenol (0.12 g, 0.96 mmol) in acetic acid 
(10 mL) was treated as described for 201a to afford 205c as a green solid (0.32 g, 90%), mp. 
245–247 ℃ (EtOH); νmax (ATR) cm-1; 577.2, 684.6, 753.1, 815.3, 890.2, 1010.8, 1087.2, 1130.3, 
1301.5, 1449.2, 1487.6, 1600.8, 1647.3, 3429.0 cm-1; δH (500 MHz, CDCl3) 3.17 (1H, dd, J = 
13.0 and 12.5 Hz, HA), 3.32 (1H, dd, J = 12.5 and 4.5 Hz, HM), 5.54 (1H, dd, J = 12.5 and 4.5 
Hz, HX), 6.82 (1H, s, J = 2.0 Hz, 3-H), 7.40 (2H, t, J = 8.0 Hz, Ar), 7.43-7.547 (8H, m, Ar), 7.69 
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(2H, d, J = 8.5 Hz, Ar), 8.00 (1H, d, J = 1.5 Hz, 4-H), 8.02 (1H, d, J = 1.5 Hz, 6-H), 11.60 (1H, 
s, NH); δC (125 MHz, CDCl3) 37.4, 59.9,111.6, 111.7, 115.0, 122.5, 122.6, 123.6, 125.2, 126.3, 
128.6, 129.1, 129.2, 129.3, 129.8, 131.3, 132.5, 133.3, 135.3, 136.7, 140.9, 143.1, 153.0, 154.3, 
159.9; HRMS (ES): MH+, found .544.0199 C9H20N2S
79BrCl+ requires 544.0219. 
 
4-(5-Bromo-2-phenylbenzofuran)-2-phenyl-2,3-dihydrobenzo[b][1,4]thiazepine (205d); X 
= O, R1 = H, R2 = H 
 
A mixture of 203a (0.20 g, 0.50 mmol) and 2-aminothiophenol (0.07 g, 0.60 mmol) in acetic 
acid (4 mL) was treated as described for 201a to afford 205d as a green solid (0.22 g, 86 %), mp. 
189–191 ℃ (EtOH); νmax (ATR) 567, 680, 758, 853, 972, 1097, 1176, 1283, 1365, 1491, 1574, 
1596, 1605 cm-1; δH (500 MHz, DMSO-d6) 3.18 (1H, t, J =12.5 Hz, HA), 3.82 (1H, dd, J = 12.5 
and 4.5 Hz, HM), 5.57 (1H, dd, J = 12.5 and 4.5 Hz, HX), 7.23 (1H, t, J = 7.5 Hz, Ar) 7.32 (1H, 
t, J  = 8.5 Hz, Ar), 7.34–7.38 (8H, m, Ar), 7.40 (1H, d, J = 7.0 Hz, Ar), 7.54 (1H, s, =CH), 7.56 
(1H, d,  J = 8.5 Hz, Ar), 7.75 (2H, d, J = 7.5 Hz, Ar), 8.08 (1H, dd, J = 2.0 Hz, H-4), 8.25 (1H, 
d, J = 2.0 Hz, H-6); δC (125 MHz, DMSO-d6) 39.5, 59.5, 102.1, 113.9, 117.7, 122.4, 123.8, 124.2, 
125.2, 125.7, 126.0, 127.4, 127.9, 129.0, 129.5, 130.0, 130.2, 131.0, 133.2, 134.9, 135.5, 142.4, 
151.5, 155.8, 165.2; HRMS (ES): MH+, found .511.0449 C29H20NOS
79Br+ requires 511.0429. 
 
4-(5-Bromo-2-phenylbenzofuran)-2-(4-fluorophenyl)-2,3-dihydrobenzo[b][1,4]thiazepine 
(205e); X = O, R1 = H, R2 = F 
 
A mixture of 203b (0.39 g, 0.93 mmol) and 2-aminothiophenol (0.14 g, 1.11 mmol) in acetic 
acid (10 mL) was treated as described for 201a to afford 205e as a green solid (0.31 g, 79%), 
mp.179–181 (EtOH); νmax (ATR) 550, 699, 764,783, 980, 1093, 1135, 1213, 1346, 1506, 
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1585cm-1; δH (500 MHz, DMSO-d6) 3.04 (1H, t, J =12.5 Hz, HA), 3.31 (1H, dd, J = 12.5 and 4.5 
Hz, HM), 5.07 (1H, dd, J = 12.5 and 4.5 Hz, HX), 7.21 (2H, t, J = 8.0 Hz, Ar), 7.25-7.36 (4H, m, 
Ar), 7.5 (1H, s, =CH), 7.54 (2H, d, J = 8.5 Hz, Ar), 7.67 (2H, t, J = 8.0 Hz, Ar), 7.80 (2H, t, J = 
9.0 Hz, Ar) 8.05 (1H, dd, J = 9.0 and 1.5 Hz, Ar) 8.23 (1H, d, J = 2.0 Hz, H-4), 8.30 (1H, d, J = 
2.0 Hz, H-6); δC (125 MHz, DMSO-d6) 39.1, 59.7, 101.9, 116.1 (d, 2JCF = 21.8 Hz) , 123.3, 
123.7, 125.6, 125.7, 126.2, 126.5, 126.7, 128.2, 129.2, 129.3, 130.0, 130.4 (d, 3JCF = 8.5 Hz) 
130.9 (d, 4JCF = 3.3 Hz) 133.4, 135.3, 144.3, 151.6, 151.9,157.5, 162.1 (d, 
1JCF = 250.2 Hz), 
165.6; HRMS (ES): MH+, found .529.0334 C29H20NOS
79FBr+ requires 529.0355. 
 
4-(5-Bromo-2-phenylbenzofuran)-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]thiazepine 
(205f); X = O, R1 = H, R2 = 4-Cl 
 
A mixture of 203c (0.50 g, 1.14 mmol) and 2-aminothiophenol (0.17 g, 1.37 mmol) in acetic acid 
(10 mL) was treated as described for 201a to afford 205f as a green solid (0.41 g, 82%), mp. 
181–183 ℃ (EtOH); νmax (ATR) 549, 694, 797, 866, 999, 1023, 1171, 1248, 1349, 1481, 1569, 
1598, 1603 cm-1; δH (500 MHz, DMSO-d6) 3.04 (1H, t, J =12.5 Hz, HA), 3.31 (1H, dd, J = 12.5 
and 4.5 Hz, HM), 5.07 (1H, dd, J = 12.5 and 4.5 Hz, HX), 7.25–7.27 (5H, m, Ar), 7.28-7.31 (5H, 
m, Ar), 7.47 (1H, s, =CH), 7.64 (2H, d,  J = 8.0 Hz, Ar), 7.79 (1H, d, J = 7.5 Hz, Ar), 7.99 (2H, 
d, J = 2.0 Hz, Ar); δC (125 MHz, DMSO-d6) 39.5, 59.4, 102.1, 117.2, 122.9, 123.3, 123.8, 124.9, 
125.4, 126.3, 127.4, 127.6, 129.0, 129.4, 130.2, 131.0, 132.2, 133.5, 135.1, 135.2, 142.4, 151.5, 
151.9, 155.8, 165.2; HRMS (ES): MH+, found 543.0059 C29H20NOS
79BrCl+ requires 543.0039. 
 
 
 164 
 
4-(5-Bromo-2-(3-chlorophenyl)benzofuran-7-yl)-2-phenyl-2,3-dihydrobenzo[b][1,4]-
thiazepine (205g); X = O, R1 = H, R2 = OCH3 
 
A mixture of 203d (0.50 g, 1.15 mmol) and 2-aminothiophenol (0.17 g, 1.38 mmol) in acetic 
acid (10 mL) was treated as described for 201a to afford 205g as a solid (0.39 g, 78%), mp.197–
199 ℃ (EtOH); νmax (ATR) 550, 646, 784, 982, 1098, 1173, 1254, 1346, 1436, 1579 cm-1; δH 
(500 MHz, DMSO-d6) 3.05 (1H, t, J = 13.0 Hz),3.31 (1H, dd, J = 13.0 and 5.0 Hz), 3.83 (3H, s, 
OCH3), 5.25 (1H, dd, J = 13.0Hz and 5.0 Hz), 6.88 (2H, d, J = 8.0 Hz, Ar), 7.22 (2H, d, J = 7.5 
Hz, Ar), 7.29 (2H, d, J = 7.5 Hz, Ar), 7.53 (2H, d, J = 7.5 Hz, Ar), 7.57 (2H, d, J = 8.0 Hz, Ar), 
7.62 (2H, d, J = 8.0 Hz, Ar), 7.72 (1H, d, J = 8.0 Hz, Ar), 8.03 (1H, s, =CH),8.33 (1H, d, J = 1.5 
Hz, H-4);8.39 (1H, d, J = 1.5 Hz, H-6); δC (125 MHz, DMSO-d6) 39.8, 55.1, 59.5, 95.4, 110.8, 
113.8, 113.9,122.5, 124.8, 125.3, 125.8, 127.2, 129.6, 129.9, 130.0, 130.4, 131.2, 133.4, 
134.9,136.0, 144.4, 151.2, 154.0, 154.3, 158.7, 159.8; HRMS (ES): MH+, found 541.0534 
C30H23O2S
79Br+ requires 541.0555. 
 
4.8 Synthesis of benzofuran derivatives 207a–e. 
 
       207a–e 
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1-(5-Bromo-2-phenylbenzofuran-7-yl)ethanone (207a); R = 4-H 
 
A mixture of 197b (1.02 g, 2.99 mmol), phenylacetylene (0.366 g, 3.59 mmol), PdCl2(PPh3)2 
(0.10 g, 0.15 mmol), Cs2CO3 (1.16 g, 3.59 mmol) and CuI (0.06 g, 0.29 mmol) in 10:1 dioxane-
water (20 mL). The mixture was purged with nitrogen gas for 20 min. and a balloon filled with 
nitrogen gas was connected to the top of the condenser and was heated at 80 °C for 2 h and then 
quenched with an ice-cold water. The product was extracted with chloroform and the combined 
organic layers were washed with brine and dried over MgSO4. The salt was filtered off and the 
solvent was evaporated under reduced pressure on a rotary evaporator. The residue was purified 
by column chromatography on silica gel using 30% toluene-hexane mixture as an eluent to afford 
207a as a solid (0.69 g, 73%), Rf = 0.33, mp. 130–133 °C; νmax (ATR) 684, 790, 884, 989, 1095, 
1179, 1279, 1360, 1490, 1567, 1586, 1677, 3064 cm-1; δH (CDCl3) 2.95 (3H, s, CH3), 7.03 (1H, 
s, H-3), 7.42 (2H, d, J = 7.0 Hz, Ar), 7.48 (1H, t, J = 7.5 Hz, Ar) 7.85 (2H, d, J = 8.0 Hz, Ar), 
7.98 (1H, d, J = 1.5 Hz, H-4), 7.99 (1H, d, J = 1.5 Hz, H-6); δC (CDCl3) 31.0, 100.5, 116.4, 
122.9, 125.2, 127.5, 128.1, 128.6, 129.0, 129.5, 132.8, 152.1, 157.8, 194.6; HRMS (ES): found 
316.9743. C16H12O2
79Br+ requires 316.9726. Anal calcd for C16H11O2Br: C, 60.98; H, 3.58. 
Found: C, 60.96; H, 3.44. 
 
1-(5-Bromo-2-(3ʹ-fluorophenyl)benzofuran-7-yl)ethanone (207b); R = 3-F 
 
A mixture of 197b (0.99 g, 2.90 mmol), 3-fluorophenylacetylene (0.418 g, 3.48 mmol), 
PdCl2(PPh3)2 (0.10 g, 0.14 mmol), Cs2CO3 (1.13 g, 3.48 mmol) and CuI (0.06 g, 0.29 mmol) in 
10:1 dioxane-water (20 mL) was treated as for the preparation of 207b to afford 207b as a solid 
(0.73 g, 76%), Rf  = 0.32, mp. 161–164 °C; νmax (ATR) 667, 781, 878, 987, 1081, 1163, 1280, 
1365, 1488, 1556, 1686; δH (CDCl3) 2.94 (3H, s, CH3), 7.06 (1H, s, H-3), 7.12 (1H, t, J = 8.5 
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Hz, Ar),  7.40 (2H, dd, J = 8.5 and 2.0 Hz, Ar), 7.64 (1H, d, J = 8.5 Hz, Ar), 7.89 (1H, d, J 2.0 
Hz, H-4), 8.00 (1H, d, J 2.0 Hz, H-6); δC (CDCl3) 30.9, 101.6, 112.1 (d, 2JCF =23.6 Hz) 116.4 (d, 
2JCF = 21.9 Hz), 116.5, 120.9 (d, 
4JCF = 2.8 Hz), 123.1, 127.5, 128.1, 128.4, 130.7 (d, 
3JCF = 7.5 
Hz), 132.5, 152.1, 156.4 (d, 4JCF = 2.9 Hz), 163.1 (d, 
1JCF = 249.4 Hz) 194.4; HRMS (ES): found 
332.9828. C16H11O2F
79Br+ requires 332.9826. Anal calcd for C16H10O2FBr: C, 57.68; H, 3.03. 
Found: C, 57.50; H, 2.99. 
 
1-(5-Bromo-2-(4ʹ-fluorophenyl)benzofuran-7-yl)ethanone (207c); R = 4-F 
 
A mixture of 197b (0.99 g, 2.90 mmol), 4-fluorophenylacetylene (0.418 g, 3.48 mmol), 
PdCl2(PPh3)2 (0.10 g, 0.14 mmol), Cs2CO3 (1.13 g, 3.48 mmol) and CuI (0.06 g, 0.29 mmol) in 
10:1 dioxane-water (20 mL) was treated as for the preparation of 207b to afford 207c as a solid 
(0.82 g, 76%), Rf = 0.31, mp. 178–180 °C; νmax (ATR) 668, 784, 898, 987, 1029, 1166, 1280, 
1365, 1488, 1555, 1682 cm-1; δH (CDCl3) 2.93 (3H, s, -CH3), 6.98 (1H, s, H-3), 7.18 (2H, t, J = 
8.5 Hz, H-2',6'), 7.83 (2H, t, J = 8.7 Hz, H-3',5') 7.86 (1H, d, J 1.8 Hz, H-4), 7.97 (1H, d, J 1.8 
Hz, H-6); δC (CDCl3) 30.9, 100.1, 116,3 (d, 2JCF = 22.8 Hz), 125.6, 127.1, 127.6, 128.1, 128.5 
(d, 3JCF = 12.2 Hz), 132.2 (d, 
4JCF = 10.3 Hz), 132.8, 151.9, 156.9, 163.4 (d, 
1JCF = 249.4 Hz) 
194.5; HRMS (ES): found 332.9848. C16H11O2F
79Br+ requires 333.9828. Anal calcd for 
C16H10O2ClBr: C, 57.68; H, 3.03. Found: C, 57.63; H, 3.01. 
 
1-(5-Bromo-2-(3-chlorophenyl)benzofuran-7-yl)ethanone (207d); R = 3-Cl 
 
A mixture of 197b (1.00 g, 2.93 mmol), 3-chlorophenylacetylene (0.479 g, 3.52 mmol), 
PdCl2(PPh3)2 (0.10 g, 0.15 mmol), Cs2CO3 (1.14 g, 3.52 mmol) and CuI (0.05 g, 0.29 mmol) in 
10:1 dioxane-water (20 mL) was treated as for the preparation of 207b to afford 207d as a solid 
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(0.76 g, 74%), Rf = 0.28, mp. 139–141 °C; νmax (ATR) 682, 788, 882, 1078, 1144, 1275, 1359, 
1474, 1561, 1587, 1675, 3081 cm-1; δH (CDCl3) 2.94 (3H, s, CH3), 7.07 (1H, s, H-3), 7.41 (2H, 
dd, J = 1.5 and 8.0 Hz, Ar), 7.78 (1H, d, J = 8.0 Hz, Ar), 7.83 (1H, d, J = 2.0 Hz, H-4), 7.90 (1H, 
d, J = 1.5 Hz, Ar), 7.97 (1H, d, J = 2.0 Hz, H-6); δC (CDCl3) 30.9, 101.6, 116.6, 123.1, 123.2, 
125.2, 128.1, 128.4, 129.4, 130.4, 130.9, 132.5, 135.1, 152.1, 156.3, 194.4; HRMS (ES): found 
348.9634. C16H11O2
35Cl79Br+ requires 348.9631. Anal calcd for C16H10O43ClBr: C, 54.97; H, 
2.88. Found: C, 54.64; H, 2.95. 
 
1-(5-Bromo-2-(4ʹ-(trifluoromethoxy)phenyl)benzofuran-7-yl)ethanone (207e); R = 4-
OCF3 
 
A mixture of 197 (1.04 g, 3.04 mmol), phenylacetylene (0.679 g, 3.65 mmol), PdCl2(PPh3)2 (0.11 
g, 0.15 mmol), Cs2CO3 (1.18 g, 3.65 mmol) and CuI (0.06 g, 0.30 mmol) in 10:1 dioxane-water 
(20 mL) was treated as for the preparation of 207b to afford 207d as a solid (0.93 g, 77%), Rf = 
0.35, mp. 170–173 °C; νmax (ATR) 666, 746, 854, 987, 1033, 1199, 1267, 1363, 1405, 1502, 
1614, 1676, 3082 cm-1; δH (CDCl3) 2.92 (3H, s, CH3), 7.03 (1H, s, H-3), 7.34 (2H, d, J = 8.1 Hz, 
Ar), 7.85 (2H, d, J = 9.3 Hz, Ar), 7.98 (2H, d, J = 1.8 Hz, Ar); δC (CDCl3) 30.8, 101.1, 116.6, 
121.5, 123.0, 126.7, 127.7, 127.9, 128.0, 128.3, 130.2 (t, J = 25.6 Hz) 132.6, 152.1, 156.4, 194.4; 
HRMS (ES): 398.9663. found C17H11O3F3
79Br + requires 398.9745. Anal calcd for 
C17H10O3F3Br: C, 51.15; H, 2.53. Found: C, 51.32; H, 2.67. 
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4.9 Synthesis of oxime derivatives 208a–e. 
 
       208a–e 
 
1-(5-Bromo-2-phenylbenzofuran-7-yl)ethanone oxime (208a); R = 4-H 
 
A mixture of 207a (0.78 g, 2.49 mmol) and NH2OH.HCl (0.25 g, 3.74 mmol) in pyridine (20 
mL) was heated at 120 °C for 1 h. The mixture was quenched with an ice-cold water and the 
product was filtered. The resultant precipitate was washed thoroughly with cold hexane and then 
recrystallized from ethanol to afford 208a as a solid (0.76 g, 93%), mp. 177–179 °C; νmax (ATR) 
748, 777, 874, 1029, 1230, 1366, 1429, 1445, 1562, 1601, 3107, 3200 cm-1; δH (DMSO-d6) 2.42 
(3H, s, CH3), 7.41 (2H, d, J = 7.0 Hz, Ar), 7.47 (1H, s, H-3), 7.53 (1H, t, J = 8.5 Hz, Ar), 7.58 
(2H, d, J = 8.5 Hz, Ar), 7.61 (1H, d, J = 1.5 Hz, H-4), 7.84 (1H, d, J = 1.5 Hz, H-6), 11.5 (1H, s, 
OH); δC (DMSO-d6) 14.0, 102.2, 117.8, 122.9, 124.7, 125.3, 126.4, 129.2, 129.8, 130.8, 131.8, 
151.0, 151.6, 156.9; HRMS (ES): found 330.0031. C16H13O2N
79Br+ requires 330.0051. Anal 
calcd for C16H12O2NBr: C, 58.20; H, 3.66; N, 4.24. Found: C, 58.33; H, 3.71; N, 4.00. 
 
1-(5-Bromo-2-(3ʹ-fluorophenyl)benzofuran-7-yl)ethanone oxime (208b); R = 3-F 
 
A mixture of 207b (0.64 g, 1.92 mmol) and NH2OH.HCl (0.19 g, 2.87 mmol) in pyridine (20 
mL) was heated at 120 °C for 1 h and was treated as for the preparation of 208b to afford 208b 
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as a solid (0.57 g, 86%), mp. 199–201 °C; νmax (ATR) 748, 906, 1029, 1154, 1262, 1316, 1453, 
1555, 1603, 3108, 3187 cm-1; δH (DMSO-d6); 2.38 (3H, s, CH3), 7.48 (1H, s, H-3), 7.49 (1H, d, 
J = 8.0 Hz, H-6'), 7.54 (1H, t, J 7.5 Hz, H-4'), 7.59 (1H, d, J = 7.5 Hz, H-2'), 7.86 (1H, t, J = 7.0 
Hz, H-5'), 7.88 (1H, d, J = 2.0 Hz, H-4), 7.94 (1H, d, J = 2.0 Hz, H-6), 11.6 (1H, s, OH); δC 
(DMSO-d6) 14.0, 103.3, 112.1 (d, 
2JCF =23.6 Hz) 116.1 (d, 
2JCF = 21.9 Hz), 119.5, 120.9 (d, 
4JCF 
= 2.8 Hz), 123.9, 127.7, 129.6, 130.8, 131.5 (d, 3JCF = 7.5 Hz), 132.2, 134.4, 150.7 (d, 
4JCF = 2.9 
Hz), 156.5, 163.1 (d, 1JCF = 249.4 Hz); HRMS (ES): found 348.0028 C16H12NO2F
79Br+ requires 
348.0035. Anal calcd for C16H11NO2FBr: C, 55.20; H, 3.18; N, 4.02. Found: C, 55.43; H, 3.33; 
N, 3.99. 
 
1-(5-Bromo-2-(4ʹ-fluorophenyl)benzofuran-7-yl)ethanone oxime (208c); R = 4-F 
 
A mixture of 207c (0.73 g, 2.19 mmol) and NH2OH.HCl (0.22 g, 3.29 mmol) in pyridine (20 
mL) was heated at 120 °C for 1 h and was treated as for the preparation of 208b to afford 208c 
as a solid (0.61 g, 81%), mp. 216–218 °C; νmax (ATR) 690, 769, 852, 944, 1029, 1188, 1276, 
1339, 1411, 1503, 1574, 1604 3108, 3187 cm-1; δH (DMSO-d6) 2.39 (3H, s, CH3), 7.36 (2H, t, J 
= 8.7 Hz, H-2',6'), 7.43 (1H, s, H-3),  7.56 (1H, d, J = 2.0 Hz, H-4), 7.86 (2H, d, J = 2.0 Hz, H-
6), 7.97 (2H, t, J = 8.7 Hz, H-3',5'), 11.6 (1H, s, OH); δC (DMSO-d6) (125 MHz, CDCl3) 14.0, 
101.7, 115.9, 116,7 (d, 2JCF = 21.9 Hz), 123.9, 124.0, 125.2, 126.1, 126.2, 127.7 (d, 
3JCF = 8.5 
Hz), 132.5, 150.7 (d, 4JCF = 4.7 Hz), 156.3, 163.1 (d, 
1JCF = 245.6 Hz), HRMS (ES): found: 
348.9934. C16H12NO2F
79Br+ requires 348.9937. Anal calcd for C16H11NO2FBr: C, 55.20; H, 
3.18; N, 4.02. Found: C, 55.41; H, 3.31; N, 4.00. 
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1-(5-Bromo-2-(3ʹ-chlorophenyl)benzofuran-7-yl)ethanone oxime (208d); R = 3-Cl 
 
A mixture of 207d (0.50 g, 1.43 mmol) and NH2OH.HCl (0.19 g, 2.87 mmol) in pyridine (20 
mL) was heated at 120 °C for 1 h and was treated as for the preparation of 208b to afford 208d 
as a solid (0.39 g, 81%), mp. 192–195 °C; νmax (ATR) 748, 849, 916, 1006, 1090, 1162, 1278, 
1314, 1337, 1429, 1448, 1561, 1604, 3106, 3211 cm-1; δH (DMSO-d6) 2.29 (3H, s, CH3), 7.47 
(1H, s, H-3), 7.58 (1H, dd, J = 2.0 and 8.5 Hz, H-6'), 7.58 (1H, t, J = 8.5 Hz, H-5'), 7.67 (1H, d, 
J = 2.0 Hz, H-4), 7.85 (1H, d, J = 2.0 Hz, H-6), 7.67 (1H, d, J = 8.0 Hz, H-4'), 7.98 (1H, d, J = 
2.0 Hz, H-2), 11.0 (1H, s, OH); δC (DMSO-d6) 14.0, 103.3, 116.1, 123.9, 124.1, 124.3, 124.9, 
125.7, 129.6, 131.5, 131.6, 132.2, 134.4, 150.7, 150.8, 155.5; HRMS (ES): found: 364.9722. 
C16H12NO2
35Cl79Br + requires 364.9641. Anal calcd for C16H11NO2ClBr: C, 52.70; H, 3.04; N, 
3.84. Found: C, 52.65; H, 3.14; N, 3.88. 
 
1-(5-Bromo-2-(4ʹ-(trifluoromethoxy)phenyl)benzofuran-7-yl)ethanone oxime (207e); R = 
OCF3 
 
A mixture of 207e (0.51 g, 1.88 mmol) and NH2OH.HCl (0.21 g, 2.82 mmol) in pyridine (20 
mL) was heated at 120 °C for 1 h and was treated as for the preparation of 208b to afford 208e 
as a solid (0.61 g, 78%), mp. 167–169 °C; νmax (ATR) 681, 777, 908, 1029, 1161, 1279, 1337, 
1449, 1460, 1510, 1583, 3074, 3208 cm-1; δH (DMSO-d6) 2.51 (3H, s, CH3), 6.99 (1H, s, H-3), 
7.30 (2H, d, J = 8.5 Hz, H-3',5'), 7.61 (1H, d, J = 1.5 Hz, H-4), 7.72 (1H, d, J = 1.5 Hz, H-6), 
7.88 (2H, d, J = 8.0 Hz, H-2',6'), 8.34 (1H, s, OH); δC (DMSO-d6) 13.6, 101.3, 116.3, 121.3, 
121.3, 122.7, 124.3, 126.1, 126.8, 130.1 (t, JCF = 25.6 Hz), 133.2, 149.6, 150.9, 153.1, 156.1; 
HRMS (ES): found 414.9932. C17H12NO3F3
79Br+ requires 414.9854. Anal calcd for 
C17H11NO3F3Br: C, 49.30; H, 2.68; N, 3.38. Found: C, 49.19; H, 2.59; N, 3.42. 
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4.10 One-pot Beckmann rearrangement and hydrolysis of the oxime derivatives 208a–e. 
 
      208a–e 
 
5-Bromo-2-(phenyl)benzofuran-7-amine (210a); R = 4-H 
 
A mixture of 208a (0.78 g, 2.00 mmol) and triflic acid (0.12 g, 0.80 mmol) in acetonitrile (20 
mL) was heated at 120 °C for 1 h. The mixture was cooled to room temperature and quenched 
with ice-cold water. The resultant precipitate was washed thoroughly with cold hexane and then 
recrystallized from ethanol to afford 210a as a solid (0.35 g, 62%), mp. 177–179 °C; νmax (ATR) 
736, 915, 1156, 1214, 1309, 1433, 1502, 1572, 1583, 1611, 3351, 3464 cm-1; δH (DMSO-d6) 5.70 
(2H, s, NH2), 7.21 (1H, s, H-3), 7.28 (2H, d, J = 8.5 Hz, Ar), 7.41 (2H, d, J = 8.0 Hz, Ar), 7.50 
(1H, t, J = 8.5 Hz, Ar), 7.65 (1H, d, J = 1.5 Hz, H-6), 7.84 (1H, d, J = 7.5 Hz, Ar); δC  (DMSO-
d6) 103.3, 111.1, 125.2, 128.7, 129.3, 129.4, 130.1, 133.6, 134.2, 136.2, 145.9, 156.1; HRMS 
(ES): found 287.9946. C14H11NO
79Br+ requires 287.9925. Anal calcd for C14H10NOBr: C, 58.36; 
H, 3.50; N, 4.85. Found: C, 58.68; H, 3.20; N, 4.77. 
 
5-Bromo-2-(3ʹ-fluorophenyl)benzofuran-7-amine (210b); R = 3-F 
 
A mixture of 208b (0.51 g, 1.47 mmol) and triflic acid (0.09 g, 0.58 mmol) in acetonitrile (15 
mL) was heated at 120 °C for 4 h and was treated as for the preparation of 210a to afford 210b 
as a solid (0.34 g, 78 %), mp. 124–126 °C; νmax (ATR) 721, 765, 834, 1100, 1261, 1309, 1433, 
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1572, 1583, 1611, 3375, 3482 cm-1; δH (DMSO-d6) 5.81 (2H, br s, NH2), 6.68 (1H, d, J = 1.5 Hz, 
H-6), 6.95 (1H, d, J = 1.5 Hz, H-4), 7.22 (1H, t, J 8.0 Hz, H-4'), 7.35 (1H, s, H-3), 7.52 (1H, dd, 
J 1.5 and 7.5 Hz, H-5'), 7.79 (1H, d, J = 8.0 Hz, H-6'), 7.82 (1H, s, H-2'); δC (DMSO-d6) 103.5, 
110.5, 111,7 (d, 3JCF = 8.5 Hz), 111.9,  115.9 (d, 
2JCF = 20.9 Hz), 116.7, 121.3 (d, 
4JCF = 2.9 Hz), 
130.8, 131.5 (d, 3JCF = 8.5 Hz), 132.4 (d, 
3JCF = 8.6 Hz), 135.7, 142.1, 154.3 (d, 
4JCF = 2.8 
Hz),163.1 (d, 1JCF = 240.6 Hz); HRMS (ES): found: 305.9852. C14H10NOF
79Br+ requires 
305.9831. Anal calcd for C14H9NOFBr: C, 54.93; H, 2.96; N, 4.58. Found: C, 54.87; H, 3.09; N, 
4.72. 
 
5-Bromo-2-(4ʹ-fluorophenyl)benzofuran-7-amine (210c); R = 4-F 
 
A mixture of 208c (0.63 g, 1.82 mmol) and triflic (0.11 g, 0.73 mmol) in acetonitrile (15 mL) 
was heated at 120 °C for 4 h and was treated as for the preparation of 210a to afford 210c as a 
solid (0.39 g, 71%), mp. 121–123 °C; νmax (ATR) 688, 765, 915, 1100, 1214, 1309, 1433, 1502, 
1583, 1612, 3370, 3473 cm-1; δH (DMSO-d6) 5.75 (2H, brs, NH2), 6.66 (1H, d, J = 2.0 Hz, H-6), 
6.93 (1H, d, J = 2.0 Hz, H-4), 7.23 (1H, s, H-3), 7.34 (2H, t, J 8.7 Hz, H-3',5'), 7.99 (2H, t, J = 
8.5 Hz, H-2',6'); δC (DMSO-d6) 102.1, 110.5, 111.4, 116,4 (d, 2JCF = 21.8 Hz), 116.6, 126.8 (d, 
4JCF = 2.9 Hz) 127.4 (d, 
3JCF = 8.5 Hz), 131.1, 135.6, 142.1, 154.8, 162.7 (d, 
1JCF = 244.7 Hz); 
HRMS (ES): found 305.9715. C14H10NOF
79Br+ requires 305.9776. Anal calcd for C14H9NOFBr: 
C, 54.93; H, 2.96; N, 4.58. Found: C, 54.88; H, 3.07; N, 4.70. 
 
5-Bromo-2-(3ʹ-chlorophenyl)benzofuran-7-amine (210d); R = 3-Cl 
 
A mixture of 208d (0.55 g, 1.51 mmol) and triflic acid (0.10 g, 0.60 mmol) in acetonitrile (15 
mL) was heated at 120 °C for 4 h and was treated as for the preparation of 210a to afford 210d 
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as a solid (0.31 g, 65%), mp. 106–108 °C; νmax (ATR) 737, 854, 879, 1126, 1270, 1429, 1593, 
1615, 3372, 3482 cm-1; δH (DMSO-d6) 5.82 (2H, br s, NH2), 6.68 (1H, d, J = 2.0 Hz, H-6), 6.94 
(1H, d, J = 2.0 Hz, H-4) 7.37 (1H, s, H-3), 7.43 (1H, d, J = 8.0, H-4'), 7.51 (1H, t, J = 7.5 Hz, H-
5'), 7.90 (1H, d, J = 7.5 Hz, H-6'), 8.05 (1H, d, J = 8.0 Hz, H-2'); δC (DMSO-d6) 103.6, 110.6, 
111.7, 116.7, 123.7, 124.7, 128.9, 130.8, 131.3, 132.2, 134.4, 135.7, 142.2, 154.0; HRMS (ES): 
found 321.9556. C14H10NO
35Cl79Br+ requires 321.9536. Anal calcd for C14H9NOClBr: C, 52.13; 
H, 2.81; N, 4.34. Found: C, 52.31; H, 2.66; N, 4.28. 
 
5-Bromo-2-(4ʹ-(trifluoromethoxy)phenyl)benzofuran-7-amine (210e); R = 4-OCF3 
 
A mixture of 208e (0.62 g, 1.49 mmol) and triflic acid (0.11 g, 0.60 mmol) in acetonitrile (15 
mL) was heated at 120 °C for 4 h and was treated as for the preparation of 210a to afford 210e 
as a solid (0.47 g, 85 %), mp. 118–119 °C; νmax (ATR) 685, 737, 823, 947, 1044, 1214, 1468, 
1568, 1614, 3382, 3484 cm-1; δH (DMSO-d6) 5.78 (2H, br s, NH2), 6.95 (1H, d, J = 2.0 Hz, H-
4), 6.68 (1H, d, J = 2.0 Hz, H-6), 7.32 (1H, s, H-3), 7.49 (2H, d, J = 8.5 Hz, H-3',5'), 8.05 (2H, 
d, J = 8.0 Hz, H-2',6'); δC (DMSO-d6 ) 101.3, 116.3, 121.3, 122.7, 124.3, 126.1, 126.8, 130.1 (t, 
JCF = 25.6 Hz), 133.2, 149.6, 150.9, 153.1, 156.1; HRMS (ES): found 371.9748. 
C15H10NO2F3
79Br+ requires 371.9769. Anal calcd for C15H9NO2F3Br: C, 48.41; H, 2.44; N, 3.76. 
Found: C, 48.14; H, 2.65; N, 3.89. 
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4.11 Synthesis of the 2-aryl-6-bromo-4-chloroquinazolines 214a and 214b from the 2-ary-
6-bromoquinazolin-4(3H)-ones 213a and 213b. 
 
(a) Typical procedure for the synthesis of 213a and 213b 
 
     214a and 214b 
 
6-Bromo-2-(4ʹ-fluorophenyl)quinazolin-4(3H)-one (213a); R = F 
 
A stirred mixture of 2-amino-5-bromobenzamide 211 (1.00 g, 4.65 mmol), 4-
flourobenzaldehyde 212 (0.86 g, 6.97 mmol) and iodine (2.36 g, 9.30 mmol) in ethanol (30 mL) 
in a round-bottomed flask equipped with a stirrer bar and a condenser was refluxed for 8 h and 
then allowed to cool to room temperature. An ice-cold saturated aqueous solution of sodium 
thiosulphate was added to the mixture and the resultant precipitate was filtered and washed with 
cold water. The product was recrystallized from acetonitrile to afford 213a as an off white solid 
(0.95 g, 91%), mp. 278–280; νmax (ATR) 493, 563, 622, 824, 924, 1237, 1271, 1316, 1387, 1462, 
1603, 1688, 2809, 3445 cm-1; δH (500 MHz, DMSO-d6) 7.20 (2H, t, J 8.5 Hz, Ar), 7.42 (2H, t, J 
8.5 Hz, Ar), 7.93 (1H, dd, J = 2.5 and 8.5 Hz, Ar), 8.12 (1H, d, J = 8.5 Hz), 8.16 (1H, d, J = 2.0 
Hz,), 12.40 (br s, 1H);. δC (125 MHz, DMSO-d6) 64.8, 108.5, 109.3, 115.7 (d, 2JCF Hz), 118.3, 
128.6 (d, 3JCF 21.7 Hz), 129.8, 138.4, 138.8 (d, 
4JCF 3.0 Hz), 143.8, 161.5, 162.4 (d, 
1JCF 242.4 
Hz); HRMS (ES): MH+, found 317.9794. C14H9BrFN2O
+ requires 317.9804. 
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6-Bromo-2-(4ʹ-chlorophenyl)quinazolin-4(3H)-one (213b); R = Cl 
 
A mixture of 2-amino-5-bromobenzamide (1.00 g, 4.65 mmol), 4-chlorobenzaldehyde (0.97 g, 
6.97 mmol) and iodine (2.36 g, 9.30 mmol) in ethanol (30 mL) and was treated as described for 
213a to afforded 213b as a white solid (1.45 g, 93%), mp. 342–344 ℃; νmax (ATR) 538, 559, 
649, 728, 831, 940, 1091, 1276, 1413, 1460, 1556, 1601, 1672, 3442 cm -1; δH (500 MHz, 
DMSO-d6) 7.60 (2H, d, J = 8.5 Hz, Ar), 7.66 (1H, d, J = 8.5 Hz, Ar), 7.95 (1H, dd, J = 2.5 and 
8.5 Hz, Ar), 8.16 (2H, d, J = 8.5 Hz, Ar), 8.19 (1H, d, J = 2.0 Hz, Ar), 12.76 (1H, brs, NH); δC 
(125 MHz, DMSO-d6) 104.7, 112.5, 112.9, 119.9, 128.4, 129.2, 129.9, 130.2, 138.0, 139.1, 
155.3, 159.3; HRMS (ES): MH+, found 334.9578. C14H9Br
35ClN2O
+ requires 334.9587. 
 
(b) Typical procedure for the synthesis of 2-aryl-6-bromo-4-chloroquinazoline (214a); R 
= F.  
 
6-Bromo-4-chloro-3-(4ʹ-flourophenyl)quinazoline (214a); R = F. 
 
A mixture of 213a (0.50 g, 1.06 mmol) and POCl3 (10 mL) was heated at 120° C for 3 h. The 
reaction mixture was then allowed to cool to room temperature and then quenched slowly with 
a mixture of ice and ammonia and the product was extracted with chloroform. The combined 
organic layers were washed with an aqueous solution of NaHCO3, dried over Na2SO4, filtered, 
and evaporated under reduced pressure. The crude product was recrystallized from ethanol to 
afford 214a as a white solid (0.46 g, 85%), mp. 208–210; νmax (ATR) 499, 539, 850, 1021, 1169, 
1271, 1352, 1389, 1468, 1474, 1560, 1630, 2932 cm-1; δH (500 MHz, DMSO-d6) 7.20 (2H, t, J 
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8.5 Hz, Ar), 7.42 (2H, t, J 8.5 Hz, Ar)8.06 (1H, dd, J = 2.5 and 8.5 Hz, Ar), 8.16 (1H, d, J = 2.0 
Hz, Ar), 8.44 (1H, d, J = 2.0 Hz, Ar); 
 
6-Bromo-4-chloro-3-(4ʹ-chlorophenyl)quinazoline (214b); R = Cl 
 
A stirred mixture of 213b (0.50 g,1.49 mmol) and phosphoryl chloride (10 mL) was treated as 
for the preparation of 214a to afford 214b as a yellow solid (0.48 g, 91%), mp. 244–246 ℃; νmax 
(ATR) 505, 531, 732, 829, 991, 1090, 1294, 1318, 1402, 1415, 1469, 1493,1539, 1556, 1592, 
1633 cm-1; δH (500 MHz, DMSO-d6) 7.48 (2H, d, J = 8.5 Hz,), 7.93 (1H, d, J = 8.0 Hz,), 7.99 
(1H, dd, J = 2.5 and 8.5 Hz,), 8.40 (d, J = 2.0 Hz, 1H), 8.51 (d, J = 8.5 Hz, 2H); δC (125 MHz, 
DMSO-d6) 104.8, 112.5, 112.9, 128.5, 129.2, 129.9, 130.2, 138.0, 139.2, 149.1, 152.0 159.3; 
HRMS (ES): MH+ found 334.9571. C14H9
79Br35Cl2
+ requires 334.9587. 
 
4.12  Amination of 214a and 214b with the 7-aminobenzofurans 210a–e to afford 215a–j. 
     
        215a–j 
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6-Bromo-N-(5-bromo-2-phenylbenzofuran-7-yl)-2-(4-fluorophenyl)quinazolin-4-amine 
(215a); R = 4-H, X=F 
 
A mixture of 210a (0.18 g, 0.63 mmol), 214a (0.21 g, 0.63 mmol) and HCl (0.001 g, 0.03 mmol) 
in isopropanol (10 mL) was stirred under reflux for 2 h. After completion of the reaction (tlc 
monitoring) the mixture was cooled to room temperature and quenched with an ice-cold water. 
The resultant precipitate was washed thoroughly with hot acetonitrile and then recrystallized 
from DMSO to afford 215a as a solid (0.28 g, 75%) mp. > 300 °C; νmax (ATR) 688, 782, 873, 
911, 1047, 1161, 1221, 1373, 1515, 1603, 1631, 3082, 3169 cm-1; δH (DMSO-d6) 7.29 (2H, t, J 
= 8.5 Hz, Ar), 7.34 (2H, d, J = 8.5 Hz, Ar), 7.47 (1H, s, =C-H), 7.78–7.79 (5H, m, Ar), 7.85 (1H, 
d, J = 8.5 Hz, Ar), 8.04 (1H, d, J = 8.0 Hz, Ar), 8.11 (2H, d, J = 8.5 Hz, Ar), 8.91 (1H, d, J = 1.5 
Hz, Ar), 10.89 (1H, s, NH); δC (DMSO-d6) 103.3, 115.8 ,116.2 (d, 2JCF = 21.8 Hz), 119.5, 121.1, 
122.9, 125.4, 126.9, 128.4, 128.8, 129.4, 129.8, 130.2, 131.0 (d, 4JCF = 2.8 Hz) 131.2 (d, 
3JCF = 
9.5 Hz), 133.0, 135.7, 137.9, 147.9, 150.7, 152.5, 157.4, 158.3, 162.7 (d, 1JCF = 272.1 Hz); 
HRMS (ES): found 589.9715. C28H16N3OFBr2
+ requires 588.9624. Anal calcd for 
C28H15N3OFBr: C, 57.07; H, 2.74; N, 7.13. Found: C, 57.11; H, 2.97; N, 7.12. 
 
6-Bromo-N-(5-bromo-2-(3-fluorophenyl)benzofuran-7-yl)-2-(4- fluorophenyl)quinazolin-
4-amine (215b); R = 3-F, X=F 
 
A mixture of 210b (0.20 g, 0.65 mmol), 214a (0.23 g, 0.65 mmol) and HCl (0.001 g, 0.03 mmol) 
in isopropanol (10 mL) and was treated as for the preparation of 215a to afford 215b as a solid 
(0.32 g, 82%) mp. > 300 °C; νmax (ATR) 683, 775, 874, 937, 1089, 1086, 1239, 1365, 1454, 
1594, 1632, 3070, 3171 cm-1; δH (DMSO-d6) 7.16 (2H, t, J = 9.0 Hz, Ar), 7.39 (2H, d, J = 8.5 
Hz, Ar), 7.60 (2H, d, J = 8.5 Hz, Ar), 7.61 (1H, s, =C-H), 7.81 (1H, dd, J = 1.5  and 9.0 Hz, Ar), 
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7.99 (1H, d, J = 8.5 Hz, Ar), 8.12 (1H, d, J = 8.5 Hz, Ar), 8.16 (2H, t, J = 8.5 Hz, Ar), 8.22 (1H, 
t, J = 8.5 Hz, Ar), 9.03 (1H, d, J = 1.5 Hz, Ar), 11.02 (1H, s, NH); δC (DMSO-d6) 103.5, 112.0 
(d, 2JCF = 23.8 Hz), 115.3 (d, 
3JCF = 8.5 Hz), 115.6, 116.1, (d, 
2JCF = 21.9 Hz), 116.5, (d, 
2JCF = 
20.9 Hz), 119.8, 121.7, 123.0, 126.8, 128.4, 130.0, 130.2, 131.5 (d, 3JCF = 9.5 Hz), 130.6 (d, 
2JCF 
= 8.5 Hz), 131.7, 132.3, 136.5, 137.9, 147.2, 148.0, 152.5, 155.5, 158.0 (d, 4JCF = 2.9 Hz), 162.7 
(d, 1JCF = 224.7 Hz) 164.7 (d, 
1JCF = 231.3 Hz); HRMS (ES): found 607.9629. 
C28H16N3OF2
79Br2
+ requires 607.9628. Anal calcd for C28H15N3OF2Br: C, 55.38; H, 2.49; N, 
6.97. Found: C, 55.62; H, 2.57; N, 6.85. 
 
6-Bromo-N-(5-bromo-2-(4-fluorophenyl)benzofuran-7-yl)-2-(4- fluorophenyl)quinazolin-
4-amine (215c); R = 4-F; X=F 
 
A mixture of 210c (0.20 g, 0.65 mmol), 214a (0.22 g, 0.65 mmol) and HCl (0.001 g, 0.03 mmol) 
in isopropanol (10 mL) and was treated as for the preparation of 215a to afford 215c as a solid 
(0.19 g, 87%) mp. 287–289 °C; νmax (ATR) 737, 846, 943, 1088, 1156, 1289, 1365, 1454, 1572, 
1607, 1627, 3064, 3170 cm-1; δH (DMSO-d6) 7.15 (2H, t, J = 8.5 Hz, Ar), 7.22 (1H, t, J = 8.5 
Hz, Ar), 7.38 (1H, t, J = 8.5 Hz, Ar), 7.48 (1H, s, =C-H) 7.66 (1H, d, J = 8.5 Hz, Ar), 7.77–7.82 
(2H, m, Ar), 7.94–7.97 (2H, m, Ar), 8.08 (1H, d, J = 7.5 Hz, Ar), 8.16 (1H, t, J = 8.5 Hz, Ar), 
8.20–8.23 (1H, m, Ar), 8.99 (1H, d, J = 1.5 Hz, Ar), 10.89 (1H, s, NH); δC (DMSO-d6) 102.1, 
115.8, 116.2 (d, 2JCF = 21.8 Hz), 116.5 (d, 
2JCF = 21.8 Hz) , 119.5, 121.3, 122.9, 123.5, 124.3, 
126.0 (d, 4JCF = 3.9 Hz), 126.6, 127.7 (d, 
3JCF = 8.5 Hz), 128.5, 129.4 (d, 
4JCF = 2.8 Hz), 130.2, 
130.8 (d, 3JCF = 8.5 Hz), 130.9, 132.6, 137.5, 147.9, 157.8, 161.6, 164.5 (d, 
1JCF = 248.8 Hz), 
164.5 (d, 1JCF = 267.3 Hz); HRMS (ES): found 605.9629. C28H16N3OF2Br2
+ requires 605.9628. 
Anal calcd for C28H15N3OF2Br: C, 55.38; H, 2.49; N, 6.97. Found: C, 55.59; H, 2.61; N, 7.01. 
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6-Bromo-N-(5-bromo-2-(3-chlorophenyl)benzofuran-7-yl)-2-(4-fluorophenyl)quinazolin-
4-amine (215d); R = 3-Cl; X=F  
 
A mixture of 210d (0.11 g, 0.30 mmol), 214a (0.12 g, 0.30 mmol) and HCl (0.001 g, 0.03 mmol) 
in isopropanol (10 mL) and was treated as for the preparation of 215a to afford 215d as a solid 
(0.14 g, 78%) mp. > 300 °C; νmax (ATR) 738, 856, 938, 1030, 1129, 1254, 1347, 1458, 1596, 
1634, 3109, 3169 cm-1; δH (DMSO-d6) 7.09 (2H, t, J = 8.0 Hz, Ar), 7.38 (2H, d, J = 8.5 Hz, Ar), 
7.58 (1H, s, =C-H), 7.85 (1H, d, J = 8.5 Hz, Ar), 7.96 (1H, dd, J = 2.5 and 8.5 Hz, Ar), 8.05 (1H, 
dd, J = 1.5 and 8.5 Hz, Ar), 8.07 ( 2H, d, J = 8.5 Hz, Ar), 8.15 ( 2H, t, J = 8.5 Hz, Ar), 8.20 (1H, 
d, J = 1.5 Hz, Ar), 8.90 (1H, d, J = 1.0 Hz, Ar), 10.45 (1H, s, NH); δC (DMSO-d6) 103.6, 115.3, 
115.5, 116.1 (d, 2JCF = 21.9 Hz), 119.0, 121.9, 123.6, 124.9, 126.3, 127.3, 128.4, 128.7, 129.2, 
129.4, 130.3 (d, 3JCF = 8.7 Hz), 132.3, 134.6, 137.0, 137.8, 147.3, 149.0 (d, 
4JCF = 3.8 Hz) 149.9, 
155.4, 157.5, 158.8, 164.1 (d, 1JCF = 246.5 Hz); HRMS (ES): found 621.9328. 
C28H16N3OF
35Cl79Br2
+ requires 621.9327. Anal calcd for C28H15N3OFClBr: C, 53.92; H, 2.42; 
N, 6.74. Found: C, 53.97; H, 2.35; N, 6.848. 
 
6-Bromo-N-(5-bromo-2-(4-(trifluoromethoxy)phenyl)benzofuran-7-yl)-2-(4-fluorophenyl) 
quinazolin-4-amine (215e); R = 4-OCF3, X=F 
 
A mixture of 210e (0.19 g, 0.56 mmol), 214a (0.20 g, 0.56 mmol) and HCl (0.001 g, 0.03 mmol) 
in isopropanol (10 mL) and was treated as for the preparation of 215a to afford 215e as a solid 
(0.36 g, 82%) mp. > 300 °C; νmax (ATR) 736, 856, 938, 1060, 1128, 1259, 1347, 1455, 1599, 
1634, 3111, 3169 cm-1, δH (DMSO-d6) 7.09 (2H, t, J = 8.0 Hz, Ar), 7.38 (2H, d, J = 8.5 Hz, Ar), 
7.56 (1H, s, =C-H), 7.82–785 (4H, m, Ar), 8.04 ( 1H, d, J = 8.5 Hz, Ar), 8.15 ( 2H, t, J = 8.5 Hz, 
Ar), 8.20 (1H, d, J = 1.5 Hz, Ar), 8.90 (1H, d, J = 1.0 Hz, Ar), 10.45 (1H, s, NH); δC (DMSO-
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d6) 103.6, 115.3, 115.5, 116.1 (d, 
2JCF = 21.9 Hz), 119.0, 121.9, 123.6, 124.9, 126.3, 127.3, 128.4, 
128.7, 130.3 (d, 3JCF = 8.7 Hz), 130.9 (t, JCF = 25.6 Hz) 132.3, 134.6, 137.0, 137.8, 147.3, 149.0 
(d, 4JCF = 3.8 Hz) 149.9, 155.4, 157.5, 158.8, 164.1 (d, 
1JCF = 246.5 Hz); HRMS (ES): found 
672.9227. C29H16N3O2F4
79Br2
+ requires 672.9447. Anal calcd for C29H15N3OF4Br: C, 51.74; H, 
2.25; N, 6.24. Found: C, 51.68; H, 2.11; N, 6.35. 
 
6-Bromo-N-(5-bromo-2-phenylbenzofuran-7-yl)-2-(4-chlorophenyl)quinazolin-4-amine 
(215f); R = 4-H, X=Cl 
 
A mixture of 210a (0.21 g, 0.62 mmol), 214b (0.24 g, 0.62 mmol) and HCl (0.001 g, 0.03 mmol) 
in isopropanol (10 mL) and was treated as for the preparation of 215a to afford 215f as a solid 
(0.32 g, 83%) mp. > 300 °C; νmax (ATR) 683, 775, 874, 937, 1089, 1086, 1239, 1365, 1454, 
1594, 1632, 3070, 3171 cm-1; δH (DMSO-d6) 7.31–7.37 (3H, m, Ar), 7.61 (1H, d, J = 8.5 Hz, 
Ar), 7.65 (1H, d, J = 7.0 Hz, Ar), 7.68 (1H, s, =C-H), 7.75 ( 1H, d, J = 7.5 Hz, Ar), 7.89 ( 1H, d, 
J = 8.7 Hz, Ar), 7.96 (1H, dd, J = 2.5 and 8.5 Hz, Ar), 8.07 (1H, d, J = 8.7 Hz, Ar),  8.17 (1H, d, 
J = 8.5 Hz, Ar), 8.21 (1H, d, J = 2.5 Hz, Ar), 8.26 (1H, d, J = 8.5 Hz, Ar), 8.42 (1H, d, J = 1.5 
Hz, Ar), 8.97 (1H, d, J = 8.5 Hz, Ar), 10.71 (1H, s, NH); δC (DMSO-d6)  103.3, 115.6, 119.6, 
120.9, 126.4, 127.0, 128.5, 128.7, 129.1, 129.4, 129.9, 130.2, 130.8, 131.7, 132.9, 135.8, 136.9, 
137.2, 137.9, 147.9, 150.7, 152.5, 157.2, 157.8, 158.8 161.6; HRMS (ES): found 605.9349. 
C28H17N3O
35Cl79Br2
+ requires 605.9328. Anal calcd for C28H16N3OClBr: C, 55.52; H, 2.66; N, 
6.94. Found: C, 55.65; H, 2.78; N, 7.04. 
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6-Bromo-N-(5-bromo-2-(3-fluorophenyl)benzofuran-7-yl)-2-(4-chlorophenyl)quinazolin-
4-amine (215g); R = 3-F, X=Cl 
 
A mixture of 210b (0.20 g, 0.65 mmol), 214b (0.23 g, 0.65 mmol) and HCl (0.001 g, 0.03 mmol) 
in isopropanol (10 mL) and was treated as for the preparation of 215a to afford 215g as a solid 
(0.26 g, 81%) mp. > 300 °C; νmax (ATR) 687, 777, 850, 1108, 1217, 1366, 1464, 1519, 1520, 
1627, 3102, 3170 cm-1; δH (DMSO-d6) 7.15 (1H, t, J = 8.0 Hz, Ar), 7.37 (2H, d, J = 8.0 Hz, Ar), 
7.42 (1H, s, =C-H), 7.66 (1H, d, J = 8.5 Hz, Ar), 7.57–7.60 (2H, m, Ar), 7.65 (1H, d, J = 8.5 Hz, 
Ar), 7.83 (1H, d, J = 8.5 Hz, Ar), 7.97 (1H, dd, J = 1.5  and 9.0 Hz, Ar), 8.10 (2H, d, J = 8.5 Hz, 
Ar), 8.15 (1H, d, J = 8.5 Hz, Ar), 9.03 (1H, d, J = 1.5 Hz, Ar), 11.00 (1H, s, NH); δC (DMSO-
d6) 103.5, 112.0 (d, 
2JCF = 23.8 Hz), 115.4, 116.4 (d, 
2JCF = 20.9 Hz), 119.6, (d, 
4JCF = 2.8 Hz), 
121.4, 123.0, 123.8,  124.5, 126.6, 128.5, 129.1, 130.0, 130.2 (d, 3JCF = 8.5 Hz), 130.5 (d, 
4JCF = 
2.9 Hz), 131.7 (d, 3JCF = 8.6 Hz), 132.3, 136.5, 137.0, 137.9, 147.1, 149.0, 152.5, 155.5, 158.8, 
162.7 (d, 1JCF = 241.7 Hz); HRMS (ES): found 621.9329. C28H16N3OF
35Cl79Br2
+ requires 
621.9333. Anal calcd for C28H15N3OFClBr: C, 53.92; H, 2.42; N, 6.74. Found: C, 53.99; H, 2.35; 
N, 6.87. 
 
6-Bromo-N-(5-bromo-2-(4-fluorophenyl)benzofuran-7-yl)-2-(4 -chlorophenyl)quinazolin-
4-amine (215h); R = 4-F, X=Cl 
 
A mixture of 210c (0.12 g, 0.39 mmol), 214b (0.14 g, 0.39 mmol) and HCl (0.001 g, 0.03 mmol) 
in isopropanol (10 mL) and was treated as for the preparation of 215a to afford 215h as a solid 
(0.15 g, 78%) mp. > 300 °C; νmax (ATR) 736, 874, 1061, 1168, 1288, 1398, 1475, 1572, 1629, 
3101, 3170 cm-1; δH (DMSO-d6) 7.29 (2H, t, J = 8.5 Hz, Ar), 7.34 (2H, d, J = 8.5 Hz, Ar), 7.47 
(1H, s, =C-H), 7.78–7.79 (4H, m, Ar), 7.85 (1H, d, J = 8.5 Hz, Ar), 8.04 (1H, d, J = 8.0 Hz, Ar), 
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8.11 (2H, d, J = 8.5 Hz, Ar), 8.91 (1H, d, J = 1.5 Hz, Ar), 10.89 (1H, s, NH); δC (DMSO-d6) 
102.0, 115.4, 116.5 (d, 2JCF = 21.8 Hz), 119.5, 120.8, 122.9, 123.3, 124.8, 126.1, 126.3, 127.6, 
127.7 (d, 3JCF = 8.5 Hz), 128.8, 129.8, 130.8, 132.5, 135.8, 137.0 (d, 
4JCF = 2.9 Hz), 147.1, 149.9, 
155.9, 157.5, 158.7, 162.9 (d, 1JCF = 245.6 Hz); HRMS (ES): found 621.9333. 
C28H15N3OF
35Cl79Br2
+ requires 621.9333. Anal calcd for C28H14N3OFClBr: C, 53.92; H, 2.42; 
N, 6.74. Found: C, 53.88; H, 2.58; N, 6.91. 
 
6-Bromo-N-(5-bromo-2-(3-chlorophenyl)benzofuran-7-yl)-2-(4-chlorophenyl)quinazolin-
4-amine (215i); R = 3-Cl, X=Cl 
 
A mixture of 210d (0.24 g, 0.68 mmol), 214b (0.22 g, 0.68 mmol) and HCl (0.001 g, 0.03 mmol) 
in isopropanol (10 mL) and was treated as for the preparation of 215a to afford 215i as a solid 
(0.29 g, 67%) mp. 282–285 °C; νmax (ATR) 683, 736, 829, 940, 1012, 1159, 1372, 1501, 1530, 
1516, 3048, 3170 cm-1; δH (DMSO-d6) 7.35 (1H, d, J = 8.5 Hz, Ar), 7.38 (1H, d, J = 7.0 Hz, Ar), 
7.60 (2H, d, J = 8.5 Hz, 2H), 7.67 (2H, d, J = 8.5 Hz, Ar), 7.81 (1H, s, C-H), 7.85 (1H, d, J = 8.5 
Hz), 7.96 (1H, dd, J = 2.5 and 8.5 Hz, Ar), 8.05 (1H, dd, J = 1.5 and 8.5 Hz, Ar), 8.13 (1H, d, J 
= 8.0 Hz, Ar), 8.17 (1H, d, J = 8.5 Hz, Ar), 8.20 (1H, d, J = 2.5 Hz, Ar), 8.93 (1H, d, J = 1.5 Hz, 
Ar), 10.51 (1H, s, NH); δC (DMSO-d6) 103.6, 115.6, 119.5, 121.0, 123.0, 124.8, 126.4, 128.4, 
129.2, 129.4, 129.8, 130.2, 130.5, 131.3, 131.4, 131.7, 132.2, 134.2, 135.9, 136.9, 137.9, 147.0, 
152.4, 155.2, 157.5, 158.6; HRMS: found 637.9041. C28H16N3O
35Cl2
79Br2
+ requires 637.9037. 
Anal calcd for C28H15N3OCl2Br: C, 52.53; H, 2.36; N, 6.56. Found: C, 52.68; H, 2.50; N, 6.45.  
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6-Bromo-N-(5-bromo-2-(4-(trifluoromethoxy)phenyl)benzofuran-7-yl)-2-(4-chlorophenyl) 
quinazoline-4-amine (215j); R = 4-OCF3, X=Cl 
 
A mixture of 210e (0.19 g, 0.56 mmol), 214b (0.20 g, 0.56 mmol) and HCl (0.001 g, 0.03 mmol) 
in isopropanol (10 mL) and was treated as for the preparation of 215a to afford 215j as a solid 
(0.17 g, 82%) mp. > 300 °C; νmax (ATR)  682, 781, 858, 938, 1091, 1199, 1259, 1372, 1455, 
1553, 1615, 3082, 3170 cm-1; δH (DMSO-d6) 7.33 (1H, d, J = 8.0 Hz, Ar), 7.36 (1H, d, J = 8.0 
Hz, Ar), 7.59 (1H, s, =C-H), 7.61 (1H, d, J = 8.5 Hz, Ar), 7.67 (1H, d, J = 8.0 Hz, Ar), 7.81 (1H, 
d, J = 9.0 Hz, Ar), 7.85 (2H, d, J = 8.5 Hz, Ar), 7.96 (1H, d, J = 9.0 Hz, Ar), 8.04 (1H, d, J = 9.0 
Hz, Ar), 8.11 (1H, d, J = 8.5 Hz, Ar), 8.17 (1H, d, J = 8.5 Hz, Ar), 8.20 (1H, d, J = 1.5 Hz, Ar), 
8.91 (1H, d, J = 1.5 Hz, Ar), 10.48 (1H, s, NH); δC (DMSO-d6) 103.6, 115.3, 119.6, 121.9, 123.0, 
124.8, 126.3, 127.2, 128.4, 128.7, 129.2, 129.8, 130.7, 131.7, 132.3, 135.8, 136.9 (t, JCF = 25.6 
Hz), 137.9, 147.2, 149.0, 149.8, 152.4, 155.4, 157.5, 158.6; HRMS (ES): found 687.9236. 
C29H16N3O2F3
35Cl79Br2
+ requires 687.9250. Anal calcd for C28H15N3O2F3ClBr: C, 50.50; H, 
2.19; N, 6.09. Found: C, 50.29; H, 2.32; N, 6.02. 
 
4.13 Crystal Structure Solution and Refinement 
 
The intensity data for the eight co-crystals were collected on a Bruker APEX II CCD area 
detector diffractometer with graphite monochromated Mo-Kα radiation (50 kV, 30 mA) at 173K. 
The collection method involved ω-scans having a width of 0.5°. Data reduction was carried out 
using SAINT+ version 6.02.6 software and SADABS was used to make empirical absorption 
corrections.174 The crystal structures were solved through direct methods using SHELXS-97.187 
Non-hydrogen atoms were first refined isotropically followed by anisotropic refinement by full 
matrix least-squares calculations based on F2 using SHELXL-97.187 C-bound H atoms were first 
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located in the difference electron density map, then positioned geometrically and allowed to ride 
on their respective parent atoms, with thermal displacement parameters 1.2 times that of the 
parent C atom. Where possible, the coordinates and isotropic displacement parameters of the N-
bound and O-bound H atoms involved in hydrogen bonding interactions were allowed to refine 
freely, except for crystals 215i due to poor refinement stability. The diffraction data and 
refinement statistics of co-crystal 215i were poor even after numerous attempts at 
recrystallization. Diagrams and publication material were generated using WinGX,188 ORTEP-
3,189 PLATON190 and DIAMOND.191 
 
4.14 Computational methods 
 
The density functional theory (DFT) computations were carried out using the B3LYP exchange 
correlation functional,192 together with the 6-311++G(d,p) [16,17] basis set for all atoms. All 
computations were performed using the Gaussian 09 software suite.193 The geometrical 
optimizations were performed in the gas phase without solvent corrections because it was 
reported that gas phase calculations frequently correspond quite well with crystal structures 194. 
 
4.15  In Vitro Cytotoxicity Assay  
 
4.15.1  Cell culturing and evaluation of cytotoxicity of the benzofuran-chalcones 203a–y  
 
The human breast (MCF-7) cancer cell line was maintained in culture flasks containing 
Dulbecco’s Modified Eagles Medium (DMEM). The media was supplemented with 1% 
antibiotics (100 µg/mL penicillin, 100 µg/mL streptomycin and 250 µg/L fungizone) and 10% 
heat-inactivated fetal bovine serum. The cells were grown at 37 °C in a humidified incubator set 
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at 5% CO2. The cells were sub-cultured every two-to-three days after the cells had formed a 
confluent monolayer. Cytotoxicity was measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) method using the Cell Proliferation Kit I (Sigma-Aldrich, 
Missouri, USA) according to the method developed by Mosmann et al.155  The cells were seeded 
(100 µL) in a 96-well microtiter plates at a concentration of 1x105 cells/mL and incubated for 
24 h at 37 °C and 5% CO2 to allow the cells to attach to the bottom of the wells. The compounds 
were assessed at 0–100 µM. The control wells included vehicle treated cells exposed to 2% 
DMSO and the positive control, actinomycin D, with concentrations ranging between 5, 10, 25, 
and 50, and 100 µM. The microtitre plates were incubated for 48 h. After the 48 h incubation 
period the MTT reagent (10 µL) was added to a final concentration of 0.5 mg/mL and the plate 
was further incubated for another 4 h. After 4 h, 100 µL of the solubilisation solution was added 
to each well and the plate was allowed to stand overnight. Subsequently, the absorbance of the 
color complex was read at 550 nm with a reference wavelength set at 650 nm using a BIO-TEK 
Power-Wave XS multi-well plate reader (BioTech Instruments, Midrand, South Africa). The 
IC50 values of the compounds were calculated using OriginPro software (OriginLab Corporation, 
Northampton, MA, USA). 
 
4.15.2   Determination of apoptotic cell death by annexin V-Cy3 SYTOX staining assay 
 
The percentage population of apoptotic cells were determined using Annexin V–Cy3 SYTOX 
apoptosis detection kit (Abcam, Milton, Cambridge, UK) according to the manufacturer’s 
instructions. The MCF-7 cells were seeded into six well plates in concentration of 1.5 × 106 cells 
per well and treated with compound 203b or 203i at a concentration of 1 µM against actinomycin 
D (1 µM) as a reference standard, respectively. The cells were incubated for 48 h and then stained 
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with Annexin V–Cy3 SYTOX green dye. The cells were analyzed using BD Biosciences 
FACSAria III flow cytometer (BD Biosciences, San Jose, CA, USA).  
 
4.15.3   Caspase-3 activation of compound 203b and 203i 
 
Caspase-3 activity was detected by means of Caspase-3 Colorimetric Assay Kit (Abcam, 
Cambridge, MA, USA). The cells were cultured in 24 well plates and treated for 24 h with 203b 
or 203i at a concentration of 1 µM against actinomycin D (1 µM) as a reference standard, 
respectively. The cells were then washed with PBS buffer and lysed on ice. The experiments 
were carried out according to the manufacturer’s instructions. Optical density was measured at 
absorbance of 450 nm using the BioTek microplate reader. The concentration of active Caspase-
3 (Asp 175) were measured in duplicates and interpolated from the active caspase-3 (Asp 175) 
standard curve and corrected for sample dilution. 
 
4.15.4 Tubulin polymerization assay of compounds 203a–y 
 
Tubulin polymerization assays were carried out using the tubulin polymerization assay kit 
(Cytoskeleton, Inc., Denver, Co, USA) following the instruction by the manufacturer. 50 μL of 
1.3 mg/mL tubulin (>99% pure) proteins in G-PEM buffer (80 mmol/L PIPES, pH 6.9, 2 mmol/L 
MgCl2, 0.5 mmol/L EGTA, 1 mmol/L GTP, and 15% glycerol) were placed in a quartz cuvette 
in the presence of the test agent. Polymerization was measured at 37 °C at every three seconds 
for 1 h using an Applied Photophysics Chirascan spectroflourimeter (Applied Photophysics Ltd., 
Surrey, UK), excitation at 360 nm, and emission at 450 nm. 
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4.15.5 EGFR-TK phosphorylation inhibition assays of compounds 203e, 203i, 203o, 203p, 
and 203v 
 
The inhibitory activities of compounds 203e, 203i, 203o, 203p, and 203v against actinomycin D 
and gefitinib towards EGFR-TK were tested using enzyme-linked immunosorbent assay 
(ELISA) technique with purified Epidermal Growth Factor Receptor (Sigma-Aldrich, Bradford, 
UK). The procedure was carried out according to the manufacturer’s protocol. Ninety-six-well 
plates were pre-coated with 100 µL of a 4:1 poly(Glu,Tyr) solution (5 mg/mL) at 37 ºC overnight. 
The enzyme reaction was conducted in freshly prepared kinase reaction buffer (25 mmol/L 
HEPES, pH 7.4, 5 mmol/L MgCl2, 2 mmol/L MnCl2, 100 µmol/L Na3VO4 and 1 mmol/L 
dithiothreitol). Ten microlitres of the test samples at five different concentrations (0.02–0.4 µM) 
and 20 µL of dilute solution of purified recombinant EGFR tyrosine kinase proteins were added 
to each reaction well. The kinase reaction was initiated by the addition of 50 µL of a solution of 
adenosine-50-triphosphate, disodium salt (5 mmol/L). DMSO and EGFR (without any test 
sample) were also included in this experiment as negative and positive controls, respectively. 
The plates were then incubated at 37 ºC for 1 h and washed three times with phosphate-buffered 
saline (PBS). Phosphorylated proteins were probed with monoclonal anti-phosphotyrosine 
antibody produced in mouse (Sigma-Aldrich, St. Louis, MO, USA). After another 1 h incubation 
at 37 ºC, the plates were again washed three times with PBS, followed by the addition 100 µL of 
freshly prepared peroxidase substrate solution. After incubation in the dark for extra 10 min, the 
reaction was terminated by adding 100 µL of 2 M H2SO4 solution. The plates were analysed 
using the Thermo Varioskan Flash Spectral Scanning Multimode Reader (Thermo Fisher 
Scientific, Waltham, MA, USA) at 492 nm. The assay was performed in triplicate. The EGFR-
TK inhibition percentage was determined as follows: 
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OD: Optical Density  
The half-maximal inhibitory concentration value (IC50) were calculated using OriginPro 
software (OriginLab Corporation, Northampton, MA, USA). 
 
4.16 Cell culturing and evaluation of cytotoxicity for compounds 215a–j against panel of 
cancer cell lines 
 
The cytotoxic activities of the compounds were screened against the C3A/HepG2 human liver 
cells, human colorectal tumor (Caco-2) cells, the human lung carcinoma (A549) and the cervical 
cancer (HeLa) cells. The lethal concentration was determined using the 3-(4,5-dimethylthiazol)-
2,5-diphenyl tetrazolium bromide (MTT) assay previously developed by Mosmann.155 The cells 
were maintained in Dubelsco minimal essential medium (DMEM, Highveld Biological, South 
Africa) supplemented with 10% foetal calf serum (Adcock-Ingram, Midrand, South Africa) and 
sodium pyruvate for C3A liver cells. Cell suspensions were prepared from confluent monolayer 
cultures and plated at a density of 0.1 × 106 cells into each well of 96-well microtitre plates. For 
cell attachment, plates were incubated for 24 h at 37 oC in a 5% CO2 incubator prior to the 
exposure. The compounds were dissolved in DMSO (5 mg/mL) and appropriate dilutions were 
prepared, added to the wells and incubated for 48 h. Doxorubicin hydrochloride (Pfizer 
Laboratories, Sandton, South Africa) was used as a positive control while DMSO was the 
negative control. After incubation for 48 h, the wells were rinsed with 150 µL of phosphate 
buffered saline PBS (Sigma-Aldrich, GmBH, Schnelldorf, Germany) and 200 µL of fresh 
medium was dispensed into the wells. MTT was dissolved in PBS (30 µL) then added to each 
well and the contents were incubated for 4 h at 37 oC. The medium was removed and MTT 
 189 
 
formazan crystals were dissolved in 50 µL DMSO. The amount of MTT reduction was measured 
immediately by detecting the absorbance using a BioTek microplate reader (BioTek Synergy, 
Analytical and Diagnostic Products, Johannesburg, South Africa) at a wavelength of 570 nm. 
Each dilution of the test sample was assayed in quadruplicate and the experiments were repeated 
three times. The percentage of cell viability was calculated using the formula below:  
controlofAbsorbanceMean
100sampleofAbsorbanceMean
viabilityCell%

=  
The LC50 values (lethal concentration at which 50% of the cells are killed) were calculated as 
the concentration of the test sample that resulted in 50% reduction of absorbance compared to 
untreated cells. The intensity of the MTT formazan produced by living metabolically active cells 
is directly proportional to the number of live cells present. 
 
4.16.1 Annexin V-FITC staining assay on 215d and 215j against C3A and Caco-2, 
respectively 
 
Apoptotic cells were quantified using flow cytometry. The C3A or Caco-2 cells were cultured in 
24 well plates and each was then treated with compound 215d or 215j at concentrations 5, 12.5 
and 25 µM against doxorubicin hydrochloride (0.20 µM) as a reference standard, respectively. 
After the cells were incubated for 24 h, both treated and untreated cells were harvested, washed 
two times with ice PBS and then adjusted at a density of 1 x 106 cells/sample. Cells were 
harvested and transferred into plastic flow tubes (BD Biosciences, South Africa). The cells were, 
in turn, stained with Annexin-V-FUOS staining kit (Roche, Mannheim, Germany) according to 
the manufacturer’s instructions. The cells were analysed using Becton, Dickinson and Company 
FACS Accuri flow cytometer. 
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4.16.2 Caspase-3 analysis on 215d and 215j against C3A and Caco-2, respectively 
 
Caspase-3 activity was detected by means of Caspace-3 Colorimetric Assay Kit (Abcam, 
Cambridge, MA, USA). The cells were cultured in 24 well plates and treated for 24 h. The cells 
were then washed with PBS buffer and lysed on ice. The experiments were carried out according 
to the manufacturer’s instructions. Optical density was measured at absorbance of 450 nm using 
the BioTek microplate reader. The concentration of active Caspase-3 (Asp 175) were measured 
in duplicates and interpolated from the active caspase-3 (Asp 175) standard curve and corrected 
for sample dilution. 
 
4.16.3 Inhibition for EGFR-TK 
 
The inhibitory activities of compound 215a–j and Gefitinib towards EGFR-TK were tested using 
enzyme-linked immunosorbent assay (ELISA) technique with purified epidermal growth factor 
receptor (Sigma-Aldrich, Bradford, UK). The procedure was carried out according to the 
manufacturer’s protocol. Ninety-six-well plates were pre-coated with 100 µL of a 4:1 
poly(Glu,Tyr) solution (5 mg/mL) at 37 ºC overnight. The enzyme reaction was conducted in 
freshly prepared kinase reaction buffer (25 mmol/L HEPES, pH 7.4, 5 mmol/L MgCl2, 2 mmol/L 
MnCl2, 100 µmol/L Na3VO4 and 1 mmol/L dithiothreitol). Ten microlitres of the test samples at 
five different concentrations (0.02–0.4 µM) and 20 µL of dilute solution of purified recombinant 
EGFR tyrosine kinase proteins were added to each reaction well. The kinase reaction was 
initiated by the addition of 50 µL of a solution of adenosine-50-triphosphate, disodium salt (5 
mmol/L). DMSO and EGFR (without any test sample) were also included in this experiment as 
negative and positive controls, respectively. The plates were then incubated at 37 ºC for 1 h and 
washed three times with phosphate-buffered saline (PBS). Phosphorylated proteins were probed 
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with monoclonal anti-phosphotyrosine antibody produced in mouse (Sigma-Aldrich, St. Louis, 
MO, USA). After another 1 h incubation at 37 ºC, the plates were again washed three times with 
PBS, followed by the addition 100 µL of freshly prepared peroxidase substrate solution. After 
incubation in the dark for extra 10 min, the reaction was terminated by adding 100 µL of 2 M 
H2SO4 solution. The plates were analysed using the Thermo Varioskan Flash Spectral Scanning 
Multimode Reader (Thermo Fisher Scientific, Waltham, MA, USA) at 492 nm. The assay was 
performed in triplicate. The EGFR-TK inhibition percentage was determined as follows: 
)ODOD(
)ODOD(
Inhibition%
positivenegative
positivesamples
−
−
= x 100 
OD: Optical Density  
The half-maximal inhibitory concentration value (IC50) was obtained from the curves of 
percentage inhibition. 
 
4.17  Molecular Docking against Tubulin and EGFR 
 
Molecular docking of compounds 203i and 203o to the 3D structure of a tubulin heterodimer 
(PDB ID: 1SAO)196 and EGFR (PDB ID: 1M17)197 as carried out using the CDOCKER 
protocol198 in Discovery Studio 2017 (Biovia, San Diego, CA, USA). Prior to performing the 
docking, compounds were drawn using Discovery Studio and prepared using the ‘Prepare 
Ligand’ protocol. The protein structures were downloaded from the Protein Data Bank, prepared 
using the ‘Prepare Protein’ protocol in Discovery Studio, which included removing any existing 
ligands bound, leaving the water molecules unaltered in the model. The binding sites were 
defined from receptor cavities and docking was performed using default settings and the best 
conformation of the ligand were selected and evaluated. 
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The structure of epidermal growth factor receptor (EGFR) kinase domain was obtained from 
RCSB PDB (id: 1M17)199 where all heteroatoms and water molecules were first removed. Polar 
hydrogen atoms, Kollman-Amber united atom partial charges and solvation parameters were 
then added by utilizing AutoDockTools.200 The coordinates for erlotinib (control) docking were 
retrieved from the ligand co-crystallised with EGRF (PDB id: 1M17) while the coordinates for 
compounds 215a–j were generated using ChemDraw Professional 15.0 (PerkinElmer 
Informatics, Waltham, MA, USA). Minimization of compounds 215 was then performed with 
Chem3D module in ChemOffice Professional 15.0 (PerkinElmer Informatics). Ligands were in 
united atom format where only polar hydrogen atoms remained. Gasteiger charges and torsional 
angles of all ligands were assigned by AutoDockTools. Hydrated docking was performed with 
standard protocol from AutoDock4.2 where random water atoms were added around the ligand. 
A total of 200 runs were performed by AutoDock4.2.6200 with semi-empirical free energy scoring 
function, Lamarckian genetic algorithm of 1,000,000 energy evaluations each run and the 
maximum number of 27,000 generations. The number of individuals in population was set as 
350 and the rate of crossover was 0.8.  All docked conformations were clustered with root mean 
square of 2.0 Å.
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